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1.1 CYSTIC FIBROSIS 
Cystic fibrosis (CF) is the most common fatal genetic disease in 
Caucasian populations. The principal manifestations of CF include increased 
concentrations of chloride ions in exocrine gland secretions, pancreatic 
insufficiency, chronic lung disease, intestinal blockage, malabsorption of fat 
and male and female infertility [Boat et al., 19891. CF is caused by mutations in 
the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR), so named because of its postulated role in electrolyte (specifically 
chloride ion) transport [Rommens et al., 19891. The gene spans 25OKb 
containing 27 exons, which are spliced to produce mRNA of approximately 
6500 nucleotides [Zielinski et al., 1991]. 
A model of the structure of CFTR had been predicted based on 
conceptual translation of the cDNA sequence [Riordan et al., 19891 (fig. 1.1). The 
key features of the proposed structure include: 
Two hydrophobic membrane spanning domains (MSD1 and MSD 2) each 
composed of six transmembrane (x-helical segments. 
10 Two nucleotide triphosphate binding domains (NBD1 and NBD2) which are 
predicted to interact with ATP. 
*A unique highly charged cytoplasmic domain (R) which contains several 
consensus phosphorylation sequences; 
* Two external potential glycosylation sites. 
This model did not resemble previously identified ion channels, but shared 
homology with a family of membrane associated ATP-dependent transport 
proteins, the ATP-binding cassette (ABC) transporter family [Hyde et al. 1990; 
Higgins 19921. In the light of the primary symptoms of CF, the predicted 





Fig. l. 1 Cartoon representing the predicted structure of CFIR 
indicates R domain, () indicates nucleotide binding dornain, 
indicates the transmembrane domain, and Xindicates glycosylation site. 
th 
2 
molecule rather than serve as a chloride channel itself [Ringe and Petsko, 
1990]. 
1.1.1 The Cellular Functions of CFTR 
Heterologous expression systems have been used to indicate that, as 
initially predicted, CFTR acts as a chloride ion channel which appears to be 
activated by cAMP. Expression of wild-type CFTR cDNA in pancreatic [Drumm 
et al., 19901 and CF airway epithelial cells [Rich et al., 1990] restored cAMP 
regulated chloride conductance. Even following these results the question as to 
whether CFI'R forms a chloride channel itself or regulates the opening of a 
channel encoded by another gene still remained open [Frizzell and Cliff, 19911. 
This problem was addressed by expressing CFrR in a variety of non epithelial 
cells (mammalian and non mammalian) that express little or no endogenous 
CFTR [Tabcharani et al., 1991; Bear et al., 1991; Berger et al 1991; Anderson et 
al., 1991a,; Dalemans et al., 1991; Rommens et al., 1991; Rich et al 1991 and 
Kartner et al., 1991). Novel cAMP activated chloride currents were observed in 
each case. The following results gave further evidence to support the proposal 
that CFrR is itself a chloride channel. It was demonstrated that: 
0 the anion selectivity of the channel could be altered by mutagenesis of the 
transmembrane regions of CFTR [Anderson et al., 1991b]; 
ii) functional channel activity could be restored in lipid bilayers containing 
reconstituted CFTR [Bear et al., 1992; Tilly et al., 19921; 
iii) antisense oligonucleotides to the CF gene inhibit sweat duct chloride ion 
permeability in both a time and dose dependent manner [Sorcher et al., 1991]. 
The steps required in the activation of the CFTR encoded chloride 
channel appear to be phosphorylation of a number of sites on the R domain by 
protein kinase A [Cheng et al., 1991; Berger et al., 1991; Tabcharani et al., 1991] 
and hydrolysis of ATP on the NBF domains [Thomas et al., 1991; Anderson 
and Welsh, 19921. Further studies will be needed to elucidate the exact 
mechanism of CFTR chloride channel activity. 
3 
The conclusion that CFTR is a chloride channel gives CFTR a unique 
function relative to other members of the ABC transporter family. However, it 
is possible that CFTR may have other transport functions, especially in the 
light of the observation that the human multiple drug resistance (MDR) gene 
(a member of the ABC transporter family closely related to CFTR) may 
function as a volume-regulated chloride channel [Valverde et al., 1992; Gill et 
al., 19921 and as an ATP channel [Abraham et al., 19931, as well as a 
unidirectional transporter of hydrophobic drugs [Gottesman and Pastan, 1988; 
Endicott and Ling, 1989; Juranka et al., 19891. 
A variety of reports indicate that CFTR may indeed act as a multi- 
functional protein [Wine, 1993]: 
0 The protein may participate in cAMP dependent plasma membrane recycling 
[Bradbury et al., 19921 and in the acidification of intracellular organelles 
[Barasch et al., 19911. However, there is still some debate over the actual 
involvement of CFrR in these roles [Dunn et al., 1994, Prince et al., 19941. 
0 ATP channel activity of CFrR has been identified recently [Reisin et al., 1994; 
Cantiello et al., 19941, which may serve to regulate activation of CFrR and 
perhaps other channels by selective delivery of nucleotides to the extracellular 
domain [Reisin et al., 1994.1. Involvement of CFrR has been implicated in the 
regulation of sodium ion transport [Jiang et al., 1993; Boucher et al., 19881. 
-0 A recent report suggests that the amino-terminal portion of CFrR (MSD1, 
NBD1 and the R domain) alone is sufficient to form a regulated chloride ion 
channel [Sheppard et al., 19941. Examination of this channel on a sucrose 
density gradient led to the conclusion that the functional protein was 
composed of dimerised amino-terminal portions of CFrR. If the amino- 
terminal portion alone is sufficient to form a functional chloride channel, the 
role of the apparently superfluous carboxyl-terminus of CFTR (NBD2 and 
MSD2) has yet to be determined. 
From this it is clear that certain features of the activity of this protein 
still need to be elucidated. 
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1.1.2 Mutations in the CFrR Gene 
By far the most common mutation identified in the gene is a three base 
pair deletion, resulting in the loss of a phenylalanine residue at position 508 of 
the protein sequence [Kerem et al., 19891. The worldwide frequency of this 
mutation varies between 30% and 88%, but it is thought to be the predominant 
cause of the high incidence of CF in Caucasian populations [Cutting et al., 
19921. A CF Genetic Analysis Consortium has been established to coordinate 
efficient analysis of the numerous other CF producing mutations which occur 
at diverse sites within CFI'R [Tsiu, 1992]. 
CFTR mutations have been classified into four groups based on the 
mechanisms by which they disrupt the function of the protein [Welsh and 
Smith, 19931. These mechanisms are: 
i) defective protein production [White et al., 1990; Hamosh et al., 19911, 
ii) defective protein processing [Cheng et al., 1990; Denning et al., 1992b; 1992c; 
Armstrong, 1992; Lukacs et al., 1993; Yang et al., 1993], 
iii) defective regulation of the CFTR channel [Anderson and Welsh, 1992], and 
iv) defective conductance through the the CFTR chloride channel [Sheppard et 
al., 1993; Yang et al, 19931. 
The varied nature and complex mechanisms of mutations responsible 
for CFTR makes the establishment of a universal therapy for the disease 
difficult. A possible way forward in treating CF, regardless of the mechanism 
of mutation in any particular case, would be to insert wild type CFTR into 
affected cells. This may be achieved by introducing the gene encoding CFI7R or 
by delivery of the wild type protein itself to the appropriate cells. Much of the 
effort in CF research is now concentrated in these areas [Rosenfeld et al., 1991; 
1992; Hyde et al., 1993; Porteous and Dorin, 1993; Zabner et al., 1993; Crystal et 
al. 1994, Marshall et al., 19941, especially with the recent availability of mouse 
models for CF [Snouwaert et al., 1992; Dorin et al., 1992; Colledge et al., 19921. A 
full awareness of the expression of CFrR in different tissues is critical for the 
progress of gene and protein therapy strategies. 
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1.1.3 Location of CFTR 
Northern blot analysis has identified CFTR mRNA in epithelial tissues 
affected by CF [Riordan et al., 19891. These studies have been extended using in 
situ hybridisation in rat tissues which demonstrated CFTR mRNA in 
pancreas, salivary gland, lung, gastrointestinal tract, uterus and testis [Trezise 
and Buchwald, 19911. Other researchers have followed a range of procedures to 
raise monoclonal and polyclonal antibodies to different epitopes within CFTR 
[e. g. Gregory et al., 1990; Crawford et al., 1941; Cohn et al., 1991; 1992; Marino et 
al., 1991; Denning et al., 1992a, 1992b; Kartner et al., 1991; Zeitlin et al., 19921. 
Antibodies raised to CFTR have been used in a variety of experiments ranging 
from immunoprecipitation and immunoblot analyses to immunofluorescence 
assays and immuno-electron microscopy. 
The main focus of antibody work has been in immunohistochernical 
tissue distribution studies of both developing and mature tissues. CFrR has 
primarily been located in the apical membranes of epithelial cells of organs in 
which the clinical manifestations of CF are apparent [see Tizzano and 
Buchwald, 1993; Welsh et al., 1992 and McCintosh and Cutting, 1992 for 
relevant recent reviews]. Somewhat surprisingly, the expression of CFI'R in 
the lungs is not generally found in the respiratory epithelia, but appears to be 
concentrated in the submucosal glands of the bronchus [Eitgelhardt et al., 1,991; 
Crawford et al., 19911, whereas expression is found in the epithelia of kidneys 
[Crawford et al., 19911 which are not usually associated with the pathogenesis of 
the disease. Immunohistological analysis of the location of CFTR is covered in 
more detail in chapter 4. 
1.1.4 Topology of CFTR 
Information about the topology of CFrR currently available agrees with 
predictions made from the primary sequence. Functional considerations place 
the R domain and probably the NBDs inside the cell (see section 1.1.1 above). 
Studies with antibodies in permeabilised and unpermeabilised cells have 
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confirmed the intracellular location of the R domain along with the carboxyl 
terminus and placed the loop between the first two membrane spanning 
domains on the extracellular surface [Denning et al., 1992b]. As there is no 
signal sequence the amino terminus is probably intracellular. 
A more accurate model of CFrR would be of great benefit in terms of 
elucidating its exact biochemical functions (see section 1.1.2 above). The use of 
antibodies to different regions of CFTR would clearly help in the generation of 
such a model since they would provide information concerning both the 
topology of the protein in the membrane and the nature of those residues 
exposed on the surface of the folded protein. The success of using sequence 
specific antibodies to 'map' complex eukaryotic membrane proteins has been 
previously shown [Hughes, and August, 1981; Georges et al., 1993; Banting et 
al., 1989; Wilde et al., 19921. A panel of antibodies would also allow further 
detailed analysis of the cell and tissue distribution of CFTR to give a more 
complete understanding of the role it plays in the clinical manifestations of the 
disease, which in turn may influence approaches to therapy. 
L2 CHARACTERISATION AND PRODUMON OF ANTIBODIES 
The antibody molecule is composed of four polypeptide chains, two 
smaller (light) and two larger (heavy) chains. These chains fold into domains 
which have conserved three-dimentional conformations stabilised by 
disulphide bonds (Fig. 1.2). Each antibody domain consists of a sandwich of P- 
sheets which are stabilised by intra-chain disulphide bonds [see AmzeI and 
PoIjak, 1979 for a relevant review] . The domains associate to form structural 
regions, the functions of which have been characterised [see Davies and 
Metzger, 1983 for a relevant review]. 
The antigen binding domains are formed by the variable light (VL) and 











Fig. 1.2 The basic structure of IgG. 
Modified from Burton and Barbas, 1993b. 
antigen are formed by the amino acids in the six loops which connect the P- 
strands in the variable domains. These are hypervariable in sequence and 
length and are called the complementarity determining regions (CDRs) [Wu 
and Kabat, 19701. 
The rest of the molecule is relatively constant in sequence and 
structure. The constant region domains are formed by the interaction of the 
remainder of the light chain with the first constant domain of the heavy chain 
and by the association of the remainder of the two heavy chains (see fig-1.2). 
The hinge region is a section of heavy chain between the first two constant 
region domains. The two 'arms' of the antibody are linked at this point by 
disulphide bonds and a degree of flexibility exists in this area allowing the two 
antigen binding domains to operate independently. The heavy chain constant 
re gions are responsible for effecter functions, e. g. binding to receptors and 
complement fixation [see Davies and Metzger 1983, for a relevant review]. 
1.2.1 Antibody Fragments 
The domain organisation of the antibody molecule means that it can 
easily be divided into a number of fragments. Several proteases are known to 
cleave the structure into component parts which have been very valuable in 
structural and functional studies of the antibody molecule [Roift et al., 1993). 
Some smaller units, like Fv fragments, cannot be easily prepared by protein 
cleavage and have therefore only really been amenable to characterisation 
since the advent of gene expression systems (see section 1.2.6.2 below) 
[Pluckthun, 1992]. 
1.2.1.1 The Fab Fragment 
The Fab fragments can easily be prepared by proteolytic cleavage with 
papain [Porter, 19591 and have been thoroughly characterised. They are 
composed of the complete light chain and the heavy chain Fd region which 
9 
consists of the variable domain and first constant domain of the heavy chain. 
They have frequently been shown to bind antigens as well as the whole 
antibody [Nisonhoff et al., 1975]. Fab fragments are stable and associate well 
because the constant region contributes significant binding energy mainly 
from the formation of a disulphide bridge between the two chains. 
1.2.1.2 The Fv Fragment 
The Fv fragments consist of the heavy and light chain variable domains 
and as such are the smallest element containing the complete antigen binding 
site. Unlike Fab fragments they are not stabilised by interchain disulphide 
bonds. Initial reports indicated that they give good antigen binding activity 
[Skerra and Pluckthun, 19881. These fragments are of particular importance in 
key areas of research, such as: 
* Immunotoxin Therapy - genetic fusions of Fv fragments with potent toxins 
have demonstrated selective cytotoxicity [Chaudery et al., 1989; 1990]. 
* Tumour Medicine - ScFvs (discussed below) show a more even tumour 
penetration than larger, intact antibody counterparts [Yokota et al., 1992]. 
* Structural research - Fv fragments typically give better ordered crystals than 
Fab fragments [Bhat et al., 19901. 
A major disadvantage, however, is that when diluted the Fv fragments 
have a tendency to dissociate into component chains. The dissociation 
constants will vary between Fv fragments because they are dependent on 
specific interactions between amino acids present in the variable loops 
[Chothia et al., 19851. The consequence of this dissociation between VH and VL 
can be an apparent loss of binding activity. This problem can be alleviated by 
covalently linking the the two variable chains. 
Three ways of covalently linking the VH and VL domains have been 
described. The first involves chemically cross linking the two domains with 
glutaraldehyde [jaenicke and Rudolph, 1986]. The second uses a disulphide 
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bond cross fink, thus imitating the disulphide bridge formed between CH1 and 
CL in the Fab fragment [Reiter et al., 1994]. The third, and most commonly 
adopted means of cross linkage, connects the the two fragments by a peptide 
linker to produce a single-chain Fv fragment (ScFv) [Bird et al., 1988; Huston 
et al., 1988]. All three methods have been shown to give functional expression 
in vivo [Glockshuber et al., 1990]. The first two methods are advantageous 
because they provide considerably more stability to the antibody fragment 
than the linker approach, however they are not as universally applicable. A 
range of different linkers have been used, all of which tend to be hydrophilic 
and flexible. A sequence most frequently adopted for ScFv construction is 
(GIy4Ser)3- This 15-residue linker was designed to be unstructured and flexible 
to avoid strain on the native VH and VL domain interactions and its 
hydrophilic nature should reduce interference at the hydrophobic domain 
interface. The variable chains have been linked effectively in both 
orientations, Vjý-Iinker-VH and VH-linker-VL [Huston et al., 1993]. 
1.2.1.3 Single Domain and Smaller Antibody Entities 
The next smallest units available for antigen binding are the VH or VL 
domains. Both VL and VH have a rather hydrophobic interface which is 
necessary for heterodimer formation [Chothia et al., 19851. Different 
consequences result if both are not present. The VL domains tend to dimerise 
[Azuma et al., 19741, thus blocking the antigen binding site. This 
homodimerisation phenomenon is not observed for the VH domains which 
therefore have a tendency to be rather insoluble. A proportion Of VH 
fragments will remain soluble, but the exposed hydrophobic surface can lead 
to non specific interactions which may be wrongly interpreted as specific 
antigen binding. The formation of complexes between antigen and heavy 
chains has been demonstrated [Spielgelberg and Weigle, 1966., Ward et al., 
19891, but the viability of using single VH domains to obtain high affinity 
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antigen binding has to be questioned. 
Attempts have been made to bind antigens with even smaHer peptides 
derived from the CDR regions of antibodies [Williams et al., 19891. The affinity 
of such binding is very low (103-106 mol-1). 
1.2.2 The Generation of Immunoglobulins 
In the immune system, antibodies are created during the differentiation 
of hematopoietic stem cells into B lymphocytes. The sequence diversity for 
antibody binding sites is generated by the rearrangement of variable gene 
segments (VD and j regions) to form variable genes [see Tonegawa 1983 for 
relevant review]. Because the potential diversity of the primary immune 
repertoire is far greater than the number of antibody displaying cells, each of 
these cells is likely to display an immunoglobulin of unique structure and 
antigen binding specificity. 
Antibodies are displayed on the surface of the B lymphocytes. Antigen 
bound by a specific antibody is endocytosed, processed and presented to helper 
T cells in association with molecules of the major histocompatibility complex 
(class 11). This induces the proliferation and differentiation of the relevant B 
lymphocyte to either plasma cells (which secrete considerable amounts of 
antibody into the bloodstream) or to memory cells which are involved in 
subsequent immune responses to the same antigen. The rearranged variable 
genes of the the memory cells undergo somatic mutations, resulting in the 
generation of altered antibodies, some of which have higher affinities than 
the initial antibody to the original antigen [Roitt et al., 1993]. 
1.2.3 Antibody - Antigen Interactions 
Greater understanding of the nature of antibody-antigen interactions of 
immune complexes has been gained through X-ray crystallographic studies 
and molecular modelling [Poljak et al., 1973 and see Webster et al., 1994 and 
Rees et al., 1994 for relevant recent reviews]. The size, shape and charge 
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composition of the antigen binding site is defined by the length and 
configuration of amino acids in the six CDR loops. The number of 
hypervariable loops actually involved in antigen binding varies [Wilson and 
Stanfield, 19931. Despite various proposals [Kelley and CyConnell, 1993; Teno et 
al., 1993; Ito et al., 19931, the thermodynamic basis of the antigen-antibody 
interactions is still under debate. However, evidence suggests that water 
molecules may play a key role in improving the fit between the interacting 
surfaces [Mariuzza and Poljak, 19931. Several examples of such an 'induced fit' 
mechanism for antigen- antibody interactions have been identified [such as 
Bhat et al., 1990; Rini et al., 19921 and it seems likely that this is a common 
phenomenon [see Wilson and Stanfield, 1993 for a relevant recent review]. 
1.2.4 Polyclonal Antibodies 
Polyclonal antisera. derived from an immunised source are effective 
reagents in most immunochemical techniques [Harlow and Lane, 19881. They 
are relatively easy to obtain, but their supply is dependent on the animal in 
which they are raised. Polyclonal antisera contain a heterogenous mixture of 
antibodies which will have a specificity biased towards the unnmunogen, but 
will also recognise many other antigens. The heterogeneity of the antisera is, 
however, reduced with repeated immunisations [Harlow and Lane, 19881. 
Polyclonal antisera will usually contain antibodies that bind to a number of 
sites on an antigen, although one epitope is likely to be dominant. Multiple 
binding confers the advantage of higher avidity which makes them 
particularly useful tools for immunoprecipitations. Lack of specificity of 
polyclonal antisera can be a problem in certain immunochemical techniques. 
The preparation of homogeneous antibodies with a defined specificity was 
only possible after the development of hybridomas. 
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1.2.5 Monoclonal Antibodies 
Since the mid 1970's, hybridoma technology [Kohler and Milstein, 19751 
has led to many practical applications for monoclonal antibodies in research, 
industry and medicine. They are produced by the immortalisation of 
lymphocytes from an immunised animal by fusion with myeloma cells. Stable 
hybridomas secreting a monoclonal antibody (Mab) of the required specificity 
are identified by extensive screening. The technology has improved over the 
years. Manipulation of DNA sequences encoding specific Mabs has enabled the 
construction of a new generation of engineered antibodies [Winter and 
Milstein, 19911. This includes a number of 'humanised' rodent antibodies 
[Winter and Harris, 19931 where rodent-derived CDR regions are grafted into 
a human-derived antibody. Humanised antibodies have a greatly reduced 
immunogenicity to humans, relative to rodent-derived Mabs, and are 
therefore very useful clinical tools [Hale et al., 1988; Isaacs et al., 19921. 
The production and use of monoclonal antibodies does have 
limitations. Despite the painstaking and lengthy processes involved in 
obtaining hybridomas that produce Mabs, only a fraction of the B cells from an 
immunised source are successfully immortalised, at best a few hundred 
individual clones from a potential repertoire of tens of millions. In addition, 
the production of human monoclonal antibodies is restricted by the limitation 
of human immunisation protocols and the lack of a myeloma cell line that 
can routinely produce stable hybridomas when fused to human B cells [James 
and Bell, 1987; Thompson, 19881. 
On commencement of this project, a selection of novel, monoclonal 
antibodies, raised to synthetic peptides corrisponding to specific regions of 
CFTR, were available. However these antibodies had not been fully 
characterised. 
14 
1.2.6 Combinatorial Antibody Libraries 
More recently vector systems have been described that enable antibody 
fragments to be produced and isolated in prokaryotic systems (see section 
1.2.6.2 below). The concept of the combinatorial approach to antibody 
production is based on the ability to directly clone diverse repertoires of genes 
coding for the antigen binding regions of the heavy and light chain 
immunoglobulin molecule in an appropriate expression vector. The two 
chains are cloned in a random combinatorial manner, such that any light 
chain could be joined with any heavy chain. The genes are then expressed to 
produce antibody fragments potentially capable of binding antigen. The 
antibody fragments are then exposed to antigen to directly select for binding 
combinations of heavy and light chains. The development of oligonucleotides 
capable of priming the amplification of heavy and light chain variable gene 
repertoires (see section 1.2.6.1 below) and the demonstration that functional 
antibody fragments can be expressed in Ecoli. (see section 1.2.6.2 below) paved 
the way for the construction of combinatorial antibody libraries. 
1.2.6.1 Amplification of Antibody Fragments by Polymerase Chain Reaction 
To amplify a target sequence by polymerase chain reaction (PCR), 
oligonucleotide primer sequences need to be designed to anneal to either end 
of the target sequence [Saiki et al., 19851. Amplification of antibody genes by 
PCR was initially demonstrated from hybridomas [Larrick et al., 1989a]. The 
first report of using 'universal' PCR primers, suitable for amplifying a range of 
heavy and light chain variable regions, was a key step towards making 
expression repertoires of rearranged V-regions [Orlandi et al., 1989; Larrick et 
al., 1989b]. The incorporation of restriction sites into the primers facilitates 
direct cloning into an appropriate expression vector. Nucleotide sequences of 
the variable region genes were extracted from the Kabat data base where all 
known antibody sequences are listed [Kabat et al., 19871. Areas where 
nucleotide sequences were sufficiently conserved were used to design 
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degenerate PCR primers. The design of further sets of PCR primers has been 
prompted by the continuously increasing knowledge of antibody sequences. 
These include primer sets for the amplification of human, mouse and rabbit 
antibody repertoires, with back primers based in the V-gene region and 
forward primers based in the J-segment or the constant region [e. g. Sastry et al., 
1989; Huse et al., 1989; Jones and Bendig, 1991; Kang et al., 1991a; Persson et al., 
1991; Marks et al., 1991a; Orum. et al., 1993; Zhou et al., 1994; Sassano et al., 
19941. 
LZ6.2 Cloning Antibodies in EcolL 
The development of genetic engineering has made it possible to express 
antibodies in E. coli. [Pluckthun and Skerra, 1989; Pluckthun, 19921. Much is 
known about prokaryotic gene expression systems and they offer a number of 
important advantages, which include: 
" The fast rate of E. coli. growth. 
" The efficient transformation of E. coli. with DNA. 
" The availability of selection markers. 
" The ability to genetically manipulate cloned DNA using the immense range 
of molecular biological techniques available. 
* The fact that larger scale fermentation is far less expensive and involves 
more straight forward conditions than are required for eukaryotic systems. 
An essential requirement for a good antibody expression system is that 
the antibody fragment is expressed in a functional state so that the selection or 
purification procedures can make use of the antigen binding property. 
Initial reports were of direct expression of antibody fragments without a 
signal sequence [Boss et al., 1984; Kenton et al., 19841. Subsequently, the 
expression of antibody fragments in cytoplasmic fusion proteins [Baldwin et 
al., 19891 and in secreted fusion proteins [Pluckthun and Skerra, 1989] were 
described. A leading development was the employment of bacterial signal 
sequences to enable expression of secreted Fv [Skerra and Pluckthun, 1988] and 
16 
Fab, [Better et al., 1988; Better and Horwitz, 19891 antibody fragments that were 
shown to bind antigen. 
The success of signal peptide strategy was due to the ability to mimic in 
E. coli. the normal folding and assembly pathway in the eukaryotic cell. In 
antibody producing cells, heavy and light chains are targeted to the lumen of 
the endoplasmic reticulum. where N-terminal signal sequences are cleaved off 
prior to the assembly of the antibody molecule [Wall and Kuehl, 1983]. The 
periplasm encapsulated by the inner and outer membranes of E. coh. provides 
an equivalent oxidative environment to that found in the endoplasmic 
reticulum [Wulfing and Pluckthun, 1994]. This provides conditions for the 
necessary steps of protein foldin& disulphide bond formation and association 
of heavy and light chains into heterodimeric: molecules to produce functional 
antibody molecules. A further advantage of periplasmic assembly is a 
reduction of the problem of protein degradation found in cytoplasmic 
expression systems. This reduction is due to the presence of fewer proteases in 
the periplasm, the protection achieved by disulphide bond formation and the 
folding to globular domains [Pluckthun, 19911. Although correct folding of 
secreted heterologous proteins had been previously demonstrated [Briggs et al, 
19861, antibody formation in the periplasm of E. coli. was the first 
demonstration of heteromeric assembly. The demonstration that antigen 
binding Fv and Fab fragments could be functionally expressed in E. coli. was a 
major advance leading to the development of antibody expression libraries. 
As yet, there are no reports of the efficient expression of correctly folded 
whole antibodies ( i. e. including the Fc region) in Exo1i.. Not only is the large 
size of the entire antibody molecule a limiting factor, but also many of the 
functions of the whole antibody molecule depend on proper glycosylation of 
appropriate sites on the constant regions. Most antibodies are glycosylated in 
the CH2 domain and others such as ISA and IgM can be glycosylated in the CH1 
and other domains [Nisonhoff et al., 19751. Glycosylation of IgG is essential for 
the efficiency of the constant domain effector functions [Tao and Morrison, 
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19891. It is also thought that glycosylation of the CH2 domain may be an 
important requirement for the correct folding and the stability of the antibody 
structure, because at least in IgG1, only sugar residues are involved in the 
interaction of the two domains [Sutton and Phillips, 19831. E. coli. cannot 
glycosylate proteins, therefore for Fc expression a eukaryotic host is preferred 
[see Morrison 1992 for relevant review]. Eukaryotic expression systems should 
be considered as complementary to prokaryotic systems and have been used in 
tandem to produce whole antibodies [Bender et al., 1993; Jespers et al., 19941. 
DNA encoding for antigen binding antibody fragments that are selected from a 
phage library can be subcIoned into a eukaryotic expression vector together 
with DNA encoding the rest of the complete antibody molecule. Thus fully 
glycosylated antibodies containing antigen selected variable sequences can be 
expressed in eukaryotic cells. However, glycosylation is not necessary for the 
functional expression of antigen binding antibody fragments because most 
antibody variable regions do not contain glycosylation sites and it has been 
shown that glycosylation of the whole molecule normally has no influence on 
the antigen-binding properties of the antibody [Wall and Kuehl, 19831. 
I. M. 3 Combinatorial Libraries in Lambda Phage 
The coding sequences for numerous immunoglobulin heavy and light 
chain antigen binding sequences were inserted in a random combinatorial 
manner into modified bacteriophage %vectors (called %Zap vectors [Short et 
al., 19881) and expressed in E. coli. to produce the first antibody combinatorial 
library [Huse et al., 1989]. The basic steps in the production of antibody 
fragments for cloning and expression in a bacteriophage X library are outlined 
below and summarised in fig. 1.3. 
STEP 1- mRNA is isolated from an appropriately immunised source. 
STEP 2- mRNA is converted to cDNA by reverse transcription. 
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Fig. 1.3 Cartoon representing the basic steps in 
the preparation of antibody gene segments for 
cloning into a bacteriophage k expression library. 
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STEP 3- Heavy chain specific and light chain specific primers are used to 
amplify cDNA sequences by PCR. 
STEP 4-A heavy chain library is prepared by pooling and ligating the heavy 
chain amplification products into aX Zap heavy chain vector and, likewise, a 
light chain library is prepared by pooling and ligating the light chain 
amplification products into aX Zap light chain vector. The vectors were 
designed to have antisymmetric EcoR 1 and Not 1 restriction sites flanking the 
cloning and expression region so that a library expressing light chains could be 
combined with one expressing heavy chains in order to construct a 
combinatorial antibody expression library. 
STEP 5- To construct a library for coexpression, the right arm of the the heavy 
chain vector is digested at multiple Hind 111 sites while the left arm of the 
vector containing the heavy chain inserts remains intact. Similarly the left 
arm of the light chain vector is digested at multiple MIu 1 sites while the right 
arm of the vector containing the light chain inserts remains intact. Both 
products are then digested with EcoR 1 and ligated to create a combinatorial 
library. 
Once assembled, the 1% phage combinatorial antibody libraries are 
incorporated into bacteriophage with an in vitro packaging extract and, in turn, 
are infected into E. coli. (see Fig. 1.4a). Antibody molecules are transcribed in 
the E-coli. and subsequently directed to the periplasmic space by a leader signal 
incorporated in the expressed region. The antibody fragment is able to fold 
correctly in the periplasmic space before it is secreted from the cell. Expressed 
antibody fragments that bound to antigen are identified in a filter lift plaque 
assay. The antibody fragments are 'lifted' from phage plaques grown on E. coli. 
lawns using nitrocellulose filters and subsequently incubated with labelled 
antigen. Detection of bound antigen at certain locations on the filter identifies 
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This methodology was first used to express Fab fragments from an immunised 
mouse [Huse et al., 1989; Caton and Koprowski, 1990] and subsequently to 
generate aX phage Fab library derived from immunised human peripheral 
blood lymphocytes [Mullinax et al., 1990; Persson et al., 19911. Although the 
construction of the X phage libraries was successful, the screening procedure 
had the disadvantages of: 
0 being very laborious because they were solid phase (i. e. based on membrane 
supports); 
ii. ) requiring a large amount of antigen; 
iii. ) potentially revealing false positives with certain antigens that bind to the 
membranes in the absence of antibodies. 
Because of these intrinsic problems in library screenin& this system is limited 
by the size of the combinatorial library that can be effectively examined 
(approximately 106 clones). 
1.2.6.4 Combinatorial Libraries in Filamentous Phage 
An alternative approach to screening larger libraries involves the 
expression of antibody fragments on the surface of filamentous phage. New 
expression systems have been developed, inspired by a method where diverse 
peptides are displayed on the surface of phage [Smith 1985; Palmer and Smith, 
1988; Scott and Smith, 1990; Greenwood et al.; 1991 and see Cesareni, 1992 for 
relevant review]. In these systems, an antibody fragment is cloned into a 
phagemid vector (see section 1.2.6,4.2 below) next to a gene encoding a phage 
coat protein and subsequently expressed attached to the coat protein on the 
surface of the phage (see fig. 1.4b). Such surface expression allows the selection 
of specific antibodies based on their ability to bind to immobilised antigen. The 
phage particles displaying a particular antibody fragment contain the gene 
encoding that fragment, thus creating a 'genetic display package'. This mimics 
the immune system where the rearranged gene encoding an antibody is found 
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within the B lymphocyte on whose surface the antibody is displayed. 
1.16.4.1 Filamentous Bacteriophage 
Filamentous phage are long thin bacteriophage with a diameter of 6 to 
10 nm and a native length of about 1-2tim, however the length can vary 
according to the length of DNA encapsulated by the phage coat (Model and 
Russel, 19881. They consist of a single molecule of circular single stranded DNA 
contained within a protein coat (Beck et al., 1978; Newman and Swinney, 1977]. 
On completion of their life cycle, filamentous phage are secreted into the 
surrounding medium without damaging the host cell envelope (in contrast to 
virulent bacteriophage which lyse the infected bacterial cell) [ see Rasched and 
Oberer, 1986 for a review]. 
The phage utilise the replication machinery of the host cell. The 
infecting single stranded circular DNA (the (+) strand) is converted to the 
double stranded replicative form (RF) by the combined action of the host RNA 
polymerase and the host DNA synthesis apparatus. The RF molecule serves as 
a template for transcription and protein synthesis. Subsequently the RF form 
undergoes rolling circle replication to generate single (+) strand DNA which 
either undergoes the same reaction as the incon-ting strand (i. e. becomes a new 
RF molecule) or is sequestered for packaging into new phage particles [Model 
and Russel, 19881. 
While DNA synthesis goes on, there is concomitant synthesis of phage 
encoded proteins. The phage genome encodes 10 proteins of which 5 are virion 
structural proteins, 3 are necessary for phage DNA synthesis and 2 are required 
for phage assembly [Beck and Zink, 19811. In addition, there is an 'intergenic 
region' which does not code for proteins, but contains signal sequences for the 
initiation of synthesis of both the (+) and (-) DNA strands, the initiation of 
capsid formation and the termination of RNA synthesis [Model and Russel, 
19881. 
The phage coat is made up of approximately 2710 copies of a 50 amino 
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acid helical protein, the product of gene VIII [Pratt et al., 1969; Newman and 
Swinney., 19771. Both ends of the phage particle have structures formed by 
minor coat proteins, the products of gene VII and IX on one end and of VI and 
HI on the other end. There are thought to be 3 to 5 copies of each of the minor 
coat proteins on each phage particle [Rasched and Oberer, 1986]. 
The genes encoding the major coat protein VIII (g8p) and the minor coat 
protein III (g3p) have been used to generate fusion proteins, facilitating the 
expression of antibody fragments on the surface of the phage particle (see 
section 1.2.6.4.3 below). These two coat proteins have a number of features in 
common. Both proteins have an acidic amino terminus which is exposed to 
the outside of the mature phage particle. They have a central hydrophobic core 
and carboxyl termini which are basic in nature and are an integral part of the 
phage coat [Armstrong et al., 1983]. 
The fate of the g3p and g8p coat proteins on bacteriophage infection of 
E. coh. and subsequent extrusion is represented in fig. 1.5. On infection, the 
phage coat is removed and the g8p and g3p coat proteins are deposited in the 
inner membrane of the host cell [Trenker et al., 19671. During phage replication 
both g8p and g3p are initially synthesised as precursor proteins with amino 
terminal signal peptides [Sugimoto et al., 1977; Wickner et al., 1978]. These new 
coat proteins are also deposited in the inner membrane prior to phage 
assembly [Smilowitz et al., 1972]. In phage packaging the replicated viral DNA 
strands become associated with the inner membrane and encased by the coat 
proteins as they pass out of the host with the g3p proteins emerging last 
[Armstrong et al., 1983; Nambudripad et al., 19911. 
Proteolytic cleavage of g3p with subtilisin yields two similarly sized 
domains [Armstrong et al. 1981] which have distinct functions. The exposed 
amino terminal domain is responsible for phage infection as it binds to the 
phage receptor on the F pilus of male bacteria [Nelson et al., 1981], whereas the 
membrane bound carboxyl terminal domain has a morphogenic role in the 
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Crissman and Smith, 19841. After production of the g3p, the host bacterium 
becomes resistant to further bacteriophage infection [Boeke et al., 19821. 
The filamentous phage are resistant to pH extremes and proteolytic 
(except with subtilisin (see above)) and nucleolytic digestion. They are, 
however, sensitive to detergents, organic solvents and mechanical shearing 
[Marvin and Hohn, 1969; Rasched and Oberer, 19861. 
1. Z6.4.2 Phagemid Expression Vectors 
Phagemid systems have been developed in which the benefits of phage 
and plasmid vectors are combined [Dente et al., 1983; Vieira and Messing, 19871- 
The phagemid vector incorporates both bacteriophage and plasmid origins of 
replication enabling phagemids to be propagated as plasmids within a bacterial 
cell or, with the aid of helper phage, to be packaged into recombinant phage 
particles. Helper phage is added to provide the phage protein genes required 
for the replication of phagemid DNA and assembly of the mature phage 
particles. A plasmid derived selectable marker for antibiotic resistance is 
contained within these phagemid vectors. 
L2.6.4L3 Antibody Display Phagemid Systems 
Several variations of antibody phage display vectors have been 
described. Antibody fragments have been fused to the amino terminal domain 
of g3p [Hoogenboom et al., 1991 and Breitling et al., 19911, the carboxyl domain 
of g3p [Barbas et al., 1991, Garrard et al., 1991 and Akamatsu et al., 19931 and to 
g8p Wang et al., 1991b, Chang et al., 1991 and Huse, 1992; Gram et al., 19921. Each 
of these systems has involved PCR amplification of the relevant regions of 
antibody genes. The oligonucleotide primers used have included rare 
restriction sites in order to reduce the chances of digesting the imported 
immunoglobulin genes when restricting PCR products prior to cloning 
[Chaudary et al., 1990; Soderlind et al., 19921. The two systems adopted within 
this study are outlined below. More extensive descriptions are given in the 
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introductions to the relevant chapters. 
1.2.6.4.3.1 pCANTABS 
This phagemid vector was developed by Cambridge Antibody 
Technology and is commercially available from LKB-Pharmacia. In this system 
the antibody variable regions are constructed into a single gene (ScFv) using a 
DNA linker fragment and then cloned between the native leader sequence and 
the amino terminus of the g3p. The g3p leader sequence directs the fusion 
protein to the inner membrane of the E. coli. and the ScFv assembles in the 
periplasm. 
1. Z6.4.3.2 pComb3H 
This phagemid vector is a modified version of pComb3 [Barbas et al., 
19911 and is designed for the cloning of Fab fragments. It has been derived from 
the phagemid pBluescript [Short et al., 19881. The heavy and light chains are 
cloned sequentially into the phagemid vector. The heavy chain is fused to the 
carboxyl domain of the g3p. Appropriate signal sequences direct the fusion 
protein and the light chain to the periplasmic space of the Exo1i.. The g3p, 
domain with the heavy chain fused to it is anchored in the inner membrane. 
The Fab fragment is assembled as the light chain combines with the anchored 
heavy chain. 
1.2.6.4.4 Strategies for Phage Display of Antibody Fragments 
The detailed methods for the two systems used within this study are 
given in the appropriate chapters. However, the basic steps required for 
expressing antibody repertoires using phage display technology are outlined 
below and summarised in Fig. 1.6. 
BOX 1- RNA is prepared from tissue rich in antibody producing cells (e. g. 
spleen, bone marrow or peripheral blood lymphocytes) from immunised or 
non-immunised animals or humans. 
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BOX 1 Preparation of RNA from 
Spleen, Bone Marrow, PBLs 
BOX 2 cDNA synthesis PCR of antibody variable genes 
Restriction of PCR products 
BOX 3 Ligation of PCR products 
into the phagemid vector 
BOX 4 
Transformation and 
culture of the phagemid 
library 
BOX 5 
Rescue of the library with 
helper phage 
Fig. 1.6 Basic strategy for expressing combinatorial 
antibody fragments on the surface of bacteriophage. 
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BOX 2- Reverse transcription of antibody heavy and light chain mRNA into 
first strand cDNA and amplification of the genes by polymerase chain reaction 
(see section 1.2-6.1 above). When ScFv fragments are being cloned, additional 
PCR assembly and further amplification steps are required. The prepared 
antibody fragments are digested with the appropriate restriction enzymes ready 
for ligation. 
BOX 3- The antibody fragments are cloned into the prepared vector adjacent to 
a leader peptide of a protein that is transported to the periplasm. (This signal 
sequence can be bacterial or phage in origin). As a result of cloning, some part 
of the antibody fragment is attached to the required domain of a bacteriophage 
coat protein (either to the amino or carboxyl domains of g3p or to g8p). For the 
construction of Fab fragments, the heavy and light chains are cloned 
sequentially into the phagemid vector. 
BOX 4- The cloned antibody libraries are transformed into a suitable E. coli. 
strain. The bacterial strains used allow high efficiency transformation and 
harbour an F factor that encodes the proteins forming the F pili, necessary for 
the absorption of the male specific phage. Bacterial cells carrying phagemid are 
selected by growth in medium containing the appropriate antibiotic dependent 
on the antibiotic resistance gene present on the phagemid (usually 
lactamase). 
BOX 5- Helper phage is added to the library culture to initiate phage 
replication and eventually yield recombinant phage particles that display 
antibody fragments. Since the helper phage contains a defective origin of 
replication, the phagemid DNA is more efficiently replicated and packaged 
than the helper phage genome [Vieira and Messing, 19871. Helper phage with a 
selectable marker are used such that infected bacteria can be selected. The 
majority of phage produced therefore contain phagemid DNA encoding the 
antibody fragment expressed on their surface. 
A combinatorial antibody library thus produced can be selected or 
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enriched for phage displayed antibody fragments capable of binding a specific 
antigen. This procedure is called 'panning'. 
1.2.6.4.5 Selection of Antigen Binding Clones by Panning 
Each phage particle in a combinatorial library contains the recombinant 
genome encoding the specific antibody displayed on its surface, allowing the 
antibody gene to be selected directly using the binding properties of the 
expressed protein. 
The random combinatorial principles of the library construction result 
in a complete scrambling of association between protein sequences encoded by 
the heavy and light chain genes, i. e. any heavy chain can associate with any 
fight chain. As a result, the original heavy and light chain pair are unlikely to 
be recovered [Winter and Milstein, 19911 and high affinity (>108 mol-1) antigen 
binding heavy and light chain combinations are likely to be rare. Certain 
factors which improve the frequency of antigen binders in a library have been 
identified: 
0 Chain promiscuity - the ability of particular heavy chains to effectively bind 
antigen when combined with different light chain partners [Hudson et al., 
1987; Caton and Kaprowski, 1990; Clackson et al., 1991; Kabat and Wu, 1991; 
Collet et al., 19921. 
9 Immunised sources - RNA from an immune source in library construction 
[Barbas et al., 1991; Clackson et al., 19911. However, this is not always possible, 
for example tolerance mechanisms prevent a human immune response to self 
antigens. Methods are being established to circumvent this problem where 
necessary (see section 1.2.6.4.6 below). 
Affinity purification of phage antibodies by 'panning' makes it possible 
to select even rare antigen binding antibody combinations from a library. 
Antibody fragments can be displayed to antigen in the following ways: 
antigen adsorbed to a plastic surface [Barbas et al., 1991; Marks et al., 1991b], 
columns of antigen linked to a matrix [McCafferty et al., 1990], 
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" biotinylated antigen in solution, subsequently captured on streptavidin 
coated magnetic beads [Hawkins et al., 1992], 
" antigen expressed on the surface of an immobilised cell [Marks et al., 1993]. 
Non-binders can be removed by washing and the bound phage can then be 
eluted at low pH [Barbas et al., 19911, high pH [Marks et al., 1991b] or by addition 
of excess antigen [Clackson et al. 1991]. Successive rounds of selection can be 
achieved by infecting bacteria with the enriched phage and panning the phage 
prepared from the culture. The enrichment resulting from repeated rounds of 
selection should be sufficient to isolate specific phage occurring only singly in 
the initial library (i. e. about 1 in 107) [Burton and Barbas, 1993a]. 
Selected clones, either as phage [McCafferty et al. 19901 or as expressed 
antibody fragment [Barbas et al., 1991; Hoogenboom et al., 19911, can be screened 
for reactivity with antigen, usually by conventional enzyme linked 
immunosorbant assay (ELISA). 
1. Z6.4.6 Recent Advances in Antibody Phage Display Technology 
Phage display technology has provided particular advantages in the 
production of antibodies against human antigens [Burton and Barbas, 1993b; 
Griffiths and Hoogenboom, 19931. Several approaches have been adopted to 
circumvent the ethical and self-tolerence problems of human immunisation 
[French, 19921. 
In one method, libraries have been constructed from mRNA derived 
from the bone marrow or peripheral blood lymphocytes of a sero-positive 
donor, being an individual shown to have antisera with high antibody titres 
against particular antigens [Burton et al., 19911. Such humans have not been 
actively immunised, but have come in contact with antigen, usually in the 
form of an infectious disease. For donors who had not recently been exposed to 
antigen, the library could be constructed from RNA isolated from memory 
cells that had been selected with antigen coated magnetic beads [Hawkins and 
Winter, 1992]. Antibody fragments against several viral antigens have been 
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isolated from these human combinatorial libraries. Some of these anti-viral 
antibodies appear to be capable of inhibiting the infection of the particular 
virus, i. e. neutralising the virus by binding to its surface [Barbas et al., 1992b, 
1992c; Williamson et al., 1993; Barbas et al., 1993]. Severe combined immune 
deficiency (SCID) mice [Bosma et al., 19831 can be used in conjunction with the 
combinatorial library approach [Duchosal et al., 1992]. Peripheral blood 
lymphocytes can be transferred from a sero-positive donor to SCID mice which 
are then stimulated with the appropriate antigen to boost a human antibody 
response outside the human body [Mosier et al., 1988). RNA derived from 
antibody producing cells of these SCID mice can then be used to construct a 
combinatorial library from which antibody fragments binding the antigen can 
be selected. 
An alternative approach which avoids human immunisation is to 
prepare naive libraries using RNA from an unimmunised source. However, 
the antibodies selected from such libraries tend to have only low or medium 
affinity (105-107 Mol-1) [Marks et al., 1991b; Gram et al., 19921. Several strategies 
have been proposed for improving antibody affinities [Chiswell and 
McCafferty, 1992; Marks et al., 1992b]. These include chain shuffling (the 
process of pairing a specific heavy chain with several different light chains and 
vice versa) [Kang et al., 1991b; Marks et al., 1992a; Barbas et al., 1993d], or in vitro 
mutagenesis using, effor-prone PCR [Lueng et al., 1989; Hawkins et al., 1992; 
Gram et al., 19921, spiked oligonucleotide primers [Derbyshire et al., 1986; 
Hermes et al., 19891 or growth of phage in mutator strains of Exoli. [Schaaper, 
19881. 
A process of 'guided selection' has been used to obtain antigen specific 
human antibodies from phage display repertoires using rodent derived 
monoclonal antibodies as a template [Johnson and Chiswell, 1993; Jespers et al., 
1994; Figini et al., 1994). In this approach, the rodent derived heavy chain is 
expressed paired with a phage library of human light chains. The phage are 
selected for binding to the specific antigen. The selected human light chains are 
32 
then paired with a repertoire of human heavy chains displayed on phage. The 
phage are selected again to obtain human Fab fragments that bind the same 
antigen as the original rodent derived monoclonal antibody. 
Recently a novel approach of combinatorial infection has been used to 
increase a possible library size [Waterhouse et al., 19931. This involves the 
infection of a library of light chains in a phagemid vector into Exo1i. that 
have already been transformed with a library of heavy chains in a plasmid 
vector. In viw recombination of the two libraries occurs to create a phage 
combinatorial library whose diversity is only limited by the efficiency of E-coli. 
infection (>1012), rather than transformation (: r. 108). Theoretical studies have 
suggested that the larger and more diverse an antibody repertoire, the greater 
the chance of finding high affinity antibodies [Perelson and Oster, 19791. High 
affinity human antibodies have been isolated from a large antibody repertoire 
[Griffiths et al., 19941. 
As an alternative to the use of human genetic material, synthetic or 
semi-synthetic antibody libraries have been produced from cloned germline 
antibody genes or by randomising regions of single antibody clones [Barbas et 
al., 1992a; Hoogenboom and Winter, 1992 Lerner et al., 1992; Akamatsu et al., 
1993; Barbas et al., 1993a; 1993b; Garrard and Henner, 1993]. In semi-synthetic 
libraries the antibody frameworks are derived from natural antibodies, but 
some or all of the CDRs are replaced by synthetic gene segments. 
1.2.6A. 7 Future Prospects for Antibody Phage Display Technology 
Antibody phage display systems have progressed rapidly and are 
becoming a powerful research tool. Immunised sources still seem to be the 
most appropriate for the construction of libraries with high affinity antibodies. 
However, it seems likely that with a greater appreciation of antigen-antibody 
interactions, the current methods for the production of phage display 
antibodies will be adapted to facilitate the isolation of high affinity antibodies 
to any antigen without the need for animal immunisation. The rapid progress 
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towards this goal has been promoted by the application to phage display 
technology of various known biological and molecular techniques, many of 
which are outlined above (section 1.2.6.4.6). Further advancement of the 
technology will no doubt be enhanced by the adoption of other innovative 
developments such as mutagenic DNA shuffling Csexual PCR') [Stemmer, 
1994a; 1994b; Smith, 19941 or transgenic mice that express human antibodies 
[Lonberg et al., 1994; Green et al., 19941. 
In 'sexual PCR', recombination is promoted artificially by cleaving an 
initial population of DNA molecules into random fragments followed by a 
number of cycles of PCR in the absence of added primer. Fragments with 
complementary sequences (from the same or different original molecules) 
recombine during the annealing step to produce 'shuffled' molecules which 
are further amplified in a second conventional PCR with added primers. This 
process could be adapted to mimic the somatic mutation of the natural 
immune system. 
Two groups have recently reported the insertion of elements of the 
human heavy and light chain locus into mice in which production of 
endogenous murine heavy and light chain was disrupted [Lonberg et al., 1994; 
Green et al., 19941. These transgenic mice have been shown to express specific 
human antibody sequences in response to antigenic challenge. They may 
therefore prove to be an important immunisable source for the production of 
phage display libraries of human antibody sequences. 
As antibody phage display technology continues to develop, it could 
become as widely used as the current monoclonal and polyclonal approaches. 
Antibody fragments isolated from phage display libraries will no doubt prove 
to be valuable tools in therapy and research. 
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1.3 PROJECT'OBJECIMS 
The primary objective of this study was to raise a comprehensive range 
of antibodies to CFTR in order to facilitate a greater understanding of the 
topology and distribution of the protein. Such insights would in turn help 
elucidate the seemingly complex range of functions of CF17R and ultimately 
provide necessary information to direct therapeutic approaches to the disease. 
In this study all three methods of antibody production described above 
(polyclonal, monoclonal, and phage display antibodies) have been adopted to 
raise a whole range of antibodies to CFTR. Polyclonal antibodies have been 
raised to CFTR fusion proteins and extensively characterised. Monoclonal 
antibodies raised to synthetic peptides corresponding to different regions of 
CFTR have been further characterised. The emphasis however is on the 
cloning and expression of antibody fragments (from sources immunised 
against CFFR) in combinatorial libraries using two different phagemid vector 
systems (pCANTAB5 and PComb3). The advantages and disadvantages of the 
two systems are compared and contrasted. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 General Chemicals and Materials. 
The following were all purchased from Sigma Chemical Company Ltd., 
UX: Ethidium bromide, HEPES (C81412N204S), octyl phenoxy poly 
ethaxyethanol (Triton X-100), polyoxyethylene sorbitan nionolaurate (Tween 
20), DNAsel, RNAseA, Lysosyme, 5-bromo-4-chloro-3-indole-phosphate 
(BCIP), nitroblue tetrazolium (NBT), N, N', N', N'-Tetrimethylenediamine 
(TEMED), Ponceau S solution, phenyl methyl sulfonyl flouride (PMSF), 
Aprotonin, Benzamidine, Lysosyme, BCIP, ortho-phenylenediamine (OPED) 
and Coomassie Brilliant Blue R. 
Acrylamide/bis-acrylamide stock solutions were obtained from Severn. 
Biotech Ltd. and agarose from FMC Bioproducts. Bind Silane was obtained 
from LKB-Produkter AB. 
Ethylenedinitro tetra-acetic acid disodium salt (EDTA) and Mowiol were 
purchased from CalBiochem Novabiochem (UK) Ltd., bovine serum albumin 
fraction V (BSA) from Park Scientific Ltd., and Marvel from Cadbury. The 
protease inhibitors, Antipain, Leupeptin and Pepstatin A were all supplied by 
Cambridge Research Biochemicals. 
Conjugated antibodies were obtained from Dako Products. Streptavidin 
conjugated magnetic beads were purchased from Dynal, Oslo as was a (MPC-E) 
magnet. 
Radiochemicals were obtained from Du Pont-NEN Ltd., UK. 
Radiolabelled gels were exposed to Amersham Hyperfilm. Polaroid 667 film 
was obtained from Polaroid (UK) Ltd.. 
Ampicillin (Penbritin) and Carbenicillin (Pyropen) were obtained from 
Beecham Research. Tetracycline (Achromycin) was obtained from Cyanamid of 
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Great Britain Ltd. and Kanamycin (Kannasyn) from Sanoji Winthop, Ltd.. 
Penicillin, Streptomycin and Geneticin (G418) were purchased from Gibco BRL 
Ltd.. 
The following were obtained from LKB-Pharmacia: DNA molecular 
weight standard markers, Helper Phage M13KO7, nuclease-free BSA, RNA 
extraction kit (27-9270-01), mRNA purification kit (27-9258-01) and cDNA first 
strand synthesis kit (27-9661-01). Helper Phage VCSM13 was purchased from 
Strategene Ltd., Cambridge. Molecular weight standard markers for protein 
gels were obtained from Amersham International p1c. 
Preparative DNA columns were obtained from Qiagen Inc. and Promega 
Corporation (magic mini prep columns). A Promega TA cloning kit was also 
used. DNA purification columns were obtained from Clontech Laboratories 
Inc.. Centricon microconcentrators were supplied by Amicon Ltd-, UK- 
Sequenase version 2.0 sequencing kit was obtained United States 
Biochemicals (USB), Amersham Life Sciences. 
Restriction endonucleases and their appropriate reaction buffers were all 
obtained from Boehringer Mannheim UK Ltd., as were lithium salts of 2'- 
deoxy-nucleotides, Thermus aquaticus (Taq ) Polymerase, pre-hybridisation 
solution, random prime DNA labelling kit and DNA Ligase. DNA Ligase was 
also obtained from Gibco BRL Life Technologies Ltd.. 
Unless stated otherwise, oligonucleotide primers and peptides 
(including biotinylated peptides) were synthesised within the SERC funded 
Molecular Recognition Centre, University of Bristol. 
Nitrocellulose membranes for Western blotting were obtained from 
Schlescher and Schuell. Millipore 0.025pm membranes were used for 
microdialysis. Dialysis tubing obtained from Medicell International Ltd. was 
used for electroelution of DNA. 
Bacto-tryptone and bacto-yeast extract were obtained from Difco, Detroit. 
Agar was obtained from Lab M, Bury, Lancs. Tissue culture media were 
obtained from Gibco, BRL Ltd.. Sterile pipettes for tissue culture work were 
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obtained from Sterilin Ltd., UK and tissue culture flasks and dishes from 
Costar Europe Ltd., Coming Glass Works and Falcon, Becton Dickinson. 
All other chemicals were purchased from BDH Chemicals Ltd., unless 
otherwise stated and were of AnalaR grade or the purest grade available. 
2.1.2 Bacterial Strains and Growth Media. 
Three different E. coli. strains were used. These were XL1-bIue [Bullock 
et al., 19871, JM109 [Yanish-Perron et al., 19851 and TG2 (a recombination- 
deficient derivative of TG1) [Gibson 19841. 
The foHowing growth media were used: 
LB broth : lOg/ I bacto-tryptone, 5g/ I bacto-yeast extract, 5g/ I NaCl. 
2TY. - 16gll bacto-tryptone, lOg/l bacto-yeast extract, 5g/l NaCl. 
SOBAG: 20g/l bacto-tryptone, 5g/l bacto-yeast extract, 0.5g/l NaCl, lOmM 
MgC12,0.1M glucose and 100jig/ml ampicillin. 
SOC: 20g/l bacto-tryptone, 5g/l bacto-yeast extract, 0.5g/l NaCl, 2.5mM KCI, 
10mM MgC12 and 20mM glucose. 
SB: 30g/ I bacto-tryptone, 20g/ I bacto-yeast extract, lOg/ I MOPS. 
To propagate the E. coli. on solid media, agar was added to the 
ap ropriate broth to a final concentration of 1.6%. Fp 
11.3 Eukaryotic Cell Lines 
A variety of different cell lines were used. They are listed below. 
2wt - C127 cell line transformed with CL3AXBPVXT-NEO vector expressing 
CFTR [Marshall et al., 1994) 
BPV - C127 cell line transformed with CL3AXBPVXT-NEO vector 
not expressing CFIR. 
CaCo2 - human colon carcinoma cell line [Fogh et al., 19771 
Panci - human pancreatic carcinoma cell line expressing Cl-TR 
[Leiber et al., 19751 
38 
C127 - mouse mammary tumour cell line [Lowry et al., 19781 
Heb7a - Hela derived cell line [Wallace et al., 19751 
HT29 - human colon carcinoma cell line [Fogh et al., 19751 
T84 - human colon carcinoma cell line [Murakami et al., 1980] 
2.2 METHODS 
2.11 Small Scale Preparation of Plasmid DNA by Alkaline Lysis 
This method is based on that described by Birnboim and Doly [19791. A 
single colony of E. coli. cells was used to inoculate 5ml of LB amp broth 
containing 100jug/jil ampicillin and incubated at 37*C (or at 30*C when the 
pUEX 1 plasmid was involved [Bressan and Stanley 19871) with vigorous 
shaking for a minimum of 16 hours. The cells were harvested from 3ml of 
culture by centrifugation in a microfuge for 2 minutes. The cell pellet was 
resuspended in 100til of solution I (50mM glucose, 10mM EDTA, 25mM Tris- 
HCl pH8.0). 2001il of solution Il (17oSDS, 0.2M NaOH) was added to lyse the 
cells while incubating on ice for 5 minutes. The solution was neutralised by 
the addition of 1501d of solution III (5M potassium acetate pH4.8). The solution 
was spun in a microfuge for 5 minutes, the pellet was discarded and an equal 
volume of phenol/ chloroform/ isoamyl alcohol (24: 24: 1) added to the 
supernatant. An emulsion was produced by vortexing and ihe two phases were 
separated by spinning in a microfuge for 2 minutes. iml of ethanol was added 
to the upper aqueous phase, the solution mixed and then kept at -20"C for 30 
minutes. The precipitated DNA was collected by spinning in a n-dcrofuge for 15 
minutes. The DNA pellet was washed with 400pl of 7017o ethanol before 
vacuum drying. The pellet was resuspended in 501d of 10mM Tris/HCI, pH8.0 
and 1mM EDTA, pH8.0 (TE buffer) containing 20tig/ ml RNaseA. The resultant 
solution of plasmid DNA was now suitable for analysis by restriction 
endonuclease digestion. 
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This method is based on Promega Wizard Mini Prep system. A single 
colony of E. coli. cells were used to inoculate 5ml of LB amp broth containing 
100pg/jil ampicillin and incubated at 37*C (or at 30"C where the pUEX 1 
plasmid was involved [Bressan and Stanley 19871) with vigorous shaking for a 
minimum of 16 hours. The cells were harvested from 3ml of culture by 
centrifugation in a microfuge for 2 minutes. The cell pellet was resuspended 
200pl of cell resuspension solution (50mM Tris/HCI, 10mM EDTA pH7.5 
containing 100lig/ml RNaseA). 200pl of cell lysis solution (0.2M NaOH, 
1%SDS) was added and mixed by inverting the tube several times prior to 
addition of 2001il neutralisation solution (2.55M potassium acetate, pH4.8). 
Mixing was again achieved by inverting the tube before removing the cell 
debris by spinning in a microfuge for 5 minutes. The supernatant was 
removed to a fresh microcentrifuge tube containing 1ml of Wizard Mini Prep 
DNA purification resin and mixed by inverting the tube. The resin containing 
the bound DNA was decanted into the barrel of a 5ml syringe which was 
attached to the luer-lok extension of a Wizard Mini Prep column. The syringe 
plunger was inserted and the slurry gently pushed into the mini column. The 
mini column was washed with 2ml column wash solution (200mM NaCl, 
20mM Tris/HCI, 5mM EDTA diluted with 50% (v/v) ethanol). The column 
was then dried by placing it in a microcentrifuge tube and spinning for 20 
seconds. The mini column was then transferred to a fresh microcentrifuge 
tube and the DNA eluted by applying 501d H20 to the top of the mini-column 
and spinning for 20 seconds. The resultant solution of plasmid DNA was 
suitable for sequencing or analysis by restriction endonuclease digestion. 
2.2.2 Medium Scale Preparation of Plasmid DNA 
A single colony of E. coli. cells were used to inoculate 5ml of LB amp 
broth containing 10OR91MI ampicillin and incubated at 37"C with vigorous 
shaking for several hours until the broth was turbid. This culture was used to 
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inoculate 100ml LB amp broth, containing 100lig/ml ampicillin, which was 
incubated at 37"C with vigorous shaking for at least 16 hours. Cells were 
collected by centrifugation at 45OOg for 20 minutes at 40C, and resuspended in 
4ml of 50mM Tris/HCl, 10mM EDTA containing 100mg/ml RNaseA. Cell lysis 
was achieved by adding 4ml of 200mM NaOH, 1%'SDS, mixing gently and 
incubating at room temperature for 5 minutes. The solution was neutralised 
by adding 4ml of 2.55M potassium acetate pH4.8 and mixing gently. Cellular 
debris was pelleted by centrifugation at 300OOg for 30 minutes at VC. The 
supernatant was applied to a Qiagen-tip 100 which had been pre-equilibrated 
with 4ml of buffer QBT (75OmM NaCl, 5OmM MOPS, 15% ethanol adjusted to 
pH7.0 and then 0.15% Triton X-100 added). The column was then washed with 
2x1Oml of buffer QC (LOM NaCl, 5OmM MOPS, 15% ethanol, pH7.0). The DNA 
was eluted from the column with 5ml buffer QF (1.25M NaCl, 50mM MOPS, 
1576 ethanol, pH8.2) and precipitated with 0.7 volumes of isopropanol. The 
DNA was recovered by centrifugation at 150OOg at 40C for 30 minutes. The 
DNA pellet was washed with 5ml 707o ethanol and air dried for 5 minutes 
before redissolving in a suitable volume of TE buffer or water. 
2.2.3 Preparation of Total RNA 
RNA was obtained using a LKB-Pharmacia RNA Extraction Kit (27-9270- 
01), following the manufacturer's protocol. Precautions were taken to 
minimise RNA digestion by ribonucleases present in the cells from which the 
RNA was being extracted. For RNA preparation from tissue culture cells the 
extraction buffer containing guanidinium thiocyanate was added directly to the 
cells in the tissue culture flask. For preparation of RNA from animal tissues 
the appropriate tissue (spleen from mice and bone marrow from rabbits) was 
removed aseptically and directly transferred to an aliquot of extraction buffer 
(in an Oakridge tube) [Chirgwin et al., 1979]. This was immediately 
homogenised with a polytron apparatus. RNA was separated from other 
cellular components by centrifugation through a caesium trifluoroacetate 
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(CsTFA) gradient [Okayama et al., 19871. 
ZZ4 Preparation of mRNA from Total RNA 
Total RNA was applied directly to oligo(dT)-cellulose spun columns for 
the affinity purification of polyadenylated RNA supplied in a LKB-Pharmacia 
mRNA Purification Kit (27-9258-01). mRNA was isolated following the 
manufacturer's protocol. 
2.2.5 First Strand cDNA Synthesis 
First strand cDNA was prepared from either total RNA or on mRNA 
using a LKB-Pharmacia First Strand cDNA Synthesis Kit (27-9261-01), 
following the manufacturer's protocol. The reaction was primed with primers 
supplied with the kit, using either 5tig of a Not I-d(T)18 bifunctional primer or 
0.04pg pd(N)6 in the reaction. 
2.2.6 Digestion of DNA with Restriction Enzymes 
Restriction endonuclease digests were carried out at 3711C (unless stated 
otherwise) using the stock concentrated buffers provided with the enzymes. 
The enzymes were generally diluted 1 in 10 in the final reaction solutions. The 
quantity of DNA digested, the amount of enzyme used and the incubation 
time varied according to requirements. 
2.2.7 Polymerase Chain Reaction (PCR) 
DNA sequences were amplified by PCR [Kawasaku 1990; Saiki 19901 in a 
Perkin Elmer-Cetus DNA thermal cycler, using Taq DNA polymerase (2.5 
units) and the reaction buffer supplied by the manufacturer. Added to each 
reaction mix were: i) deoxyribonucleotides (dATP, dCTP, dGTP and dTrP) to a 
final concentration of 0.2mM, ii) 1, uM of each the two specific primers 
required to recognise the DNA template and iii) an appropriate concentration 
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(between lOng and 1jig depending on the source) of template DNA. The 
reaction components were overlaid with mineral oil. Unless otherwise stated, 
PCR reactions were incubated for 1 minute denaturation at 94"C, 2 minutes 
annealing at 52"C and 2 minutes extension at 72*C for 30 cycles followed by a 
10 minute incubation at 72*C to allow complete extension of all the reactions. 
2.18 Purification of DNA on Chromaspin Columns 
Clontech chromaspin columns were used according to the 
manufacturer's protocol for rapid and efficient purification of DNA in the 
following situations: a) to selectively eliminate unextended PCR primers, b) to 
separate DNA away from enzymes and other proteins and c) to remove 
unincorporated nucleotides from DNA labeffing reactions. 
2. Z9 Agarose Gel Electrophoresis 
All gel electrophoresis, was carried out in TAE buffer (0.2M Tris base, 
O. SmM EDTA and 0.12% acetic acid adjusted to pH7.8). Multi purpose agarose 
was used for analytical gels and genetic technology grade (GTG) agarose was 
used for preparative gels. The concentration of agarose in each gel used varied 
depending on the sizes of the DNA fragments to be separated but was chosen 
from the following table. 




Each gel contained 0.2 mg/ml ethidium bromide and the DNA was visualised 
on a UVP UV transilluminator at wavelength of 302nm. Prior to loading 
samples onto the gel, 1/10th volume of sample buffer (0.4% xylene orange, 
1mM EDTA pH8.0 and 50% glycerol) was added. 
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2.2.10 Purification of DNA from Agarose Gels 
Method-A - Phenol Freeze Extraction 
Ethidium stained DNA was illuminated within the agarose gel by UV 
light (as described above) and a gel fragment cut from the gel containing the 
desired DNA band. The gel fragment was diced, transferred to a 1.5ml 
Eppendorf tube and an equal volume of TE buffered phenol added. The 
mixture was vigorously vortexed, snap frozen in liquid nitrogen and 
centrifuged in a microfuge for 15 minutes. The upper aqueous phase was 
removed and saved whilst the lower phenolic phase was back extracted with 
2001A of TE buffer. The two aqueous phases were combined and the DNA 
precipitated by the addition of 1/10th volume of 5M ammonium acetate and 
two volumes of ethanol. The solution was mixed and incubated on dry ice for 
20 minutes or at -70"C for 1 hour. The precipitated DNA was collected by 
centrifugation at 480OOg for 30 minutes at 411C. The DNA pellet was washed in 
7076 ethanol, air dried and resuspended in 101d of TE buffer. 
Method B- Electroelution of DNA 
Ethidium. stained DNA was illuminated within the agarose gel by UV 
fight (as described above) and a gel fragment containing the appropriate band 
was cut from the gel. The gel chip was transferred to a length of pre-boiled 
dialysis tubing (size 5) with 400pl 0.1 x TAE buffer. All the air bubbles were 
removed before the tubing was clipped at both ends and allowed to rest just 
submerged, in an electrophoresis tank containing 0.2 x TAE. Electrophoresis 
was carried out at 200V for 30-60 minutes. The buffer containing DNA was 
illuminated over a UV transilluminator and removed to an Eppendorf tube. 
The solution was chilled on ice for 2 minutes, prior to spinning in a microfuge 
for 10 minutes, to remove any residual gel material. The supernatant was 
removed to a fresh tube, extracted first with an equal volume of phenol and 
then with an equal volume of phenol/ chloroform/ isoamyl alcohol (24: 24: 1). 
The DNA was precipitated out of the supernatant as described above. 
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2.2.11 Quantification of DNA 
The concentration of DNA samples was ascertained on a 0.7% agarose 
plate containing 0.7lig/ml ethidium. bromide. 1pl of the DNA solution to be 
assessed was dotted onto the plate along with 11d of dilutions of plasmid DNA 
(of known concentration). The intensity of fluorescence of the dots was 
examined and compared by illumination with UV. The concentration of the 
DNA sample was estimated from the fluorescence it gave relative to 
fluorescence observed from the plasmid DNA dilutions of known 
concentration. 
2. Z12 Subcloning Procedures 
Unless otherwise stated, ligations were performed in a final reaction 
volume of 20MI using Boehringer Mannheim ligase and ligation buffer. 
Between 50 and 100ng of plasmid vector was used per reaction with a3 fold 
molar excess of "insert" as recommended by Reevie et al., [19881. Ligations 
were incubated at 16*C overnight. The ligation mixtures were microdialysed 
with water on 0.025tum membranes prior to electroporation into Ecoli. 
2.2. IL3 Preparation of Electrocompetent Cells 
Method A -For preparation of TG2 cells [Gibson, 19871 and JM109 cells 
[Yannish-Perron, 19851. 
A single colony of E. coli. was picked from a fresh overnight agar plate 
into 5 ml of LB amp broth and incubated at 370C with vigorous shaking until a 
swirl of cells could be seen (usually about 2 hours). The whole of this culture 
was transferred to 500 ml of LB broth (pre-warmed to 37*Q and shaken 
vigorously at 37"C until the optical density of the culture at 600 nm was 
between 0.5 and 0.7. The cells were then chilled on ice before being harvested 
by centrifugation at 4500 rpm and 411C for 25 minutes in pre-chilled 
centrifugation bottles in a Sorvall ROB. All further manipulations of the cells 
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were performed on ice and all further solutions used were pre-chilled on ice. 
The supernatant was removed and the cells resuspended in 500ml of 1mM 
HEPES, pH7.0 before being harvested by centrifugation as described above. A 
second wash with 200ml 1mM HEPES pH7.0 was performed as described above. 
The cells were resuspended in 50ml of sterile deionised water and harvested as 
described above. The cell pellet was then resuspended in 10ml of 10% glycerol 
in sterile deionised water and harvested as before. The final cell pellet was 
resuspended in 0.5ml of 10% glycerol in sterile deionised water to give a final 
volume of approximately 2ml. Aliquots (usually 40pl) of these cells could then 
be used for transformation by electroporation. Cells not to be used immediately 
could be stored at -7011C following the addition of an equal volume of 40% 
glycerol in sterile deionised water and snap freezing in liquid Nitrogen. Frozen 
cells were defrosted slowly on ice prior to their use in transformation. 
Method B- For the Preparation of XL1-Blue Cells [Bullock et al., 1987] for 
transformation with Fab fragment antibody libraries. 
A single colony was picked from a SB plate containing 10ttg/ml tet into 
10ml SB and incubated overnight at 370C with vigorous shaking. 2.5ml of this 
overnight culture was inoculated into 0.5 litre of SB with 10ml 10% glucose 
and 5ml 1M MgC12. This was incubated with vigorous shaking at 37'*C for 
approximately 4 hours until the optical density of the culture at 600nm was 
between 0.7 and 0.8. The culture was chilled on ice for 15 minutes before being 
harvested by centrifugation at 45OOrpm and 0"C in bottles (pre-chilled to -70"C) 
in a Sorvall ROB. All further manipulations were performed on ice using 
solutions pre-chilled on ice and pipettes chilled at -70*C. The supernatant was 
poured off and the cells were resuspended with gentle pipetting in 250ml 10% 
glycerol prior to recovering the cells by centrifugation as described above. A 
second wash with 250ml 10% glycerol was performed as above. The cellular 
pellet recovered after centrifugation following the second wash was 
resuspended in 25mls 10% glycerol and transferred to a 50ml conical tube (pre- 
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chilled to -70'C). The cells were harvested by centrifugation at 35OOrpm for 15 
minutes at OIC in a Sorvall ROB. The supernatant was decanted off from the 
cells until the loose cell pellet began to dislodge from the bottom of the tube. 
The cells were resuspended briefly, with a pipette, in the solution remaining in 
the tube and immediately aliquoted into 40pl or 200pl volumes into tubes 
placed in a ethanol/dry ice bath so that the cells froze instantaneously. These 
aliquots were stored at -70*C prior to their use in electrotransformation. 
2.2.14 Transformation of Competent Ecoli. by Electroporation 
Electroporation was carried out as described by Dower et al. [19881, in 
0.2cm gap cuvettes; using a Bio Rad gene pulser set at 2.5kV, 250hms and 25jiF. 
A frozen aliquot of cells was defrosted on ice. The DNA to be transformed was 
added to the cells and left on ice for 1 minute before transferring to a cuvette 
pre-chilled on ice. After pulsing the cuvette was immediately flushed with 1- 
3ml SOC medium at room temperature. The cells were usually allowed to 
recover by incubation at 3711C for 1 hour before an aliquot of this solution 
(between 10 and 100pl) was plated onto a LB agar plate containing 100, ug/ml 
ampicillin. The plates were then incubated at 370C (or 300C in the case of cells 
electroporated with the pUEX series of plasmids) for at least 16 hours. 
2.115 Double Stranded DNA Sequencing 
This was performed using the Sequenase version 2.0 kit. 4ýtg of plasmid 
or phagemid DNA in 18gl H20 was used for each sequencing reaction. To the 
DNA solution 21il of 2M NaOH/2mM EDTA was added, n-dxed and incubated 
at room temperature for 5 minutes. The DNA was precipitated by the addition 
of 16pl of ice cold 5M ammonium acetate and 200p] of ethanol. After 
incubation at -20"C for 30 minutes, the DNA was collected by centrifugation at 
480OOg for 15 minutes at VC. The DNA pellet was washed in 70% ethanol, air 
dried and resuspended in 10jul of annealing buffer (40mM Tris/HCI, pH7.5, 
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20mM MgC12,5OmM NaCl) containing lOng of sequencing primer. The 
annealing reaction was performed at 65"C for 5 minutes prior to cooling slowly 
to 35*C over 15-30 minutes and subsequent quenching on ice. The labelling 
reaction was set up by adding 5.5#1 of labelling mixture (0.55liM each of dGTP, 
dCT? and dTTP, 18mM DTT, 5 units Sequenase enzyme and 5mCi a35S dATP 
[800 Ci / mmoll) and incubating at room temperature for 2 minutes. 3.5111 of this 
solution was added to 5#1 of each of the termination mixes (each consisting of 
80juM of each of the dNTPs and also 8, uM of the same ddNTPs in 5OmM NaCl) 
and incubated at 370C for 5 minutes. The reaction was stopped by the addition 
of 41d of stop solution (959o' formamide, 20mM EDTA, 0.057o bromophenol 
blue and 0.057o xylene cyanol FF) and incubation at 850C for 4 minutes. The 
solution could be stored at -20*C or 2.51d loaded immediately on a 67o 
acrylamide/ urea gel. 
Z2.16 Preparation and Running of Sequencing Gels 
Sequencing reactions were electrophoresed on a 0.2 mm thick, 676 
acrylamide gel preheated to 50*C. The gel mixture consisted of 1.8ml 25xTBE 
(23M Tris base, ISM orthoboric acid 0.06M EDTA finally adjusted to pH 8.3), 
1.2ml deionised water, 27ml 6.7% acrylamide solution (60ml of 38% 
acrylamide/2% bis acrylamide, 192g urea made up to 360ml with deionised 
water), 130pl 1"o ammonium persulphate and 170 TEMED. This mixture was 
poured between 2 glass plates 0.2mm apart. Both glass plates were washed with 
ethanol. One plate was then coated with bind silane (0.3ml bind silane A-174, 
100ml ethanol, 301d acetic acid), which would cause the gel to stick to that 
plate. The other plate was coated with Repelcote, which would prevent the gel 
sticking to it. 
The gel was assembled in a Touzart and Matignon electrophoresis 
apparatus with 0.8% TBE in the upper reservoir and 1.2% TBE in the lower 
reservoir. The gel was electrophoresed at 2500 V for approximately 1.5 hours 
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for a short run and 3-4 hours for a long run. The apparatus was disassembled 
and the gel and plate, to which the gel had stuck, was submerged in 1.5 litres of 
lWo acetic acid for 30 minutes to fix the gel. The gel was dried onto the glass 
plate in an 80"C oven. Once dry the gel, still attached to the plate, was cooled 
and exposed to X-ray film. 
2.117 Eukaryotic Cell Culture 
All manipulations were carried out in a vertical laminar flow cabinet. 
Cells were incubated at 37"C in a humidified atmosphere containing 5%(v/v) 
C02. All cells except hybridoma fusions were cultured in Dulbecco's modified 
Eagle medium (DMEM) supplemented with 10% foetal calf serum and 
0.06mg/ml penicillin and O. 1mg/ml streptomycin. For the culture of BPV and 
2wt cells 0.5mg/ml Geneticin (G418) was also added to the medium. 
Hybridoma fusions were cultured in RPMl 1640 media supplemented with 
109o' foetal calf serunt, 0.06mg/ml penicillin and O. 1mg/ml streptomycin plus 
1001M hypoxanthine, 16jiM aminopterin and 101M thymidine (HAT 
supplement) to select for fused myeloma-spleen cells [Littlefield, 1964]. 
2.2.18 Preparation of Membrane Proteins for SDS Page Electrophoresis 
For protein extraction, FM9 cells were washed five times with cold PBS 
(137mM NaCl, 2.7mM KCI, 4.3mM Na2HP04.7 H20,1.4 mM KH2PO4) and 
collected into a buffer containing 10mM Tris-HCI pH 8.0,10mM MgC12 and the 
protease inhibitors antipain (50mg/ml), aprotonin (10mg/ml), benzamidine 
(300mg/ml), leupeptin (5mg/ml), pepstatin A (5mg/ml) and PMSF 
(phenylmethylsulphonyl fluoride) (175mg/ml). Cells were lysed by repeated 
passage through a 19 gauge needle. Cellular and nuclear debris were removed 
from the lysate by a5 minute centrifugation at 300g and membranes pelleted by 
a 30 minute centrifugation at 100,000g. The membrane pellet was dissolved in 
2.5% Triton X-100 in PBS or 10% Mega -10 in PBS. 
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2.2.19 Preparation of Decanoyl-N -methylglucamide (Mega - 10) 
Mega-10 was prepared according to the method described by Hildreth, 
[19821. This consisted of mixing 19.5g of N-methyl-D-glucamide with 150ml 
methanolin a 500ml round bottom side arm flask and refluxing it at 7011C until 
dissolved. Next 17-23g of decanoic acid was added to 10g of pyridine dissolved 
100ml of ether on ice. After 10 minutes 11.5ml of ethyl chloroformate was 
rapidly added to the ether mix and allowed to stand for 20 minutes on ice. This 
mixture was then filtered through a sintered glass funnel into the side arm 
flask containing the methanol/ N-methyl-D-glucamide mixture at 50"C. The 
funnel and the flask were rinsed with 50ml cold ether which was then added 
to the side arm flask. The resulting mixture was allowed to stand at room 
temperature for one hour before being stored at 40C overnight. The solution 
was then filtered to remove any unreacted N-methyl-D-glucamide and the 
solvents removed by rotary evaporation at 30-50*C. The resulting oily liquid 
was poured into 300ml of ice cold ether, stirred and the solid product collected 
by pouring off the ether and allowing it to dry. The crude MEGA-10 was 
redissolved in the minimum volume of methanol/ether (1: 9) at 500C and 
allowed to crystallise out by cooling on ice. The powder was collected by 
filtration and allowed to air dry prior to use. Typically a yield in excess of 90% 
could be achieved using the above method. 
2. Z20 Bradford's Analysis of Protein Concentration 
Protein conncentrations were determined by the method described by 
Bradford et al., 11976]. Briefly this involves adding 1ml of Bradford reagent to a 
known volume of protein solution, leaving for 5 minutes for colour to 
develop and reading absorbance at 595nm. 
The Bradford's reagent was made by dissolving O-1g of Coomassie 
brilliant blue R in 50ml of 95% v/v ethanol, adding 100ml of 8576 














0 ýO 15 
pg BSA protein 
Fig. 2.1 Standard Bradford's Curve 
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the solution. Standard calibration curves were prepared for each batch of 
reagent using various volumes of 1mg/ml BSA solution, see fig. 2.1 for a 
typical calibration curve. 
2.2.21 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS 
PAGE) 
This method of protein separation was carried out using the Bio Rad 
mini protean H SDS PAGE gel electrophoresis system and based on the method 
first described by Laemli, [1970]. The percentage of acrylamide varied according 
to the sizes of the proteins to be separated. The running gel contained 
acrylamide diluted from a stock acrylamide solution (consisting of a mixture of 
30% w/v acrylamide and 0.8% w/v bis acrylamide) to the desired percentage, 
OAM Tris/HCl, pH 8.8,0.1% (w/v) SDS. The gel solution was polymerised by 
the addition, to a final concentration of 0.1% w/v ammonium persulphate and 
0.08% TEMED (N', N, N', N'-tetramethylenediamine). The stacking gel 
consisted of the stock acrylamide diluted to give a final acrylamide 
concentration of 5% w/v, 0.13M Tris/HCI, pH6.8,0.1% SIN and TEMED and 
ammonium persulphate added (as described above) to polymerise the gel. 
Samples were prepared by the addition of an equal volume of SDS gel sample 
buffer (200mM Tris/HCI, pH6.8,25% glycerol, 5% SDS, 0.17o Bromophenol 
blue) and DTT to a final concentration of 5OmM. The sample was either boiled 
for 5 minutes (if it was a fusion protein preparation) or heated at 37"C for 10 
minutes (if it was a eukaryotic cell membrane preparation) before loading onto 
a gel. The sample was electrophoresed at 160V until the bromophenol dye 
front had reached the bottom of the gel. The proteins separated on the gel were 
either Western blotted directly onto nitrocellulose membrane or visualised by 
Coomassie brilliant blue staining. 
To stain the proteins by Coomassie brilliant blue, the gels was soaked in 
stain solution (0.1% w/v Coomassie brilliant blue in 507o v/v tri-cholro-acetic 
acid) for 30 minutes. The background staining of the gel was removed by 
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soaking the gel in destain solution (307o v/v acetic acid and 107o v/v 
methanol) to reveal the stained protein bands. 
2.2.22 Western Blotting 
After a SDS PAGE gel had run to completion the gel was transferred to a 
piece of Whatman 3MM filter paper pre-soaked in Western blot transfer buffer 
(20mM Tris base, 150mM glycine). The gel was overlaid with a piece of 
nitrocellulose pre-soaked in transfer buffer, itself overlaid by another piece of 
Whatmann 3MM filter paper soaked in transfer buffer. This "sandwich" was 
placed between 2 buffer soaked sponges and then into the Bio Rad mini 
protean H Western blotting apparatus and immersed in chilled transfer buffer. 
The system was electro-blotted for a minimum of 45 minutes at 200mA. The 
proteins within the gel had now transferred to the nitrocellulose filter which 
could be probed with different antibodies as required. 
2.2.23 Antibody Probing of Western Blotted Nitrocellulose Filters 
On removal of the nitrocellulose filters, the proteins were visualised by 
incubation for 10 seconds in Ponceau S solution (0.1% Ponceau S w/v in 5% 
w/v acetic acid) and the molecular weight standard proteins marked in pencil. 
The Ponceau staining was washed off the filters whilst the filters were blocked. 
The nitrocellulose filters were incubated in the blocking solution 'blotto' (3% 
Marvel, 0.02 % Tween 20 in PBS) with gentle shaking for 1 hour. The filters 
were transferred to 10ml of 'blotto' containing a suitable dilution of primary 
antibody (antibody dilutions varied from neat to 1/1000 dilution depending on 
the antibody used) and incubated with gentle shaking for 1 hour. The filters 
were washed to remove the unbound antibody by 3x 10 minute washes in 
'blotto'. The filters were transferred to 10ml of 'blottol containing a 1/1000 
dilution of secondary antibody conjugated to alkaline phosphatase (obtained 
from DAKO) and incubated for 1 hour with gentle shaking. The filters were 
washed as described before and then developed. The filters were first washed 
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briefly in PBS. The filters were then equilibrated to an alkaline pH by soaking 
them in lOOmM Tris/HCI, pH9.5, lOOmM NaCl, 5mM MgC12. The colour 
reaction was started by the addition of 10ml of equilibration buffer containing 
66pl of NBT solution (50mg/ml nitroblue tetrazolium dissolved in 70% 
dimethylformamide) and 661d of BCIP solution (25mg/ml 5-bromo-4-chloro-3- 
indonyl-phosphate dissolved in dimethy1formamide). The colour reaction was 
stopped by washing the filter in 10mM Tris/HCI, 1mM EDTA adjusted to 
pH8.0. 
Z2.24 Immunofluorescence 
Cells were cultured as described in Section 2.12 on glass microscope slide 
coverslips. When the cells reached approximately 80% confluency they were 
processed. The coverslips were transferred to a well of a6 well plate and 
washed 3 times with 3ml of PBS. The cells were fixed by the addition of 3 ml of 
methanol (stored at minus 20*C) and incubated at -20"C for 5 minutes. The 
methanol was removed, replaced with 3ml of 0.2% BSA/ PBS and incubated at 
room temperature for 20 minutes to 'block' the coverslips. The coverslips were 
probed with the primary antibody diluted accordingly. A 70yl aliquot of the 
diluted antibody was pipetted onto a piece of Lab film, on which the coverslip, 
cell side down, was placed. The coverslips were incubated with the primary 
antibody for 1 hour at room temperature. The coverslips were transferred back 
into the 6 well plate and washed twice with 3ml of PBS followed by two 3ml 
washes in 0.2% BSA/PBS. The coverslips were then probed with diluted 
secondary antibody (conjugated to either fluorescein of rhodamine and 
generally diluted 1 in 1000 in 0.2% BSA/ PBS) in the same manner as described 
for the probing with the primary antibody. The coverslips Avere incubated with 
the secondary antibody for 30 minutes at room temperature. The coverslips 
were washed as described before and the mounted on microscope slides, cell 
side down on 201d of Mowiol. The coverslips were viewed using a Zeiss 
microscope and lens. Photographs were taken of the coverslips using a Contax 
54 
167 Mt 35 mm camerawith Kodak TMAX 400 film. 
2. Z25 Enzyme Linked Immunosorbant Assays (ELISAs) 
Hybridoma supernatants and antisera were screened by ELISA against 
the relevant antigen. % well microtiter plates were seeded with 50-1000 
antigen (10ILg/ml or less) in PBS or 0.05M Na2CO3 (pH9.6) and left overnight at 
4"C. All the subsequent steps were carried out at room temperature. The 
antigen was removed from the plates and 200 P 5% (w / v) BSA/ PBS was added 
to each well to block the non-specific sites. The plates were incubated for 30 
minutes and then washed 4 times with 5% (w/v) BSA/ PBS. 50td of hybridoma 
supernatant or antisera diluted (usually 1/1000) in 57o (iv/v) BSA/PBS and 
incubated for 1-2 hour. The wells were washed as before and incubated for 1 
hour with peroxidase conjugated antibodies (rabbit anti-mouse antibody or 
swine anti-rabbit antibody) diluted 1/ 1000 in57o (w / v) BSA/ PBS. The substrate 
solution containing 10ml citrate buffer (10.2g citric acid in 500ml H20), 10ml 
phosphate buffer (14.2g sodium phosphate in 500ml H20), 8mg OPED and 21LI 
H202 was prepared. The plates were washed as before and then developed with 
10ORI of substrate. The reactions were stopped after a suitable length of time by 
adding 50gl of 8M H2S04 to the wells. Assay plates were read using a 
LabSystems Multiscanplus plate reader set at 450nm. 
2.2.26 Animal Immunisations 
All animal work was performed in the animal section of the University 
of Bristol by Mike Hill a suitably qualified animal technician . 
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CHAPTER 3 
THE RAISING AND CHARACHRISATION OF POLYCLONAL 
ANTIBODIES TO FUSION PROTEINS PRODUCED BETWEEN 
CF'rR FRAGMENTS AND BETA-GALACTOSIDASE. 
3.1 INTRODUCTION 
Topological studies of CFTR would be optimised if antibodies could be 
raised to recognise any part of the protein. Preferably the whole protein would 
be utilised for immunisation. Unfortunately, native CFrR protein is only 
expressed at low levels and has yet to be isolated and purified. This problem 
can be circumvented by using the identified gene to overexpress regions of 
CFTR as fusion proteins in E. coli. and isolating the products for 
immunisation. 
A series of 0-galactosidase/CFTR fusion constructs have been produced 
in pUEX 1 [Bressan and Stanely, 19871, a bacterial fusion protein expression 
vector (see fig. 3.1). Between them they cover almost the entire region of the 
expressed CFrR gene. In this chapter the generation of the fusion proteins and 
their use in the production of polyclonal antibodies to CFTR are described. 
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Fig. 3.1 Map of the bacterial expression vector pUEX 
MCS multiple cloning site 
c1857 temperature sensitive repressor of the Pr promoter 
Pr promotor 
cro-lac Z fusion of the cro and lac Z genes 
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3.2 METHODS AND MATERIALS 
3.2.1 Construction of pUEX Fusion Proteins 
The following synthetic oligonucleotides were used to amplify specific 
regions of CFrR cDNA by standard PCR tedmiques (section 2.2.7). 
r, fic: 13 
%-JL, %j 5'- CATCGGGATCCACITCACrTCrAATGATG -3' 
CF10 5'- C17GTCrGCAGAATITCTrCACTrATTrC -3' 
CF5 5- AGACGGGATCCAGACCAATTITGAGGAAA -3' 
CR 5- TGGGGCrGCAGTTCrAGTTGGCATG= -3' 
CF9 5- AGCGGGGATCCrGTAAAGTGATGGCrAAC -3' 
CF8 5'- Crl'ITCTGCAGCCITGTATCTTGCACCrC 41 
The positions of these fragments within the CFTR cDNA sequence are 
indicated in fig. 3.2. Initially, fragments 3/4 (185bp), 5/6 (100bp), 7/8 (182bp) and 
9/10 (699bp) were amplified from genomic DNA derived from T84 cells which 
have previously been shown to express CFrR [Denning et al., 1992a]. 
Subsequently, larger fragments 3/10 (1079bp), 5/4 (1522bp) and 9/8 (2666bp) of 
CFTR were amplified from the plasmid construct pCof-1 [Rommens et al., 
19911 (a eukaryotic expression vector containing cDNA encoding for CFrR 
downstream of a metallothionein promoter), generously provided by Johanna 
Rommens, Dept. of Genetics, Toronto. All PCR products were purified on 
Chromaspin 100 columns prior to restriction enzyme digestion and ligation 
into the BamH I and Pst I sites of the multiple cloning site of pUEX1 (see fig. 
3.1). The oligonucleotide primers were designed such that, using these 
restriction enzymes, the CF1 fragments were cloned in frame at the 3' end of 
the P-galactosidase gene, thus generating DNA sequences encoding p- 
galactosidase / CFTR fusion proteins [Bressan and Stanley, 19871. The constructs 





































3.12 Screening Ecoli. Colonies with Oligonucleotide Probes 
Transformed E. coli. colonies were streaked onto nitrocellulose filters, 
overlaid on LB amp agar plates and grown at 30"C for 16 hours. The filters 
were transferred onto 3MM Whatman paper presoaked in 5% SDS for 5 
minutes and then transferred onto 3MM Whatman paper presoaked in 
denaturing solution (1.5M NaCI, 0.5M NaOH) for 5 minutes. The filters were 
blotted on 3MM Whatman paper to remove excess denaturing solution before 
being floated on neutralising buffer (0.5M Tris base, 1.5M NaCl, 377o HCI) for 5 
minutes and then submerged in the same solution for a further 5 minutes. 
The nitrocellulose filters were pressed between 2 pieces of 3MM Whatman 
paper, rinsed in 6xSSC (20xSSC being 3M NaCl, 0.3M sodium citrate all 
adjusted to pH7.0 with HCI), air dried and then baked for 2 hours at 80*C. 
The nitrocellulose filters were rehydrated by floating on 6xSSC and 
incubated in SOmM Tris/HCI, pH8.0,1M NaCl, 1mM EDTA 0.17o SDS at 420C 
in a Techne hybridiser HB1 hybridisation oven for 30 minutes. The 
nitrocellulose filters were blocked in 20ml of pre-hybridisation solution for 2 
hours at 65*C. The pre-hybridisation solution was replaced by 20ml of fresh 
pre-hybridisation solution and 50#1 of boiled cDNA probe. Hybridisation of the 
probe to the filters was allowed to proceed over a period of 16 hours at 65"C in 
hybridisation ovens. 
To remove excess unbound cDNA probe, the nitrocellulose fflters were 
washed for 20 minutes at room temperature in 2x SSC, 0.1% SDS, followed by 
3x2O minutes washes at 65"C in O. 1x SSC, 0.1% SDS. Whilst still damp, the 
filters were wrapped in Saran wrap and exposed to X-ray film. 
3.2.3 Radioactive Labelling of cDNA Probes 
Appropriate oligonucleotide cDNA probes were synthesised using the 
Boehringer Mannheim random prime DNA labelling kit. The reaction 
requires 25ng of DNA in a final volume of 20jul. This solution was boiled for 
10 minutes and snap chilled on ice. In the following order, 1 #1 of the 0.5mM 
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dATP, dGTP and dTTP nucleotide stocks, 2141 of the 10x hexanucleotide 
reaction buffer, 5pI of a 32P dCTP (10mCi/ml, 800mCi/mmol) and 1111 of 
2units/Al Klenow were added to the denatured DNA solution. The reaction 
was allowed to proceed at 37*C for 30 minutes before being stopped by the 
addition of 21d of 5OOmM EDTA and diluted to 50ttl by the addition of sterile 
deionised water. This volume is suitable for application of the sample to a 
Chromaspin column. The labelled DNA was purified from unincorporated 
radionucleotides using a Chromaspin 100 spin column. The purified labelled 
DNA solution was boiled for five minutes and was then ready to be used to 
probe the desired filters. 
3.2.4 Preparation of Bacterial Inclusion Bodies 
This method was based on that described by Brake et al., [19901. Two 5ml 
LB-amp broth aliquots containing loomg/ml ampicillin were inoculated with 
E. coli. bearing a pUEX plasmid construct containing cDNA encoding CFTR 
regions of CFTR. The pUEX 1 vector allows the inducible expression of 
correctly inserted DNA sequences as p-galactosidase fusion proteins . Induction 
of fusion protein expression is driven by the Pr promoter of bacteriophage X 
under the regulation of the temperature sensitive X repressor cl 857. At 3011C 
the repressor is active and no fusion protein is produced, at 42*C the repressor 
is inactive and the strong Pr promoter leads to high level expression of the 
fusion protein. The inoculated medium was grown for 16 hours at 3011C with 
vigorous shaking. 8ml of the cultures were then transferred to 800ml of L-amp 
broth and grown, with shaking at 300C, until the optical density of the culture 
at 600nm was 0.2. The entire culture was then transferred to a 2.5 litre flask, 
prewarmed to 42*C and then incubated for a further 2 hours with shaking. The 
bacterial cells were pelleted by centrifugation at 4500rpm for 20 minutes at VC 
in a Sorvall ROB centrifuge. The bacterial cells were resuspended in 20ml of 
100mM NaCl, 5OmM Tris/HCl pH8.0 and transferred to a 50ml Falcon tube. 
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The cells were pelleted by centrifugation as before. The supernatent was 
discarded and the cells resuspended in 8ml of 15% sucrose, 50mM Tris/HCI 
pH8.0,10mM EDTA. To this was added 2ml of a 10mg/ ml Lysozyme solution. 
Then 2mg of DNAse I and 1 ml of 1M M902 were added, mixed and 
incubated on ice for a further 15 minutes. To lyse the cells, 6ml of detergent 
mix (10mM Tris/HCl, pH7.4,100mM NaCl, 0.5% Deoxycholate, 1% Triton X- 
100) was added with complete lysis achieved after 5 minutes incubation on ice. 
The inclusion bodies were collected by centrifugation at 120OOrpm for 10 
minutes at 40C in a Sorvall RC5C centrifuge. The pellet was resuspended in 10 
ml of guanidinium, wash solution (1.75M Guanidinium HCI, 1M NaCl, 
1%Triton X-100) before centrifugation as before. These guanidinium. washes 
were repeated twice. The pellet was resuspended in 10ml of 10mM Tris/HCI 
pH8.0 and centrifuged as before. The pellet was finally resuspended in 2ml of 
10mM Tris/HCI pH8.0 before sonication to allow complete resuspension. The 
sample was aliquoted and mixed with an equal volume SDSS sample buffer and 
DTT added to a final concentration of 100mM. The samples were then placed 
in a boiling water bath for 5 minutes and stored at -20"C. 
3.2.3 Procedures for Rabbit Immunisations 
Aliquots of the fusion protein preparations were defi-osted, reboiled and 
run on 7.5% SDS polyacrylamide test mini gets prior to running larger 
preparative gels. Preparative gels were run at 10-20mA overnight until the 
loading buffer dye front had reached the bottom of the gel. The protein bands 
tl C, present in one inch width vertical strips that had been removed froMA edge of 
each gel were visualised using Coomassie blue staining. The stained gel strips 
were aligned to the unstained gels and the overexpressed bands of fusion 
protein were cut from the unstained gels and shredded using scalpel blades. 
The gel was soaked in PBS at VC overnight and then sheared by repeated 
passage through needles attached to syringes. The resultant suspensions were 
injected into New Zealand white rabbits, both subcutaneously and 
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intramuscularly, on three occasions at monthly intervals. These were followed 
by intravenous injections at monthly intervals. For the intravenous injections 
the samples to be injected had had the acrylamide removed by centrifugation. 
Test bleeds were taken from the rabbits before the first injection (pre-bleeds) 
and 10 days after each intravenous injection. The blood was allowed to clot at 
VC for 16 hours and then centrifuged at 20OOg for 10 ininutes to separate 
serum from the clots and free red cells. The sera were removed, aliquoted and 
stored in the short term at PC and in the longer term at -20"C. 
3.3 RESULTS 
3.3.1 Production of Fusion Proteins 
Specific regions of CFrR cDNA (fig. 3.2) were amplified by PCR and 
cloned into an appropriate site in the plasmid based prokaryotic expression 
vector pUEX1 [Bressan and Stanley, 19871 as described above. This vector 
allowed the expression of a correctly inserted cDNA as the carboxy -terminal 
region of a P-galactosidase fusion protein. Individual clones of each construct 
were selected and sequenced to confirm that the insert was in the correct 
reading frame (data not shown). The correct sizes of the fusion proteins were 
established by testing aliquots of the expressed fusion proteins on mini SDS 
page gels (fig 3.3). 
3. &2 Production of Polyclonal Antibodies 
Recombinant P-galactosidase fusion proteins were used to immunise 
rabbits. The antisera from immunised rabbits were designated CF3/4, CF5/6, 
CF7/8, CF9/10, CF3/10, CF5/4 and CF9/8 according to the construct used for 
immunisation. 
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Fig. 3.3 87o SIDS page gel of expressed proteins in pUEX- 
A- Markers 
B- CF 3/ 10 pcr product in pUEX - predicted size 156kDa 
C- CF 5/4 pcr product in pUEX - predicted size 171kDa 
D- CF 9/8 pcr product in pUEX - predicted size 213kDa 
E- pUEX vector alone - predicted size 116kDa 
. ......... indicates position of expressed p-galactosidase protein in pUEX alone 
indicates position of expressed p-galactosidase protein in pUEX with 
insert from CFTR 
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3.3.3 Western Blot Analysis of Antibodies 
HT29 cells had previously been shown to express CP7R [Denning et al., 
1992a]. The polyclonal antisera were screened against Western blots of i) 
membrane lysate prepared from HT29 cells, ii) cell lysates prepared from Ecoli. 
expressing the relevant CFTR fusion protein and iii) cell lysate prepared from 
E. coli . expressing P-galactosidase protein alone, as a control. 
Antisera raised to the smaller fragments of CFTR, CF3/4, CF5/6, CF7/8, 
and CF9/10 were found to cross react with the relevant bacterially expressed 
fusion protein and P-galactosidase, but not with CFTR expressed in HT29 cells 
(data not shown). 
Antibodies raised to the larger fragments of CFTR, CF3/10, CF5/4 and 
CF9/8 showed varying degrees of cross reaction to CFTR by Western blotting 
(fig 3.4). Rabbits immunised with 3/10 and 5/4 fusion proteins produced 
serum that recognised a -170kDa HT29 protein on Western blots that was not 
recognised by the pre-bleed antisera taken from these aninials. -170kDa is the 
expected size of the glycosylated form of CFrR [Gregory et al., 19901. The CF9/8 
antisera failed to recognise any HT29 protein on Western blot. Antisera to all 
three larger fusion proteins were found to cross react with the relevant 
bacterially expressed fusion protein and with p-galactosidase on Western blots 
(data not shown). 
3.3.4 Immunofluorescence Analysis of HT29 cells 
HT29 cells were processed for immunofluorescence analysis (section 
2.2.24) using the polyclonal antisera as the source of primary antibody. Each 
pre-bleed serum gave very weak background staining of HT29 cells when used 
in indirect immunofluorescence. There did not appear to be any significant 
increase in staining of the cells when polyclonal antisera CF3/4, CF5/6, CF7/8 
and CF9/ 10 were used (data not shown). However a visible increase in staining 




Fig. 3.4 Immunoblots of HT29 membrane lysate probed with 
polyclonal CF3/10 (lane 2), polyclonal 5/4 (lane, [) or polyclonal 9/8 
(lane 6) as primary antibody. Premmune sera from rabbits 
immunised with the CF3/ 10 (lane 1), CF5/ 4 (lane 3) or CF9 /8 (lane 
5) were used as controls. The relative mobilities of molecular 
I,, 
weight standards, loaded an adjacent lane, is indicated. 
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1 
Fig. 3.5 Immunofluorescence analysis of methanol fixed HT29 cells 
with polyclonal antisera 
a- CF3/10 test antiserum 
b- CF5/4 test antiserum 
c- CF9/8 test antiserum 
d- CF3/10 pre-bleed antiserum 
67 
and CF9/8 antisera. Each gave a diffuse pattern of staining across the cell, with 
a concentration of fluorescence intensity around the periphery (fig 3.5). This 
pattern is consistent with a predominantly plasma membrane (or immediately 
sub-plasma membrane) localisation. CFrR has previously been localised to 
the plasma membrane and to vesicles adjacent to the plasma membrane 
[Crawford et al., 19911. 
3A DISCUSSION 
The polyclonal. antisera raised to the smaller fragments of expressed 
CFTR (CF3/4, CF5/6, CF7/8, CF9/10) did not appear to recognise the CIFTR 
protein in any assay. The positive results seen on Western blots of the relevant 
fusion proteins would most likely have been due to the presence of high titre 
anti P-galactosidase antibodies in the antisera. The small size of the CFTR 
components of the expressed fusion proteins made it difficult to determine a 
shift in the position of the expressed fusion protein band when run out on an 
SIDS polyacrylamide gel. This problem may have resulted from the rabbits not 
being injected with the expected fragment of CFTR and therefore not raising an 
immune response to it. 
The problem described above seemed to be overcome in the generation 
of polyclonal antisera, to a second set of fusion proteins containing larger 
fragments of the CFTR protein (CF3/10, CF5/4 and CF9/8). The larger size of 
these fusion proteins meant that it was far easier to detect shifts in the size of 
fusion protein bands on SDS polyacrylamide gels. The immunoblot and 
immunofluorescence data were consistent with the assumption that these 
polyclonal antibodies recognise CFTR. However, it still had to be established 
conclusively that the -170kDa protein recognised by these antibodies was CFI'R 
and not another protein within the cell. Antibodies against bacterial fusion 
proteins can have a high level of specificity since the antigen is clonally pure 
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and contaminants in the antigen preparation are of bacterial origin and 
unlikely therefore to evoke antibodies that can cross react with mammalian 
cells [Tooze and Stanley, 19861. However, further studies -. %, ith these polyclonal 
antibodies raised doubts about their specificity and the possibility of them 
cross-reacting with proteins other than CFTR cannot not be ruled out. This 
problem is addressed in the next chapter. 
Three of the P-galactosidase fusion proteins constructed contain the 
majority of the expressed CFTR sequence between them. All three have been 
used individually to raise an apparent antibody response to CFTR in rabbits. 
Therefore, it seemed realistic to immunise a single rabbit with all three fusion 
proteins and thereby elicit an immune response to virtually the entire 
expressed CFTR protein in one animal. This was done in preparation for the 
production of an anti-CFTR coliclonal antibody library from rabbit bone 
marrow, as described in chapter 8. 
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CHAPTER 4 
CHARACTERISATION OF MONOCLONAL AND POLYCLONAL 
ANTIBODIES TO DIFFERENT REGIONS OF CFTR: 
DETECTION OF IMMUNOLOGICALLY RELATED PROTEINS 
4.1 INTRODUCnON 
The identification of the gene encoding CFTR and the its subsequent 
expression in heterologous systems has facilitated the development of a 
variety of polyclonal and monoclonal antibodies to the protein. These have 
been used in a range of immunocytochemical studies to investigate the 
patterns of expression and the biochemical functions of CFTR. Many of the 
published antibodies appear to recognise CFTR, however the specificity with 
which they do so has not always been exhaustively analysed. The lack of full 
characterisation of CF17R antibodies has been recognised as a particular 
problem by various groups in the field. This led to it being the subject of an 
international workshop sponsored by Association Franchise de Lutte contre la 
Mucovoscosidose (A. F. L. M. ) in 1993. 
The characterisation of a set of monoclonal and polyclonal antibodies 
raised to CFTR by immunoblot, immunoprecipitation, immunofluorescence 
and immunohistochemistry is reported in this chapter. The monoclonal 
antibodies were raised to thyroglobulin-peptide conjugates bearing peptides 
corresponding to different regions of human CFrR. The sequences of the 
peptides and their corresponding positions within the predicted structure of 
CFI'R are indicated in fig. 4.1. Antibodies produced by cloned hybridomas had 
been shown to recognise the corresponding BSA-peptide conjugates (by ELISA) 
and initial immunoblot and immunofluorescence results with these 
antibodies indicated that they may have been recognising CFIR Supernatants 





Cartoon indicating the positions of peptides within the sequence of CFTR. 
Ah 
indicates R domain, 0 indicates nucleotide binding domain, 
indicates the transmembrane domain, and ýindicates glycosylation site. 0 






were used in further immunocytochemical experiments as described below. 
The antibodies produced by these clones are referred to as MabCF2, MabCF3, 
MabCF6, MabCF7 and MabCF8 hereafter. 
In addition to these monoclonal antibodies, polyclonal antibodies were 
raised in rabbits (see chapter 3). A more detailed investigation of the specificity 
of these antibodies is described. 
Studies with these novel monoclonal and polyclonal antibodies to 
CFTR indicate that they recognise one or more immunologically related 
proteins with a similar molecular weight, calcium responsiveness and tissue 
distribution to CFTR. These studies are described and implications of the 
results are discussed below. 
4.2 MATERIALS AND METHODS 
4.2.1 Immunoprecipitation 
For immunoprecipitation, the final pellet from a membrane lysate 
preparation (see section 2.2.18) from HT29 cells was dissolved in 5% Decanoyl- 
N-methylglucamide (Mega-10). A1 in 25 dilution of polyclonal antiserum in 
membrane lysate solution was mixed for 1 hour at room temperature. 
Immune complexes were collected on Pepstatin A beads, which had been pre- 
washed in membrane lysis buffer, by agitating at 4"C for 1 hour. The beads were 
then washed four times before elution of the immune complexes by 
incubation in SDS-PAGE sample buffer and 5OmM DTT at 371C for 10 minutes. 
Eluted material was electrophoresed on an 8% SDS polyacrylamide gel, blotted 
onto nitrocellulose membrane and tested for reactivity with monoclonal 
antibodies to CFTIR. 
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4.2.2 Reverse Transcription PCR 
Total RNA was isolated and mRNA purified from tissue culture cells, 
then first strand cDNA synthesised using Pharmacia kits (27-9270-01,27-9258-01 
and 27-9261-01). Subsequent PCR reactions were carried out according to 
standard procedures (section 2.2.7) using the following pairs of oligonucleotide 
primers: 
CF7 5- AGACGGGATCCAAAGTGCGGCAGTACGAT -3' 
CF8 5- C=CTGCAGCCITGTATCrrGCACCrC -3' 
CF7 and CF8 both prime within exon 24 of CFTR to generate a fragment 
of 192bp from CFI'R genomic DNA or cDNA. 
CFX 5- AGACGGGATCCAGGATAGAAGCAATGCTG -3' 
CF8 and CFX prime across exons 23 and 24 of CFTR to generate a 
fragment of 255bp from CFM cDNA. 
MIC2/11 5- TACCAGAAAAAGAGATCTTGCTTCAAAG -3' 
MIC2/13 5- GATCCGCCrGGGCTGTTTCTGCCGACAAT -3' 
MIC2/11 and MIC2/13 prime within exons 7 and 8 of MIC2 to generate a 
fragment of 144bp from MIC2 cDNA [Sn-dth et al., 1990]. 
4.2.3 Immunohistochemistry (performed by Dr. C. Holmes, Department of 
Obsteterics and Gynaecology, University of Bristol. ) 
Adult human tissues were obtained either at post mortem. or from 
surgical specimens and snap-frozen in liquid N2-cooled isopentane (2- 
methylbutane). Acetone-fixed cryostat sections were prepared and stained by an 
indirect immunoperoxidase staining technique as described previously 
[Holmes et al., 19901. Negative controls included sections incubated either in 
the absence of primary antibody or with an irrelevant primary antibody. 
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4.3 RESULTS 
4.3.1 Immunoblot Analysis of HT29 Membrane Lysate 
HT29 cells have previously been shown to express CFr1R [Zeitlin et al., 
1992]. It was decided to screen immunoblots of HT29 membrane lysate with 
selected monoclonal antibodies anticipating that each antibody would detect a 
protein of -170kDa if it recognised fully glycosylated CFrR [Denning et 
al., 1992a]. The results are presented in fig. 4.2. Each of the antibodies tested 
detected a protein of the same apparent molecular weight, -170kDa. It was 
shown in the preceding chapter that two of the three polyclonal antisera also 
recognise a -170kDa band in the immunoblots of HT29 membrane lysate. 
4.3.2 Immunofluorescence Analysis of HT29 Cells 
HT29 cells were processed for immunofluorescence analysis using 
selected monoclonal antibodies as the primary antibody. As with the 
polyclonal antisera CF3/ 10, CF5/ 4 and CF9 /8 (see section 3.3.4 and fig. 3.5). Each 
monoclonal antibody gave a diffuse pattern of staining across the cell with a 
concentration of fluorescence intensity around the periphery (fig. 4.3). This 
pattern is consistent with a predominantly plasma membrane (or immediately 
sub-plasma membrane localisation). HT29 cells have previously been shown 
to express CFI7R [Denning et al., 1992a] and CFIR has previously been localised 
to the apical plasma membrane and to vesicles adjacent to the plasma 
membrane [Crawford et al., 1991). 
4.3.3 Peptide Competition (performed by Judy Watson, Department of 
Biochemistry, University of Bristol. ) 
Peptide competition experiments were performed in order to check the 
specificity of the observed monoclonal antibody-antigen interactions. An 
immunoblot of HT29 membrane lysate was probed with either MabCF2, 
MabCF3 or MabCF8, alone or with one of these antibodies following their pre- 





Fig. 4.2 Immunoblots of HT29 membrane lysate probed with 
MabCF3 (lane 1), MabCF8 (lane 2), MabCF6 (lane 3) and 
MabCF7 (lane 4) The relative mobilities of molecular weight 
standards, loaded in an adjacent lane, are indicated. 
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Fig. 4.3 Immunofluorescence analysis of methanol fixed HT29 cells using 
MabCF3 (panel a), MabCF6 (panel b), MabCF7 (panel c), MabCF8 (panel d) as first 
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Fig. 4.4 Immunoblots of HT29 membrane lysate 
probed with monoclonal antibodies in the presence of 
competing peptide. Antibodies were incubated in the 
presence or absence of competing BSA-peptide 
conjugate as indicated prior to incubation with the 
nitrocellulose membrane bearing HT29 membrane 
lysate. Detection of bound antibody was as described in 
Materials and Methods. The relative mobilities of 
molecular weight standards, loaded in an adjacent 
lane, are indicated. 
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Fig. 4.5 Immunofluorescence analysis of methanol fixed T84 
cells using monoclonal antibodies in the presence or 
absence of competing peptide. Antibodies were incubated in 
the presence or absence of competing BSA-peptide 
conjugate as indicated prior to use in immunofluorescence 
analysis of methanol fixed cells. 













all cases only the immunising peptide blocked binding of antibody to the 
-170kDa protein. Similar results were obtained with MabCF6 (data not shown). 
T84 cells were also prepared for immunofluorescence as before and incubated 
with the same antibody/ peptide cocktails used in the immunoblot analysis. 
Once again, in all cases, only the immunising peptide blocked binding of 
antibody (fig. 4.5 and additional data not shown). 
4.3.4 Immunoprecipitation 
The immunoblot and immunofluorescence data presented in figs. 4.2- 
4.5 are consistent with the assumption that the antibodies concerned 
recognised CFTR. However, it was considered that this point would be 
strengthened if protein immunoprecipitated from HT29 membrane lysate by 
any one of the polyclonal antisera was detected by the monoclonal antibodies 
in an immunoblot. The results of such an experiment are presented in fig. 4.6. 
Polyclonal antiserum 3/10 immunoprecipitated a protein of -170kDa which 
was recognised in immunoblot analysis by MabCF8 (lane 2). MabCF8 failed to 
detect anything in the lane loaded with material immunoprecipitated by pre- 
immune serum derived from the rabbit which generated the 3/10 antiserum 
(lane 3). Another polyclonal antibody, 169, previously published as being a 
polyclonal antibody to CFI7R [Crawford et al., 19911, was included in this 
experiment. MabCF8 detected a protein of -170kDa in the material 
immunoprecipitated by 169 from HT29 membrane lysate (lane U MabCF3 was 
used in immunoblot analysis of the same material and gave results identical to 
those obtained with MabCF8 (data not shown). Similar experiments were 
performed with polyclonal antiserum CF9/8 as the immunoprecipitating 
antibody and MabCF3 and MabCF8 as the immuno-detecting antibodies. Both 
monoclonal antibodies recognised the -170kDa protein immunoprecipitated 






Immunoblot analysis of material immunoprecipitated 
from HT29 membrane lysate. Polyclonal antisera 169 
[ Crawford et al., 19921 (lane 1) or 3/ 10 (1 ane 2), and 
preimmune sera from the rabbit which subsequently 
generated polycl onal 3/ 10 (lane 3) were used to 
immunoprecipitate material from HT29 membrane lysate. 
The immunoprecipitated material was subjected to SDS- 
PACE, transferred to nitrocellulose and immunoblotted 
using MabCF8 as primary antibody. Pre-stained molecular 
weight standards were loaded in lane 4. 
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4.3.5 Expression of the Protein Recognised by the Monoclonal and Polyclonal 
Antibodies is Calcium Regulated 
It has previously been shown that an increase in intracellular Ca2+ 
concentration, induced by treatment with the ionophores A23187 or 
ionomycin, reduces the level of CFTR expression in HT29, T84 and freshly 
isolated normal human bronchial epithelial cells [Bargon et al., 19921. If these 
novel antibodies recognise CFTR, then ionomycin treatment of HT29 cells 
should induce a decrease in the level of expression of the -170kDa protein that 
they detect in immunoblot analysis of HT29 membrane lysate. HT29 cells were 
therefore incubated both in the presence and absence of ionomycin for various 
times prior to processing for immunoblot analysis with MabCF3 as probe (fig. 
4.7). The level of expression of the -170kDa protein recognised by MabCF3 was 
reduced following ionomycin treatment (compare lanes 1,2 and 3). Similar 
results were obtained with MabCF8 (data not shown). This work was 
performed by Aleksander Edelman, Inserm U323, Faculte de Medecine Necker, 
Enfants Malades, Paris. 
4.3.6 Immunohistochemistry 
Since the immunoblot, immunofluorescence and Ca2+ modulation data 
were consistent with the hypothesis that MabCF3 and MabCF8 recognised 
CF'FR, it was decided to conduct preliminary immunolocalisation studies on 
cryostat sections of human tissues using MabCF3 or MabCF8 as the primary 
antibody. Some of the observed patterns of reactivity using MabCF8 are shown 
in fig. 4.8, similar results were obtained with MabCF3 (data not shown). In 
addition MabCF8 recognised epithelial cells lining ducts of the pancreas and 
showed weak reactivity in liver (where staining was more prominent on the 
bile ductular rather than the hepatocyte epithelium) and in kidney where 
some, but not all, the tubules were stained (data not shown). The antibody 






Fig. 4.7 Immunoblot analysis of lysate from ionomycin 
treated HT29 cells. MabCF3 was used as primary 
antibody in immunoblot analysis of HT29 membrane 
lysate prepared from cells which had been incubated in 
the presence (lanes 2 and 3) or absence (lane 1) of 
2mg/ml ionomycin for 18 (lane 2) or 24 hours (lane 3). 
The relative mobilities of molecular weight standards, 
loaded in an adjacent lane, are indicated. 
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Fig. 4.8 Immunoperoxidase staining of normal human 
tissues with MabCF8. Colon (W) (panel a); colon (x50) 
(panel b, negative control); endometrium (W) (panel c), 
note the reactive myometrium at upper left and the 
heterogeneity in reactivity of the glands; endometrium 
(x160) (panel d), to show the variation in reactivity within a 
single gland and also the presence of stained stromal cells 
(arrow); tracheal epithelium (WO) (panel e); tracheal mucus 
gland (WO)(panel f); tracheal mucus gland, (WO) (panel g, 
negative control); prostrate (W) (panel h); prostrate (x630) 
(panel i), to show reactivity on sub-glandular epithelial cells; 
testis, senýdniferous tubule (x63) (panel j). 
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throughout the colonic crypt epithelium (fig. 4.8a). A more complex pattern of 
reactivity was observed in the endometrium (fig. 4.8c and d); although MabCF8 
consistently stained the myometrium (fig. 4.8c, upper left field), reactivity with 
glandular and stromal elements within the tissue varied both within and 
between specimens. Thus the specimen illustrated in fig. 4.8c contains both 
reactive (right-hand field) and unreactive (left-hand field) glands, whilst in 
fig. 4.8d MabCF8 positive and negative cells are present, not only within an 
individual endometrial gland (upper and lower fields respectively), but also in 
the surrounding stroma (MabCF8-positive stromal cells are arrowed in 
fig. 4.8d). Extensive reactivity was also observed with tracheal epithelium 
(fig. 4.8e) with less pronounced staining in the underlying mucus glands 
(fig. 4.8f). In prostrate, by contrast, the antibody showed intense reactivity 
throughout a discrete cell population underlying the unreactive glandular 
epithelium (fig. 4.8h and i). Weak reactivity throughout the germinal 
epithelium in seminiferous tubules of testis was also detected (fig. 4.8j). 
These patterns of reactivity are similar to those previously described for 
CFrR [e. g. see Crawford et al., 1991; Cohn et al., 1991; Marino et al., 1991; 
Trezise and Buchwald 1991; Trezise et al., 1992; Tizzano et al., 19931, but there 
are significant differencest most notably in the fact that MabCF8 decorates the 
whole of the colonic crypt epithelium, an observation which conflicts with 
those of Trezise and colleagues who clearly show that the multidrug resistance 
and CFrR genes have complimentary patterns of epithelial expression [Trezise 
et al., 19931. 
4.3.7 Recognition of CFTR Negative Cells in Tissue Culture 
Since the pattern of tissue section immunoreactivity did not accurately 
reflect that previously described for CFTR it was decided to screen cell lines 
reported to lack CFTR expression (CFrR negative cell lines) using the 
antibodies produced. Heb7a cells were chosen as the potential CFTR negative 
cell line because they are a derivative of Hela cells which have been shown not 
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to express CFTR by mRNA analysis, functional studies [Anderson et al., 1991a] 
and by immunoprecipitation [Gregory et al., 19901. Reverse transcription PCR 
(RTPCR) was used to confirm that Heb7a cells failed to produce any mRNA 
encoding CFTR (fig. 4.9). However, the novel monoclonal and polyclonal 
antibodies all recognised methanol fixed Heb7a cells in immunofluorescence 
analysis (fig. 4.10), giving a pattern of staining similar to that observed when 
HT29 cells had been used (fig. 4.3). The monoclonal and polyclonal antibodies 
also recognised a protein of -170kDa in immunoblot analysis of Heb7a 
membrane lysate (fig. 4.11). This protein was indistinguishable in size from 
that detected in HT29 or CaCo-2 membrane lysates (compare lanes 1,2 and 3). 
Similar results were obtained using another human cell line PANC-1, also 
shown by RTPCR not to express CFTR (data not shown). 
The expression of the protein recognised by the monoclonal and 
polyclonal antibodies in CFTR negative cells also appeared to be calcium 
regulated. Heb7a. cells were incubated in the presence or absence of ionomycin 
for various times prior to processing for immunoblot analysis with MabCF3 as 
probe. The level of expression of the -170kDa protein recognised by MabCF3 
was reduced following ionomycin treatment (data not shown). Similar results 




Fig. 4.9 Agarose get analysis of PCR products from mRNA obtained from 
HT29 (lanes 1-3) and Heb7a (lanes 4-6) cell lines. Oligonucleotide primers 
designed to amplify a 255bp fragment spanning exons 23 and 24 of CFTR 
were used to amplify the material loaded in lanes 1 and 4. A band of this 
size is observed in lane 1 (HT29) but not lane 4 (Heb7a) indicating the 
presence of CFTR mRNA in HT29 but not Heb7a cells. Contamination of 
cDNA with genomic DNA was checked for using a pair of oligonucleotide 
primers designed to amplify a 192bp fragment within exon 24 of CFTR. The 
products of these reactions were loaded in lanes 2 and 5. A band of 
appropriate size is more intense in lane 2 (HT29) than lane 5 (Heb7a) but 
present in both lanes, indicating some contamination of the Heb7a cDNA 
with genomic DNA. The integrity of the template mRNA was tested using 
a pair of oligonucleotide primers designed to amplify a 144bp fragment 
spanning exons 7 and 8 of the MIC2 gene [Smith et al., 19931. MIC2 encodes 
the E2 protein [Gelin et al., 1990] and is expressed in all human tissues 
[Banting et al., 19861. A band of 144bp is present in lanes 3 (HT29) and 6 
(Heb7a) indicating that intact mRNA was present in both original samples. 
DNA fragments of known molecular weight were loaded in an adjacent 
lane, their migration position is indicated. 
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Fig. 4.10 Immunofluorescence analysis of methanol fixed Heb7a cells 
using polyclonal antibody CF5 /4 (panel a), poly clonal antibody 3/ 10 
(panel b), polyclonal antibody 9/8 (panel c), MabCF3 (panel e) or 
MabCF8 (panel f). Pre-immune serum from the rabbits immunised 
with the CF5/4 construct was incubated with cells presented in panel d. 
Bound antibody was detected with a species specific FFFC conjugated 









Fig. 4.11 Immunoblot analysis of membrane lysates using 
monoclonal or polyclonal antibodies. Heb7a (lane 1 and 4), 
CaCo-2 (lane 2 and 5) and HT29 (lane 3 and 6) membrane lysates 
were probed using MabCF3 (lanes 1-3) or MabCF8 (lanes 4-6) as 
primary antibody. Heb7a membrane lysates were also probed 
using polyclonal antibodies 3/ 10 (lane 7) or 5/4 (lane 8) as 
primary antibody. The relative mobilities of molecular weight 




Monoclonal antibodies to synthetic peptides corresponding to five 
regions of CFTR (fig. 4.1) detect a protein of -170kDa in immunoblot analysis 
of HT29 membrane lysates (fig. 4.2) and recognise HT29 cells in 
immunofluorescence analysis (fig. 4.3). Polyclonal antisera to P-galactosidase 
fusion proteins containing sequences corresponding to different regions detect 
a protein of -170kDa in immunoblot analysis of HT29 membrane lysates (figs. 
3.4), recognise HT29 cells in immunofluorescence analysis (figs. 3.5) and 
immunoprecipitate a protein of -170kDa from HT29 membrane lysate which is 
recognised by the monoclonal antibodies in immunoblot analysis (fig. 4.6). A 
previously published anti-CFTR polyclonal antiserum 169 [Crawford et al., 
19911 also immunoprecipitates a protein of -170kDa which is recognised by the 
monoclonal antibodies in immunoblot analysis (fig. 4.6). The level of 
expression of the protein recognised by these antibodies in HT29 cells is 
modulated by intracellular Ca2+ levels (fig. 4.7), a phenomenon previously 
ascribed to CFTR [Bargon et al., 1992]. All of these data indicated that the novel 
antibodies raised recognise CFTR. Two of the monoclonal antibodies were 
therefore used in immunohistochemical screening of different human tissues 
(fig. 4.8). Both antibodies show a similar pattern of immunoreactivity, 
recognising epithelial cells in pancreas, gut, liver, kidney, placenta, prostrate, 
seminiferous tubules and trachea. The gross overall pattern of protein 
expression detected by these antibodies is similar to that previously described 
using either other anti-CFTR antibodies or in situ hybridisation techniques 
[Crawford et al., 1991; Cohn et al., 1991; Marino et al., 1991; Trezise and 
Buchwald 1991; Trapnell et al., 1991; Trezise et al., 1992; Tizzano et al., 1993). 
However, significant differences are noticeable: 
* The entire length of the villi are stained in colonic epithelia (fig. 4.8a). This is 
in contrast to the data presented by Trezise et al., [1992] which show that, in rat, 
CFTR is expressed at the base of the villi and MDR at the top. 
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* There is clear expression of the protein recognised by MabCF8 in tracheal 
epithelia (Fig. 4.8e), whereas it has previously proved difficult to demonstrate 
CFTR expression in these cells by immunocytochernical means [Crawford et 
al., 19911 and assays of CFTR mRNA levels have suggested that there is low 
level expression of the protein in the respiratory tract [Trapnell et al., 19911. 
* There appears to be expression of the protein recognised by MabCF8 in 
certain non-epithelial cells in some tissues (fig. 4.8d). 
9 Others have shown, by in situ hybridisation techniques, that in the rat 
uterus CFrR expression is limited to the epithelial lining of the endometrium 
with no expression in the underlying stroma or myometrium [Trezise and 
Buchwald 19911. MabCF8 recognises the myometrium and some stromal cells 
in addition to epithelial cells of the endometrium (fig. 4.8c and d). 
These differences posed the question of whether the antibodies cross-reacted 
with other proteins within cells. 
CFrR is a member of the ABC transporter class of multiple membrane 
spanning protems [Higgins and Hyde, 19911. This family is large with almost 
100 recognised prokaryotic and eukaryotic members [see Higgins 1992 for recent 
review]. A recently described yeast metal resistance protein (YCF1) has striking 
overall similarity to MDR and CFTR, including a region with strong sequence 
homology to the previously considered unique R domain in CFTR [Szczypka 
et al., 19941. It seems likely that numerous other members of this family are 
still to be identified. It is not improbable that, since CFTR is an ABC 
transporter, anti-CFIR antibodies will recognise other members of this family. 
Indeed, it has recently been demonstrated that a monoclonal antibody raised 
against a synthetic peptide corresponding to part of the CFTR sequence 
recognises Hlyb, an E. coli. member of the ABC transporter family with 
limited linear sequence homology to CFTR (B. Holland pers. comm. 1). It 
seems highly likely that some anti-CFTR antibodies will recognise other 
I Holland, 13. 'A monoclonal antibody to the F508 region of CFTR recognises the equivalent ATPase domain of 
the haemolysin translocator HlyB1 International workshop on 'anti-CFTR antibodies' Pads, France 1993 
sponsored by Associatloon Franchise de Lutte contre Is Mucovoscosidose (AFLM) 
92 
eukaryotic members of the ABC transporter family if immuno-cross-reactivity 
can occur between prokaryotic and eukaryotic members of that family. 
Immunoblot (fig. 4.11) and immunofluorescence assays (fig. 4.12) clearly 
show that the novel antibodies described do recognise a protein in cells which 
fail to express CFTR (fig. 4.9). This protein (or possibly proteins) is of a similar 
size to CFTR (fig. 4.11) and is immunologically closely related to CFTR (as 
demonstrated by the fact that it is recognised by diverse monoclonal and 
polyclonal antibodies raised against different regions of CFTR). The data 
presented here indicate the importance of demonstrating the specificity of 
antibodies to CFTR. 
The antibodies described here should provide a means of identifying 
other members of the ABC transporter family that are not only structurally, 
but may also be functionally, related to CFTR. The anticipated way forward in 
this work is to use these antibodies to immunoprecipitate proteins both from 
cell lines known to express CFrR and from those which have been shown not 
to express CFTR. Amino acid sequence of the -170kDa proteins could then be 
ascertained by micro-sequence analysis. The antibodies could also be used to 
immunoscreen a cDNA expression library constructed using mRNA isolated 
from Hela cells. Immunopositive clones would be isolated and subjected to 
DNA sequence analysis. The identification and characterisation of novel 
sequences with strong homology to CFTR may prove to be highly significant in 
the understanding of the disease and have possible implications for therapy. 
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CHAPTER 5 
PRODUCTION AND SCREENING OF ScFv ANTIBODIES 
5.1 INTRODUMON 
Recombinant phage antibody technology has the power and versatility 
to mimic the features of immune diversity and selection. Two different 
systems for the production of phage display antibody fragments against CFTR 
have been adopted in this study, the first of which is described in this chapter. 
The phagemid vector pCANTAB5 was developed by Cambridge 
Antibody Technology and is commercially available from LKB-Pharmacia. 
Most of the reagents needed for synthesis of an antibody library using this 
vector were supplied by Pharmacia prior to their commercial availability so 
that procedures could be tried, tested and modified. The pCANTAB5 vector is 
based on pUC119 [Vieira and Messing, 19881 and contains restriction sites Sfi 1 
and Not 1 such that antibody fragments can be cloned between the leader 
sequence and the amino terminus of bacteriophage coat protein g3p (fig. 5.1). 
The expression of the antibody-g3p fusion protein is controlled by an inducible 
lac promoter. The phagemid is propagated in TG2 Lcoli. which contains the 
lac Iq gene, encoding for the lac repressor required to block transcription of the 
lac promoter and prevent accumulation of excess antibody-g3p which can be 
toxic to the cell. Further repression of the relatively leaky lac promoter is 
achieved by incubating transformed E. coli. at 30*C (allowing slower growth 
than incubation at 371C) and including glucose in the culture media which 
forces catabolite repression of cAMP stimulated transcription. When 
expression of the fusion protein is required (after the addition of helper phage) 
so that it can be accumulated into the assembling phage, the transformed 
E. coli. are grown at 3711C in the absence of glucose. 
This system is based upon the cloning of ScFv antibody fragments 







Fig. 5.1 pCANTAB 5 phagemid cloning vector, including 
ScFv inserted into Sfi 1 and Notl restriction sites 
Plac inducible lac promoter 
Ampr P lactamase gene 
ori origin of replication 
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peptide linker (Gly4-Serb [Bird et al., 1988; Huston et al., 19881 by a process of 
'Fsplicing by overlap extension' [Horton et al., 1989). The heavy and light chain 
variable regions are amplified separately by PCR. The primers are designed 
such that the ends of the amplified antibody sequences that are to be joined to 
the peptide linker contain complementary sequences to the linker nucleotide 
sequence. When the heavy and light chain PCR products are mixed with the 
linker nucleotide sequence, denatured and reannealed, the strands having the 
matching sequences will overlap. These overlapping ends can then act as 
primers and extension in the presence of Taq polymerase facilitates the 
production of a ScFv where the three components (heavy chain, light chain 
and linker) are 'spliced' together, see fig. 5.2. 
The g3p leader sequence directs the expressed antibody-g3p to the inner 
membrane of the Exoli.. The g3p coat protein portion of the fusion protein 
becomes embedded in the inner membrane with the antibody portion exposed 
in the periplasmic space. The heavy and light chains are held together by the 
flexible 15-an-dno acid linker which should facilitate chain pairing and 
minimise refolding and aggregation problems when the two variable regions 
are expressed individually [Huston et al., 19911. The mature phage extruded 
from the cell should display at least one copy of the ScFv fusion protein as well 
as copies of the native g3p protein. 
In order to characterise the processes involved in the production of 
phagemid antibody expression libraries, the initial library was generated using 
mRNA from two different hybridoma cell lines shown by ELISA to produce 
monoclonal antibodies (M&bCF2 and MabCF8) to peptides corresponding to 
regions of CFTR. Further characterisation of these monoclonal antibodies 
indicates that they recognise either CFTR or protein(s) with very similar 
characteristics to CFrR (see chapter 4). It was anticipated that using mRNA 
from these hybridoma cell lines would enable the production of a phagemid. 
library that would be useful for testing and optimising the screening strategies 
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Fig. 5.2 Cartoon representing the construction of a ScFv by the 
mechanism of gene splicing by overlap extension. 
BOX 1: Heavy (Hc) and light chain (Lc) antibody gene fragments 
which have been amplified independently by PCR are mixed with 
linker sequence, with all components in equal concentrations. Areas 
of the heavy and light chain sequences that are complementary to 
the linker sequence are depicted by 10 - 
BOX 2: The sequences are denatured and reannealed such that the 
overlapping regions can combine and act as primers for each other. 
Extension of the overlaps (depicted as --Ov ) occurs in the presence 
of Taq polymerase enabling the component parts to be spliced 
together. 
BOX 3: Addition of 5' heavy chain and 3' light chain primers 
(depicted by IIII. - ) and subsequent PCR gives amplification of the 
full length ScFv product. 
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immunised animal sources. 
5.2 MErHODS AND MATMIALS 
As mentioned in the introduction the majority of reagents were 
supplied by Pharmacia prior to their commercial availability. The Pharmacia 
'Recombinant Phage Antibody System' is now available in three modules: 
Mouse ScFv Module (27-9400-01), Expression Module (27-9401-01) and 
Detection Module (276-9402-01). 
5.2.1 Obtaining cDNA from Hybridoma Cells 
RNA was obtained from hybridoma cells producing Mabs, to the CF2 and 
CF8 peptides. Eight, T75 flasks of cells were pooled and RNA was prepared 
from them using a Pharmacia RNA Extraction Kit. mRNA was then isolated 
using a Pharinacia mRNA Purification Kit. cDNA synthesis was carried out on 
the mRNA using a Pharmacia. First Strand cDNA Synthesis Kit with 0.02t&g 
pd(N)6 primer in the reaction. 
5.2.2 Preparation and Cloning of ScFv Fragments 
The procedures followed are summarised in fig. 5.3. 
Primary PCR amplification was carried out on first strand cDNA to 
generate suitable quantities of antibody heavy (-340 b. p. ) and light (-325 b. p. ) 
chain DNA. The reactions were carried out using the primers provided by 
Pharmacia. The heavy chains were amplified using a single pair of primers 
whereas the light chains were amplified with a mixture of 10 primers (both 5' 
and Y). The individual oligonucleotide sequences of the primers were 
unspecified. Standard techniques (section 2.2.7) were followed with an 
annealing temperature of 550C and 30 cycles. The amplified heavy and light 
chain antibody products were separated from other reaction components on a 
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First strand cDNA synthesis AAAAA 
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Amplification of heavy and light chain antibody variable regions by PCR 
PCR products linked 
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PCR amplification of assembled ScFv with the introduction of restriction sites 
Sfil 
Notl 




Fig. 5.3 Cartoon representing the preparation and cloning of ScFv fragments into pCANTAB5 
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preparative 1% NuSieve 3: 1 agarose gel. The appropriate DNA bands were 
excised with a scalpel blade and the DNA was extracted from them using 
standard phenol/freeze procedures (section 2.2.9 method A). During the 
assembly reaction, the antibody heavy and fight chain DNA were joined into a 
single chain with linker DNA. When the linkers annealed to the heavy and 
light chain DNA, they served to prime a fill-in reaction in the presence of Taq 
DNA polymerase. The success of the reaction was dependent on the relative 
concentrations of the heavy, light and linker-primer fragments. Assessment of 
these concentrations was achieved by comparison of band intensities of 
samples of the fragments run out on an ethidium bromide stained gel. The 
assembly reaction included equimolar concentrations of heavy, light and 
linker-primer fragments and appropriate concentrations of Taq polymerase 
enzyme, buffer and dNTPs. The reaction components were overlaid with 
mineral oil and the tube was placed in a thermocycler and run on 7 cycles as 
follows: 94*C for 1 minute; 63*C for 4 minutes. 
In a second PCR, the assembled ScFv DNA was amplified with primers 
that added restriction sites. The primers annealed to the 5' end of the heavy 
chain (where a Sfi 1 restriction site was added) or the 3' end of the light chain 
(where a Not 1 restriction site was added). PCR was carried out using standard 
procedures (section 2.2.7) with an annealing temperature of 55*C and 30 cycles. 
The amplified ScFv product was purified on Clontech Chromaspin 100 
column and digested first with Sfi 1 at 50"C for 16 hours and then with Not 1 at 
37*C for 12 hours, to yield a product that could be cloned into a similarly 
digested phagemid vector. 
The digested ScFv was purified on Clontech Chromaspin 100 column 
prior to ligation into the prepared pCANTAB5 vector. The ligation reaction 
was set up using Boehringer lunit/ jul T4 Ligase with supplied buffer, loong 
pCANTAB5 and approximately 50ng of the prepared antibody ScFv fragment 
in a total volume of 351d and incubated for 16 hours at 1611C. Excess salt was 
removed from the ligation reaction by microdialysis prior to transformation 
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into Ecoli . TG2 ceUs [Gibson, 1984). 
5.2.3 Transformation and Rescue of the Recombinant Antibody Phage Library 
40#1 aliquots of freshly prepared competent TG2 cells (section 2.2.13 
method A) were electroporated with 31d of the ligation reaction as described in 
section 2.2.14. After incubation for one hour at 37*C the SOC media was 
supplemented with 100mg/ml ampicillin (to select for the phagemid) and 2% 
glucose, before further incubation at 37*C in a shaking incubator at 250rpm. 
After 3 hours, 2.5xlO9pfu of M13KO7 helper phage was added to the cell 
suspension to 'rescue' the phagemid with its antibody ScFv gene insert from 
the transformed cells. M13KO7 provided the necessary information for 
packaging the recombinant pCANTAB5 phagen-dd and for assembling the g3p- 
ScFv fusion protein on the tip of the assembled phage. The culture was 
incubated at 37*C for 30 minutes at 150rpm followed by 30 minutes at 250rpm, 
to facilitate helper phage infection. The sample was then centrifuged at 8OOg for 
10 minutes, the supernatant was discarded and the pellet was resuspended in a 
glucose deficient medium containing 100mg/ml ampicillin (to select for cells 
with phagemid) and 50mg/ml kanamycin (to select for cells infected with 
M13K07). In the absence of glucose, the lac promoter present on the phagemid 
was no longer repressed and synthesis of ScFv-gene3 was facilitated. The cells 
were grown for 16 hours at 370C in a shaking incubator with the M13KO7 
present to initiate phage replication and the production and release of 
complete phage particles. The cells were then pelleted by centrifugation at 
10OOg for 10 minutes and the supernatant containing the recombinant phage 
was recovered. 
5.2.4 Enrichment of the ScFv Library 
The phage-displayed antibodies capable of binding specific antigen in the 
form of the peptides CF2 and CF8 (to which the original Mabs were raised) 
were selected and enriched by two methods: 
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Method A- Panning against the antigen. 
In the panning procedure, 5ml of recombinant phage culture was pre- 
incubated for one hour at room temperature with an equal volume of PBS 
containing 2% skimmed milk powder (blocking buffer). Panning was 
performed on a Petri dish that had been coated with antigen (2.5ml of each of 
the BSA linked CF2 and CF8 peptides diluted to 10mg/ml in PBS) by an 
overnight incubation at 4"C. Prior to panning, excess antigen solution was 
removed and the the panning plates were pre-incubated with blocking buffer 
as above. The blocking buffer on the panning plate was replaced with the pre- 
blocked phage solution. After 2 hours incubation at 370C, the phage solution 
was removed and the dish was washed 20 times with PBS and 20 times with 
PBS containing 0.1% Tween 20. The bound phage was eluted by adding 1ml of 
100mM triethylamine which was left for 10 minutes at room temperature 
before'being removed and neutralised with 1M Tris-HC1, pH7.4. The 
neutralised recombinant phage solution was reinfected into log-phase TG2 
cells by incubating with the cell culture for 30 minutes at 371C with 
intermittent gentle shaking. The reinfected E. coli. were then cultured and the 
phage rescued as described previously. 
Method Biotin-capture of phage on streptavidin coated magnetic beads. 
Streptavidin-conjugated paramagnetic beads (M280 Dynal) were used to 
capture phage bound to biotinylated CF2 and CF8 peptides as described by 
Hawkins et al., [19921. 
Prior to each round of selection, the titre of recovered phage 
supernatants was increased by PEG precipitation. 476 (w/v) PEG-8000 and 3% 
NaCl were added to phage supernatants, mixed and left on ice for 30 minutes. 
The precipitated phage was spun down at 9000 rpm in a Sorvall, RC5C 
centrifuge for 20 minutes at 41*C. The supernatant was removed and the pellet 
allowed to drain before resuspension in 50-50ORI TE buffer and transferred to 
102 
an Eppendorf tube. The resuspended phage solution was spun at full speed in a 
microfuge for 5 minute to pellet any residual cellular material. The 
supernatant was transferred to a fresh Eppendorf tube. 
Precipitated phage was diluted 1: 5 with blocking buffer (2% skimmed 
milk powder in PBS) and incubated for 1 hour at room temperature with 
continuous mixing. The streptavidin-conjugated paramagnetic beads were also 
pre-incubated in blocking buffer as above. 100nM of each of the biotinylated 
peptides CF2 and CF8 diluted in blocking buffer were added to the pre- 
incubated phage and incubated as above to allow the ScFvs on the phage to 
bind to the peptides. The pre-incubated magnetic beads were then pelleted on a 
Dynal magnet, the blocking buffer was removed and the beads were 
resuspended in the phage/peptide solution. After a 15 minute incubation at 
room temperature with continuous mixing, the magnet was used to isolate the 
beads along with biotinylated peptides attached to the streptavidin on the beads 
and any phage bound by ScFvs to the peptides. The supernatant containing any 
unbound peptide and phage was removed and the beads were washed 20 times 
with 0.1% Tween 20 in PBS followed by 20 times with PBS. Washes were 
performed by resuspending the beads in the wash solution, mixing well, 
magnetically isolating the beads and removing the supernatant. The washing 
steps should remove any residual unbound phage. The bound phage were 
eluted from the beads by incubation with log phase TG2 cells at 370C for one 
hour. The beads were then isolated magnetically and the supernatant culture 
containing TG2 cells reinfected with selected phage were rescued as described 
previously. 
Four rounds of enrichment were carried out with each of the methods 
described above. After the final round of enrichment the reinfected TG2 cells 
were plated out and grown overnight on nutrient agar plates containing 
ampicillin and 2% glucose. Individual colonies on these plates were then 
picked for microtiter plate rescue of the enriched clones and ELISA. 
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5.2.5 Microtiter Plate Rescue of Enriched Phage Clones 
Single colonies from the quarternary enrichment step were picked and 
used to inoculate 9001d of 2TY containing 100pg/ml ampicillin and 2% glucose 
in wells of a 96 well microtiter plate (Falcon 3911). This master plate was 
incubated at 30*C overnight with shaking at 100-150rpm. 200PI aliquots of 2TY 
containing 100sig/ml arnpicillin, 2% glucose and 1.05x1010 pfu of M13KO7 were 
added to each well of a second microtiter plate. 20pl of saturated culture from 
each well of the master plate was transferred to a corresponding wen in the 
second plate which was then incubated at 37"C with shaking at 150rpm- At this 
point the master plate was sealed with parafilm, and stored at VC. After 2 
hours the cultures in the second plate began to appear turbid and the plate was 
spun at 400g for 10 minutes at VC in a MSE bench top centrifuge fitted with 
microtiter plate adapters. After removal of the supernatants the cell pellets 
were resuspended in 2001d of 2TY medium containing 100tig/ml ampicillin 
and 50lig/ml kanamycin. The plate was then incubated overnight at 370C with 
shaking. After centrifugation (as described above) the supernatants were 
transferred to a fresh microtiter plate and incubated at room temperature for 
about 20 minutes with equal volumes of blocking buffer, ready for ELISA 
screening. 
5.2.6 Selection of Individual Phage Clones Recognising Antigen by ELISA 
The phage-displayed recombinant antibodies were detected in an 
enzyme-linked immunosorbant assay (ELISA) as described by McCafferty et al., 
[19901. The ELISA plates were coatedwith either CF2 or CF8 peptide conjugated 
to BSA or biotin. 
Diluted conjugated peptide (5mg/ml in PBS) was added to a 96 well flat 
bottom microtiter plate (Falcon) and incubated overnight at 4"C to coat the 
wells with antigen. The antigen solution was removed from each well and 
replaced with 200#1 PBS containing 2% skimmed milk powder (blocking 
buffer) and incubated at room temperature for 1 hour. The blocking solution 
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was removed and replaced with the diluted recombinant phage supernatants 
from the microtiter plate rescue. After incubation 37'C for 1 hour the 
supernatants were removed from the wells and the wells washed 3 times in 
PBS with 0.05% Tween 20. A secondary antibody (raised to M13 phage and 
conjugated to horse radish peroxidase ), at a dilution of 1 in 5000 in blocking 
buffer was then added to each well and incubated at 37*C for 1 hour. The 
solution was removed and the wells washed with PBS as described above. The 
ELISA was developed by the addition of 200#1 of developing solution (ABTS 
(4.7mg 2', 2'-Azino-Bis(3-Ethylbenzthiazoline-6-sulphonic Acid)diammonium) 
in 21ml 0.05M citric acid, pH4.0 and 371d H202) to each well. The colour 
reaction was assessed after 40 minutes. (The intensity of the colour reaction 
was measured at 410 nm in a Labsystems Multiscanplus, plate reader. ) 
5. Z7 Sequencing of ScFv Clone8 
Sequencing was carried out using the Sequenase version 2.0 kit (see 
section 2.2.15) with the following primers: 
pCANTAB-Sl 5'- CAACGTGAAAAAATTATTATrCCC -3' 
pCANTAB-S3 5- GGTTCAGGCGGAGGTGGCrCTGG -3' 
pCANTAB-S4 5- CCAGAGCCACCrCCGCCrGAACC -Y 
pCANTAB-S6 5- GTAAATGAATMCrGTATGAGG- 3' 






- . 4- 
pCANTAB5-S6 
The oligonucleotide primers were synthesised within the SERC funded 
Molecular Recognition Centre, University of Bristol. However, they are now 
commercially available from Pharmacia as a pCANTAB5 sequencing primer 
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set (27-1585-01). Each sequencing reaction was run on short and long 
sequencing gels in order to maximise the length of readable sequence obtained. 
53 RESULTS 
5.3.1 Construction of the ScFv Library 
An ScFv antibody library was constructed from mRNA extracted and 
purified from the cells of two hybridoma cell lines which had previously been 
shown by ELISA to produce monoclonal antibodies to peptides found within 
the sequence of CFTR. Reverse transcription of the mRNA was followed by 
PCR to give amplification of heavy and light chain antibody sequences (see fig. 
5.4a). Amplified PCR products were purified from an agarose gel and mixed 
with a suitable concentration of peptide linker nucleotide sequence. The heavy 
chain, linker and light chain sequences were then 'spliced' together by a process 
of overlap extension. In this process any light chain sequence could combine 
with any heavy chain sequence in a random manner. Once constructed, the 
ScFv sequences were further amplified by PCR with primers that contained Sfi 
1 and Not 1 restriction sites to give products of approximately 750bp (see fig. 
5.4b). The amplified ScFv sequences were digested with Sfi 1 and Not 1 
restriction enzymes prior to ligation into the previously digested pCANTAB5 
vector. Thus constructed, the ScFv antibody library was used to transform 
E. coli. by electroporation and 'rescued' with M13KO7 helper phage. Phage 
particles extruded from the transformed bacteria were presumed to contain the 
single stranded phagemid DNA encoding for the specific ScFv antibody 
fragment that was expressed on its tip. Phagemid DNA prepared from six 
colonies of transformed E-coli. restricted with Sfi 1 and Not 1 and run on an 
agarose gel revealed that the majority of transformants contained a 750bp Sc]Pv 














Fig. 5.4 Construction of the phagemid antibody library from hybridoma cells 
The standard markers were X DNAHitid 111, OX174 DNA Hae 111 digests 
a) pcr products of heavy and light chain variable regions 
b) pcr of assembled ScFv fragment 
0 Not 1, Sfi 1 digests of plasmid DNA from TG2 cells trnsformed with 
pCANTAB5 showing ScFv inserts 
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ScFv Markers 
5.3.2 Sequencing ScFv Clones 
Phagemid DNA was prepared from six colonies of transformed E. coli. 
by Magic Mini Prep (see section 2.2.1 method B). The six DNA preparations 
were all sequenced with each of the four sequencing primers described above 
(section 5.2.7). The DNA sequences were then collated and analysed using the 
University of Wisconsin Genetics Computer Group (UWGCG) suite of 
programmes. The light chain sequences are given in fig. 5.5. Of the six light 
chains analysed, five have almost identical sequences (ScFvLc2 - ScFvLc6). 
The sixth light chain sequence (ScFvLcl) only has limited homology to the 
other five. ScFvLcl and ScFvLc6 were compared to sequences in the 
EMBL/Genbank data base release number 39 version 6, and the five most 
homologous sequences for each were identified and are given in fig. 5.6. The 
heavy chain sequences are given in fig. 5.7. The six heavy chains analysed can 
be divided into two sets of three (Set 1: ScFvHcl, ScFvHc2 and ScFvHc3, Set2: 
ScFvHc4, ScFvHc5 and ScFvHc6) with each set containing almost identical 
sequences. One member of each set (ScFvHcl and ScFvHc6) was compared to 
sequences in the EMBL/Genbank data base release, number 39 version 6, and 
the five most homologous sequences for each were identified and are given in 
fig. 5.8. 
5.3.3 Panning of the ScFv Library 
Enrichment of the antibody library for ScFv which bound to peptide 
antigen was attempted by carrying out four consecutive rounds of selection by 
panning. After each round of panning, phage displaying antibodies were 
reinfected into E-coli. and rescued with helper phage. After the fourth round of 
panning, enriched clones were picked, cultured and rescued in a microtiter 
plate. ELISA analysis of supernatants from individual colonies did not indicate 





























3 attttggaatgtatttctgtcaacagagtaacagctggcctctcacgttcggtgc. ggga 
4 attttggaatgtatttctgtcaacagagtaacagctggcctctcacgttcggtgc. ggga 








Fig. 5.5 Alignment of the light Chain sequences of six ScFv clones. Sequences 
ScFvLc2 - ScFvLc6 are almost identical. Discrepencies between them are 
highlighted in bold. The ScFvLc1 sequence shown in italics has only limited 
homology to the other five sequences. 
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a)ScFvLcl 
Acassým Description % 
Number 
i M37021 Mouse Ig rearranged kappa-chain mRNA V4 
region, partial cds. 96.9 
ii M32042 Mouse Ig kappa-chain mRNA V-j region, from 
hybridoma P6514-2, partial cds. 96.9 
iii M20281 Mouse Ig active kappa chain mRNA V-region ý 
Vjkl, partial cds, clone 24F3. 96.9 
iv X05796 Mouse hybridoma M-0 Ig L-chain rearranged I 
V(k)-JCk)l gene. %. 9 
v I M20279 I Mouse Ig active kappa chain mRNA V-region 
I Vjkl, partial cds, clone 4F8. 96.9 
b)ScFv Lc6 
Acoessim Description % 
Number HbnvIW 
i 2556 Mouse mRNA fragment for G1 kappa 
immunoglobulin A 20/44 light chain (V-J). 96.7 
ii X02555 Mouse mRNA fragment for G1 kappa 
immunoglobulin A 8/4 light chain (V-J). 96.7 
iii M35667 Mouse lysozyme-binding Ig kappa chain 
(HY]HEL-10) V2342 region mRNA, partial cds. 95A 
iv M93959 Mouse Ig active kappa-chain V-region partial cds. 
95.3 
v M95945 Mouse mRNA sequence, partial cds. 
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Fig. 5.6 Tables presenting the 5 most homologous 
sequences identified for 
a)ScFvLcl and b)ScFvLc6 from the EMBL/Genbank 
data base, release number 39, version 6. 
Further information and references for each of the 
sequences given can be obtained from the 







































Fig. 5.7 Alignment of the heavy chain sequences of six ScFv clones. Sequences 
ScFvHcl - ScFvHc3 given in italics are almost identical, discrepencies between 
them are highlighted in bold. Sequence ScFvHc4 - ScFvHc6 given in plain text 
are almost identical, discrepencies between them are highlighted in bold. 
Limited homology exists between the two sets of heavy chain sequences. 
ill 
a)ScFvHcl 




i L21020 Mus musculus immunoglobulin heavy chain 
(IgH) mRNA, VDJ region, partial cds. 94.4 
i M84429 Mouse rearranged heavy chain variable region 
gene sequence. 93.3 
iii j D13201 Mouse gene for innunoglobulin heavy chain 
variable region. 93 
iv M36218 I Mouse Ig heavy chain mRNA V region, partial 
cds, H220-23VH. 92.8 
v I X02554 Mouse mRNA fragment for G2a kappa 
immunoglobulin A6/24 heavy chain (V-D-J). 92.8 
b)ScFvHc6 
Acoession Description % 
Number Homology 
i U04228 Mus musculus BALB/c 57-1M Ig gern-dine heavy 
chain V region, Vh7183 family, partial cds. 
-- 
99 
ii X59192 Mouse immunoglobulin variable region heavy 
chain (T5-625) mRNA. 98.6 
iii Z11163 M. musculus non-functional rearranged Ig heavy 
chain variable region V-BK. 95.6 
iv M92390 M. musculus Ig rearranged ganuna chain mRNA, 
V-D-j region, partial cds. 94.3 
M. musculus heavy chain immunoglobulin 
VH62H3. 94.3 
Fig. 5.8 Tables presenting the 5 most homologous 
sequences identified for 
a)ScFvHcl and b)ScFvHc6 from the 
EMBL / Genbank data base, release number 39, 
version 6. 
Further information and references for each of the 
sequences given can be obtained from the 
EMBL/Genbank data base via the accession 
numbers. 
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5.3.4 Selection of ScFvs by Biotin-wCapture 
Prior to ScFv antibody selection with CF2 and CF8 biotinylated peptides, 
the ability of streptavidin to bind to serial dilutions of the biotinylated 
peptides was analysed on a dot blot (see fig. 5.9) using standard techniques 
[Harlow and Lane 19881. Streptavidin was found to bind to both CF2 and C78 
biotinylated peptides when 50ng or more peptide was present. However, 
streptavidin did not bind to non-biotinylated CF2 and CF8 peptides even when 
an excess of 5 gg peptide was present. Selection for phage harbouring antibodies 
that bound to the biotinylated peptides was performed. Parallel control 
experiments were carried out where the phage were incubated with non- 
biotinylated peptides. Phage bound to peptide could only be recovered by 
capture of the biotinylated peptides on the streptavidin coated magnetic beads, 
i. e. phage bound to non-biotinylated beads could not be recovered. If selection 
was peptide specific, enrichment of the library could only be continued after 
incubation with biotinylated peptides. However, after four rounds of selection 
no significant phage enrichment was obtained with biotinylated peptides 
relative to the non-biotinylated peptides. ELISA analysis on supernatants from 
individual colonies, after four rounds of selection with biotinylated peptide, 
did not indicate any positive clones producing antibodies to CF2 or CF8. The 
possibility that binding the antigenic peptides to the wells on the ELISA might 
have masked the peptide epitope to which the ScFv fragment binds was 
addressed. The surface of the wells were pre-coated with streptavidin before 
incubating them with biotinylated peptide, thus enabling the peptide epitope 
to be more fully exposed for antibody binding. However ELISAs of the phage 
selected by biotin-capture, using such coated plates, were still negative for ScFv 
binding. 
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Fig. 5.9 Dot blot analysis of the binding of streptavidin to serial dilutions of 
biotinylated CF2 and CF8 peptides 
Concentrations of biotinylated peptides Negative 






Confirmation that the phagemid library derived hybridoma cells did 
contain ScFv fragments was established by sequencing a selection of library 
clones. The heavy and light chain sequences obtained all showed strong 
homology with previously identified murine antibody variable regions (see 
figs. 5.6 and 5.8). Two distinct sets of sequences were identified for each of 
these heavy and light chains. This result was anticipated because the library 
was produced from two clonal populations of hybridoma cells (CF2 and CF8), 
each expressing a single antibody. A few minor differences were identified 
within the sets of apparently identical sequences. These variations were 
probably introduced during the PCR amplification steps. TheTaq polymerase 
error rate for PCR amplification of antibody variable gene segments (using 
similar PCR conditions to those used in this study) has recently been 
determined to be about 2.6xlO-5/bp per cycle [Ford et al., 1994]. As only two 
heavy and light chain sequences (disregarding minor differences) were 
obtained from the antibody library clones, it seemed reasonable to assume that 
approximately half of the heavy and light chain combinations in the 
constructed ScFvs would be those of the original pairings found within a 
donal hybridoma cell. 
ScFv antibody fragments have been found to successfully bind antigen 
by a number of different groups [Bird et al., 1988; Huston et al., 1988; Skerra and 
Pluckthun, 1988; Chaudhary et al., 1989; Glockshuber et al., 1990; Brietling et al., 
1991]. They have also been used as the antigen binding unit in much of the 
pioneering phage display antibody library research done in Greg Winter's 
laboratory in Cambridge [McCafferty et al., 1991; Clackson et al., 1991; Griffiths 
et al., 1993; Marks et al., 1993; Nissim et al., 19941. In the light of this, it seemed 
probable that ScFv fragments constructed from mRNA extracted from two 
clonal populations of hybridoma cells (CF2 and CF8) would bind to the 
peptides recognised by the monoclonal antibodies produced by the hybridoma 
cells (MabCF2 and MabCF8)- 
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A ScFv phage expression 'library 'constructed from only two clonal cell 
lines should not require enrichment by rounds of selection (either by panning 
or biotin-capture) prior to determination of clones expressing ScFv fragments 
that recognise peptide antigen by ELISA. However, full enrichment selection 
was undertaken in order to test and optimise the selection strategies that could 
subsequently be used with diverse antibody libraries. 
The apparent failure of the panning method to enrich for appropriate 
ScFv fragments could be explained by unsuccessful coating of the petri dish 
surface with peptide antigen. However, the conditions for coating the peptide 
onto the plastic surface were found to be satisfactory when the respective anti- 
peptide monoclonal antibodies were positively tested by ELISA. Another 
explanation may be that the phage displayed antibodies bound so strongly to 
the antigen that they were not eluted from it. Results did not improve when 
more stringent elution conditions were tested. It was predicted from positive 
ELISA results of the monoclonal antibodies against the peptides that the 
principal epitope for the ScFv fragments would be displayed and available for 
antibody binding on the panning dishes. Nevertheless, the epitope could have 
been more accessible if the antibodies were exposed to the peptides in solution. 
To facilitate this biotinylated peptides were prepared and the second method of 
antibody enrichment was undertaken. However, selection by biotin-capture 
and subsequent ELISA of enriched clones against biotinylated peptide also 
faded to isolate and identify ScFv fragments Chat bound to peptide antigen. 
Sequence analysis of phagemid DNA prepared from transformed E. coli. 
indicated that the library did contain correctly assembled ScFv fragments. Non 
existent or only weak binding of the antibody fragments to antigen peptides 
would explain the apparent failure of enrichment and ELISA techniques. This 
lack of binding could be caused by either the ScFv sequences being different 
from those found in the original hybridoma cells or the ScFv structures 
(formed from correct sequences) not being capable of binding antigen in the 
same way as the original monoclonal antibodies. 
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Differences in the ScFv sequences relative to the variable chains found 
in the original hybridoma cells could be explained by the introduction of Taq 
polymerase errors during the PCR amplification steps. A single base pair 
change in a region of the sequence encoding for a significant part of the antigen 
binding recognition site could be sufficient to have detrimental influence on 
the antigen binding of the expressed ScFv [Ito et al., 19931. If such a change 
occurred at the beginning of a set of PCR cycles it would be propagated through 
all subsequently amplified chains. This problem can be addressed by using 
DNA polymerase isolated from Thermococcus litoralis (Vent DNA 
polymerase available from New England Biolabs) to reduce the risk of Taq 
polymerase errors. Vent polymerase has 3-> 5' proofreading activity which 
enhances the fidelity of replication by the enzyme [Mattila et al., 1991; Kong et 
al., 19931. 
Assuming that at least some of the ScFv sequences are amplified 
correctly (i. e. without the introduction of Taq errors), then the possibility has 
to be considered that the inherent differences in the structure of ScFv 
fragments relative to the original monoclonal antibodies may have an adverse 
effect on antigen binding and possible reasons underlying this are considered 
in detail in chapter 9 of this study. 
In the light of the difficulties encountered with the Pharmacia pCantab5 
system in the screening of ScFv fragments derived from well characterised 
clonal hybridoma cells, it was decided not to pursue the use of the system in 
the production of antibody phagemid libraries from immunised animal 
sources. A second system which involved the expression of complete Fab 
fragments was adopted. This is described in chapters 6,7 and 8. 
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CHAPTER 6 
PRODUCTION AND SCREENING OF Fab ANTIBODIES FROM 
HYBRIDOMA CELLS PRODUCING Mabs TO THE CF8 PEPTIDE 
6.1 INTRODUMON 
The most complex proteins to be heterologously expressed on the 
surface of filamentous phage are antibody Fab fragments [Barbas, 1993c]. The 
cloning of these fragments is the basis of the second system adopted for the 
production of phage display antibody fragments in this study. 
The constant region domains present in Fab antibody fragments 
facilitate strong association between the heavy and light chains relative to the 
their smaller Fv counterparts [Nisohoff et al., 1975]. The binding between the 
heavy and light constant domains is both covalent (with the formation of a 
disulphide bridge) and non-covalent in nature. The resultant additional 
stability in the structure overcomes the need for an artificial covalent link 
between the chains such as the peptide linker in ScFv fragments. 
The phagemid vector pCornb3H-SS is a modified version of pComb3 
which was derived from the phagemid pBluescript [Barbas et al., 1991; Short et 
al., 19881 (see fig. 6.1). In this system unique restriction sites are provided for 
the independent cloning of the heavy chain variable domain and first constant 
domain (Fd) sequences (Xho 1 and Spe 1) and light chain sequences (Sac 1 and 
Xba 1). The SS designation (see fig. 6.1) represents the presence of stuffer 
fragments in the antibody fragment cloning sites. These sites facilitate the 
juxtaposition of heavy and light chain sequences with the carboxyl termini of 
the protein leader peptides which are transported into the periplasm. The light 
chain is inserted next to the outer membrane omp A leader peptide of E. coli. 
[Ghrayeb et al., 19841 and the Fd chain is inserted between a pel B leader peptide 
of Erwinia caratovora [Lei et al., 19871 and the C-terminal domain of of the 
phage coat protein g3p. The g3p portion of the resultant expressed fusion 
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Fig. 6.1 pComb3H-SS phagemid cloning vector 
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protein accumulates in the inner membrane of the E. coli. with the Fd region 
in the periplasmic space where it can associate with a light chain to form a 
functional Fab fragment. A5 amino acid flexible tether is located between the 
Fd and g3p components of the fusion protein to attenuate domain interaction 
[Huston et al., 19881. 
The expression of the heavy and light chain sequences is under the 
control of a lac promoter/ operator sequence. This should facilitate the 
production of equal amounts of the two chains and thereby reduce the 
likelihood of hornodimeric "Bence-Jones proteins" forming [Azuma et al., 
19741. The phagernid vector is propagated in XM-blue cells (Bullock et al., 19841 
that harbour the lac Iq allele encoding for the lac repressor required to block 
transcription of the lac promoter. Induction of transcription is accomplished 
in two possible ways. Either the lac repressor is titred out by many copies of 
the lac operator (e. g. in the presence of multiple copies of phagemids 
containing the lac operator) or added lactose analogue IPTG combines with the 
Lac repressor preventing it binding to the operator [Sambrook et al., 19891. 
Inclusion of the bacteriophage intergenic region in the vector allows 
helper phage initiated transcription of single stranded phagemid DNA. The 
helper phage infection leads to the expression of native g3p as well as 
phagemid derived Fab-g3p. Culturing of the phagemid in Ecoli. harbouring 
the lac Iq allele limits the fusion protein copy number [Bass et al., 1990]. The 
resultant packaged phage carries native g3p, which is necessary for infection, 
and the encoded Fab-g3p, which is displayed for selection. According to 
published'reports, , Fab fragments expressed with this system are monomeric in 
nature, thereby facilitating the isolation of specific, high affinity antibody 
clones [Bass et al., 1990; Burton et al., 1991; Barbas et al., 1991; 1993c]. 
in this study a series of Fab antibody libraries have been developed. The 
heavy and light chain sequences for each of these was derived from sources 
immunised to CFTR protein sequence. The construction of a Fab 'library' from 
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cloned hybridoma cells producing monoclonal antibodies (MabCF8) to a 
peptide sequence corrisponding to a region of CFrR, is described in this 
chapter. 
6.2 MATERIALS AND METHODS 
6.2.1 Obtaining cDNA from Hybridoma Cells 
RNA was obtained and mRNA purified from hybridoma cells 
producing Mabs to the CF8 peptide. Total RNA was isolated from eight T125 
flasks of hybridoma cells and then first strand cDNA synthesised using 
Pharmacia kits. 
6.2.2 Preparation and Cloning of Fab Fragments 
The procedures followed are summarised in figure 6.2. 
6.2.2.1 Preparation of Immunoglobulin DNA 
The polymerase chain reaction was used to amplify heavy and light 
chain antibody fragments. Mouse immunoglobulin primers were synthesised 
based on the original published set [Kang et al., 1991b]. 
Heavy chain Fd 3' primers: 
IGgl 5'- AGGCTTACrACTACAATCCCTGGGCACAAT - 3' 
IGg2a 5- GTTCrGACrAGTGGGCACTCrGGGCrC - 3' 
Heavy chain variable domain 5' primers: 
Hcl 5, - AGGTCCAGCrGCrCGAGTCrGG -3' 
Hc2 51 - AGGTCCAGCrGCrCGAGTCAGG -3' 
Hc3 5'- AGGTCCAGCTTCrCGAGTCrGG-3' 
Hc4 51 - AGGTCCAGCrTCrCGAGTCAGG-3' 
Hc5 5- AGGTCCAACrGCrCGAGTCrGG -3' 
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mRNA extraction and purification 
Hybridoma colle Spleen calls 
AAAAA 
+ 




Amplification of cDNA of Heavy and Light chain antibody CH1 and V domain 
+ 
Clone Light Chain into pComb3H Vector 
4 
446ý Competent Cells (XL1 - Blue) 
Clone Heavy Chain into Vector plus Light Chain 
144- 
Competent Cells (XL1 - Blue) 
I 
Package Phage -40- Helper Phage 
4 
Pan M) with Antigen 
4 
Make Soluble Fab 
4 
Test by ELISA 
Fig. 6.2 Cartoon representing the preparation and cloning 
of Fab fragments into pComb3H-SS 
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Hc6 5- AGGTCCAACrGCrCGAGTC. ACG - 3' 
HO 5'- AGGTCCAACITCrCGAGTCTGG - 3' 
Hc8 F- AGGTCCAACITCrCGAGTCAGG - 3' 
Hc9 5'-AGGTHMCrICrCGAGTC(r/A)GG-3' 
Murine k fight chain 3' primer. 
5' - GCGCCGTCrAGAATTAACACrCATTCCrMGAA - 3' 
Murine light chain variable domain 5' primers: 
Lcl 5 - CCAGTTCCGAGC7CGTTGTGACrCAGGAATCI- 3' 
Lc2 5 - CCAGTTCCGAGCrCGTGTTGACGCAGCCGCCC -Y 
Lc3 51 - CCAGTTCCGAGCrCGTGCrCACCCAGTC'FCCA - 3' 
U4 5' - CCAGTTCCGAGCrCCAGATGACCCAGTCrCC. A - 3' 
Lc5 5' -CCAGATGTGAGCrCGTGATGACCCAGACrCCA-3' 
Lc6 5' - CCAGATGTGAGCrC TCATGACCCAGTCrCCA - 3' 
LO 5 - CCAGTrCCGAGCrCGTGATGACACAGTCTCCA - 3' 
Standard techniques were followed using an annealing temperature of 5211C 
and 35 cycles. Each reaction was carried out with individual primer sets. An 
aliquot (77o) of each individual PCR reaction was run out on a 1% agarose gel 
to look for the presence of amplified antibody DNA. The mineral oil was 
carefully removed from the surface of the PCR reaction mixes and the PCR 
products with common 3' primers were pooled, purified by phenol extraction 
and phenol: chloroform: isoamyl extraction before precipitating. The recovered 
DNA was run out on a preparative 0.8% Seakem GTG agarose gel. The 
appropriate (680bp) DNA bands were excised from the gel and extracted using 
standard electroelution techniques (section 2.2.10 method B). The DNA was 
quantified and digested with restriction enzymes for 3 hours at 3711C. The light 
chain was incubated with Xba 1 and Sac 1 and the heavy chain with Xho 1 and 
Spe 1. The number of enzyme units and buffers used are summarised in table 
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Table 6.1 
Equivalent enzyme amounts and buffers for vector and PCR insert digestion 
(using enzymes and buffers obtained from Boehringer Mannheim ) 
Enzyme Buffer pComb3H-SS or pComb3H-H+L 




Spel H 3u 17u 
Xhol H 9u 70u 
Sacl A 5u 35u 
Xbal A 9u 70u 
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6.1. The restricted DNA was precipitated prior to purification for ligation by 
one of two methods. Either agarose gel electrophoresis followed by 
electroelution or by passage through a Chromaspin 100 column (section 2.2.8. ) 
prior to ligation. 
6.2.2.2 Preparation of Vector DNA 
The phagemid vector pComb3H-SS [Barbas et al., 19911 was generously 
provided by Drs. Burton and Barbas, The Scripps Research Institute, La Jolla, 
Cahfomia (see fig. 6-1). 
Phagemid DNA was prepared using the Qiagen method (section 2.2.2). 
The vector DNA was digested with restriction enzymes for 3 hours at 3711C. 
Initially pComb3H-SS was incubated with Xha 1 and Sac 1 and, after ligation of 
the light chain into the vector, restriction with Xho 1 and Spe 1 was carried 
out. The number of enzyme units and the buffers used are summarised in 
table 6.1. The digested DNA was precipitated prior to being run out on a 0.8% 
Seakem GTG gel. The appropriate DNA band was excised from the gel and the 
DNA extracted using standard electroelution procedures (section 2.2.10 method 
B). 
6.2.2.3 Ligation of DNA - 
The insert ligation efficiencies and the extent of background (vector 
alone) ligation were tested on a small scale prior to to library construction. For 
the library construction, 1400ng vector DNA was ligated with 450ng of the cut 
PCR product in the presence of 101d BRL T4 Ligase and 40pt 5x buffer in a total 
reaction volume of 2001d. After overnight incubation at room temperature, 
the ligation reaction was stopped by heating at 65*C for 10 minutes, precipitated 
and resuspended in 15pl of water. This was microdialysed against water prior 
to transformation. 
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6.2.3 M13 Helper Phage Preparation 
VCSM13 helper phage was prepared from an initial stock obtained from 
Stratagene. A series of dilutions of the phage stock were prepared in LB. 1pl of 
each dilution was added to 100pl cultures of XL1-blue cells O. D. A6OW-4 which 
were then transferred to 3ml top agar at 42"C. The top agar was immediately 
poured onto LB plates which had been prewarmed to 37*C. The plates were 
incubated at 3711C overnight. The next day a single plaque was picked from a 
plate that had an appropriate distribution of phage and used to inoculate 10ml 
of a fresh XL1-blue cell SB culture. This was incubated at 370C for 2 hours 
before being transferred to 500ml SB containing 10lig/ml tetracycline and 
70og/ml kanamycin and grown at 37"C overnight. The overnight culture was 
spun at 25OOg for 15 minutes. The supernatant was transferred to a fresh tube, 
heated at 700C for 20 minutes and recentrifuged as above. The supernatant was 
then stored at 4"C 
To calculate the titre of the helper phage preparation, serial dilutions 
were prepared in LB. 11d of each dilution was transferred to 1001d of XL1-blue 
cell culture (O. D. A600--l) which was in turn added to 3ml top agar at 420C. The 
top agar was immediately poured onto LB plates prewarmed to 3711C, which 
were then incubated overnight at 370C. The number of plaques on each plate 
were counted the following day and used to calculate the titre of the helper 
phage preparation. 
6.2.4 Transformation of the Recombinant Antibody Libraries 
The libraries were transformed into XL1-blue competent cells (section 
2.2.13 method B) by electroporation (section 2.2.14). All 151d of library DNA 
was transformed into 400pi of electrocompetent cells. Electroporation cuvettes, 
were flushed out with a total volume of 5ml SOC which was then incubated, 
shaking at 37*C for 1 hour to allow the cells to recover. 
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6.2.5 Replication and Recovery of the libraries 
10ml prewarmed (37"C) SB (20, ug/ml carbenicillin (carb) and 1011g/ml 
tetracyline (tet)) was added to the transformed cells. 101il, Ild and 0.11d of the 
culture were further diluted into 100jil SB and plated out onto LB (carb) plates. 
The plates were left to grow in a 3711C oven overnight. The cultures were 
plated in order to isolate individual library clones and to allow estimation of 
the size of the antibody library. 
The 10ml culture was incubated for a further 1 hour at 37*C, shaking 
before the carbenicillin concentration was increased to 50pg/ml. After another 
1 hour incubation shaking at 37*C, the 10ml culture was transferred to 100ml 
prewarmed (37"C) SB containing 50lig/ml carb and 100lig/ml tet and left at 
370C in a shaking incubator. For recovery of the light chain library this culture 
was left overnight. For recovery of the final Fab (heavy and light chain) library, 
1012 pfu of VCSM13 helper phage was immediately added to the culture which 
was then incubated at 370C shaking for 2 hours. 70, ug/ml of kanamycin was 
added before leaving it to grow in a shaking incubator at 3711C overnight. 
After construction of the both the light and heavy chain libraries, 
phagemid DNA was prepared from the overnight culture using the Qiagen 
method (section 2.2.2). 
After construction of the Fab (light and heavy chain) library, the 
supernatant recovered after pelleting the cells was precipitated with PEG/ NaCl 
on ice for 30 minutes. The precipitate was spun down at 90OOrpm in an SS34 
rotor at 4*C for 20 minute. The supernatant was discarded and the tubes 
containing the pellets were allowed to drain on paper towel for about 10 
minutes to remove as much PEG solution as possible. The pellets were then 
resuspended in a total volume of 2ml PBS/ I%BSA which was transferred to 
Eppendorf tubes and spun in a microcentrifuge for 10 minutes to pellet any 
residual cell debris. The supernatant was recovered to fresh tubes and stored at 
40C. Library phage preparations were always re-amplified prior to use in 
panning if they had been stored for more than 24 hours. Re-amplification was 
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achieved following the panning protocol (6.2.6) from the point marked *. 
The phage suspension was titred by infecting 501d volumes of XL1-blue 
cells (O. D. A600=0.5) with 11d of 10-3p, 10-6 and 10-8 dilutions of the phage 
suspension at room temperature for 15 minutes before plating -out on LB carb 
plates and incubating overnight at 370C. 
6.2 6 Panning 
Several rounds of panning were used to select for specific binding clones 
within the library. 
Wells of an ELISA plate were coated overnight at VC with 1jig CF8-BSA 
peptide diluted in PBS. The following day the wells were emptied and washed 
three times with water before filling them with 3% BSA in PBS, blocking 
buffer and incubating them at 37"C for 1 hour in a humidified incubator. The 
blocking buffer was then replaced with 1001d phage, suspension and incubated 
for a further 2 hours 37*C in the humidified incubator. The phage was then 
removed and the wells were washed by filling them with PBS/0.5%Tween 
(PBST), pipetting vigorously up and down and leaving for 5 minutes before 
removal. In the first round of panning, the wells were washed once in this 
fashion, in the second round they were washed five times and in the third and 
subsequent rounds they were washed ten times. After washing the wells, the 
phage were eluted by adding 50; d of elution buffer (OAM HCl (adjusted with 
glycine to pH2.2)/lmg/ml BSA) to each well. This was left at room 
temperature for 10 minutes prior to pipetting up and down vigorously and 
transferring to wells each containing 31d 2M Tris. base neutralising buffer. 
*The eluted phage was used to inoculate 2ml (per well) log phase 
(O. D. A600=1) XL1-blue cells. The cells were then incubated at room 
temperature for 15 minutes to allow reinfection of the phage, before 
proceeding with replication as described for the original Fab library in section 
6.2.5. 
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6.2.7 TA cloning of Heavy and Light Chain Sequences 
Heavy and light chain variable region sequences were amplified by PCR 
from the prepared mRNA using the primers supplied by LIKB-Pharmacia (as 
described in section 5.2.2). The PCR products were analysed and quantified by 
running 10016 of each on a 1% agarose gel. The remainder of the PCR products 
were purified on a Chromaspin 100 column prior to direct ligation into the 
Promega pGEM-T TA cloning vector. 
The linearised TA vector has 3' terminal thymidine residues at both 
ends which greatly improves the efficiency of ligation of PCR products into the 
plasmid. The ligation reactions were set up in a final volume of 10pl with 50ng 
vector DNA, lOng antibody insert DNA and T4 DNA ligase and reaction buffer 
supplied by Promega. The reaction was incubated at 1511C. After 3 hours the 
ligation mixtures were n-ticrodialysed with water (section 2.2.12) and 201 of 
each of the heavy and light chain reactions were electroporated into E. coli.. 
(section 2.2.14). 
6.2-8 Sequencing Antibody Clones 
6.2.8.1 Sequencing pComb3H - Fab Clones 
Sequencing was carried out using the Sequenase version 2.0 kit (see 
section 2.2.15) with the Wowing primers: 
Lc 5- TGGCrGCTrTCGCrACCGTG -31 
Hc 5- 1 GI IATTACFCGCTGcccAA -3, 
The primers were designed to sequence from the amino terminal of each (of 
the variable domains) to enable the comparison between variable domain 
sequences. 
6.2S. 2 Sequencing TA Cloned Antibody Variable Regions Primers 
Sequencing of TA cloned heavy and light chain variable regions was 
carried out with the foUowing primers: 
T7 5' - TAATACGACrCACrATAGGGCGA - 3' upstream of cloning site 
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SP6 51 -AT'ITAGGTGACACrATAG- 3 'downstream of doning site 
6.3 RESULTS 
6.3.1 Construction of the Fab Library 
A Fab antibody library was constructed from the mRNA of hybridoma 
cells that had been shown to produce monoclonal antibodies which recognised 
a peptide found within the CFTR sequence (see fig. 4.1). Following reverse 
transcription of the mRNA, the heavy Fd and light chain antibody sequences 
were amplified by PCX Reactions with different pairs of 5' and 3' heavy or 
light chain primers were carried out separately to maximise the amplification 
of all appropriate m. RNA sequences. 
Initial test ligations performed prior to the construction of the light 
chain antibody library revealed that the background vector ligation was about 
20% that of the test insert ligation, slightly higher than desired. The method 
for the purification of the restricted antibody chain sequences was changed 
from agarose gel electrophoresis and electroelution to passage through a 
Chromaspin column. This resulted in a reduction in the light chain 
background ligation to less than 1%, sufficiently low to proceed with the 
construction of the light chain library. The size of the light chain library was 
estimated to be 1.2x107 clones. 
The restricted heavy chain sequences which had been purified on a 
Chromaspin column, were subsequently ligated into the prepared vector 
(containing the light chain sequences). Test ligations for the heavy chain 
insertion indicated a background of 8% and the estimated size of the heavy 
chain library was 1X106 clones. Phagemid DNA prepared from eight of the 
library clones, restricted with Xba 1 and Sac 1 and with Xho 1 and Spe 1 and run 
on an agarose gel, revealed that the majority of transformants contained both 





Fig. 6.3 Agarose gel analysis of restriction enzyme digests of mini prep 
DNA obtained from CF8 Fab library clones. 
Lanes A-H: Clones 1-8 digested with Xba 1 and Sac 1 to cut out 
light chain inserts 
Lane 1: Lambda DNA-Hind III / Fx-174 DNA-Hae III digest markers 
Lanes j-Q: Clones 1-8 digested with Xho 1 and Spe 1 to cut out 
heavy chain inserts 
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6.3.2 Sequencing Analysis of Antibody Fragments 
6.3.2.1 Sequencing Fab (3ones 
Phagemid DNA was prepared from four library colonies by Wizard Mini 
Prep and sequenced using the 2 sequencing primers described above (section 
6.2.8.1). The DNA sequences were collated and aligned using the University of 
Wisconsin Genetics Computer Group (UWGCG) suite of programmes. The 
light and heavy chain sequences are given in figs. 6.4 and 6.5 respectively. 
Apart from one base difference in a heavy chain sequence, all the sequences 
were found to be identical within their respective chain groups. One heavy 
and one light chain sequence were each compared to sequences in the 
EMBL/Genbank data base, release number 39, version 6. The five most 
homologous sequences were identified for each and are given in fig. 6-6a and b. 
6.3.2.2 Comparison to ScFv Sequences 
Cells from two different hybridoma lines producing monoclonal 
antibodies that recognise either CF8 and CF2 peptide sequences were the source 
of mRNA used in the construction of the ScFv antibody library described in 
the previous chapter. Hybridoma cells producing monoclonal antibodies that 
recognise CF8 peptide were the source of mRNA used in the construction of 
the Fab library described above. Both libraries contain the variable domains of 
heavy and light chain antibody sequences. It was therefore anticipated that the 
heavy and light chain sequences amplified with the PCR primers given in 
section 6.2.2.1 would have identical regions with sequences amplified with the 
PCR primers provided by Pharmacia (see section 5.2.2. ). When the sequences 
were compared using the UWGCG suite of programmes this was not found to 
be the case. Two sets of sequences were identified for each of the heavy and 
light chain variable domains in the ScFv library (see section 5.3.3). Although 
the Fab heavy and light chain variable region sequences were not identical to 
any of the ScFv sequences they did show a far greater degree of homology to 






















Fig. 6.4 Alignment of the light chain sequences of four Fab clones. 





















Fi&6.5 Alignment of the heavy chain sequences'of four Fab clones. Only one 
base difference was identified, this is highlighted in bold type. 
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a) CF8 Lcl Light Chain Sequence Comparison 
Acoesdon Description % 
Number Homology 
i M26003 Mouse Ig rearranged kappa-chain Vk 23.32 gene, 
partial cds, from Abelson virus transformed B cells 98.5 
i X65097 M. musculus mRNA for IG light chain Vj region 
(M-T408). 95.1 
iii M35667 Mouse lysozyme binding Ig kappa chain 
(HyHEL-10) V23-J2 region mRNA, partial cds. 91.3 
iv M19913 Mouse Ig rearranged kappa-chain mRNA, clone 
AN11k. 91 
v X59211 Mouse immunoglobulin variable region light 1 
, chain (T9-1) mRNA. 
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b) CF8 Hc2 Heavy Chain Sequence Comparison 
Acomsim Description % 
Number HomolW 
i M21814 Mouse/ human Ig heavy chain constant region 
mINA, segment 1. 95.4 
i S50856 Ig VH=chimeric anti-human neuroblastoma. 
antibody (mice, Genomic, 706nt). 94.5 
iii U07204 Mus musculus done 8 anti-C5a Ig heavy chain V 
region mRNA, partial cds. 93.2 
iv J00532 Mouse Ig gem-dine H-chain, c57bi /6 b-np-related 
gene 0186-1, v-ii. 92.8 
v Z12781 M. musculus mRNA for VH-gene seq. of naturally 
occuring, somatically mutated memory B cell. 92.8 
Fig 6.6 Tables presenting the 5 most homologous 
sequences identified for 
a)FAb Lcl done and b)Fab Hc2 done 
from the EMBL/ Genbank data base, release 
number 39, version 6. 
Further information and references for each of the 
sequences given can be obtained from the 
EMBL/ Genbank data base via the accession 
numbers. 
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and 6.8). The ScFv sequences with the greater homology to the Fab sequences 
were most probably those derived from MabCF8 producing cells rather than 
MabCF2 producing cells. Although a reasonable homology was found between 
the sequences, the differences between them were considered to be too great to 
be only due to Taq Polymerase, PCR errors. A likely reason for the variations 
was that the mRNA for the production of the two antibody libraries had been 
prepared from different clonal populations of MabCF8 producing hybridoma 
cells. This explanation was investigated. 
6.3.2.3 TA Cloning of ScFv Heavy and Light Chain Sequences 
The sequence differences described above could be explained if the 
mRNA for the production of the two antibody libraries had been prepared 
from different clonal. populations of MabCF8 producing hybridoxna cells. To 
test this theory, the cDNA used in the construction of the Fab library was 
amplified using the Pharmacia. PCR amplification primers (section 5.2.2. ). The 
PCR products were ligated directly into the Promega TA cloning vector (see 
section 6.2.7). DNA, derived from colonies of Exo1i. that had been transformed 
with the TA vector, was sequenced using the primers described in section 
6.2.8.2. When aligned to the respective Fab heavy or light chain sequences they 
were found to be identical (see figs. 6.7 and 6.8). 
633 Panning of the Fab Library 
Enrichment of the antibody library for Fab fragments which bound to 
peptide antigen was attempted by consecutive rounds of selection by panning. 
After each round of pannin& eluted phage were reinfected into Exo1i. and 
rescued with helper phage. Unfortunately, effective panning was prevented by 
the occurrence of considerable cell lysis in the reinfected and rescued phage 
cultures. This problem has been encountered by two groups responsible for 
pioneering research in phage antibody display technology (Andrew Griffiths 


























Fig. 6.7 Alignment of light chain sequences of ScFv and Fab clones. 
1) Fab fragment Lcl sequence (see fig. 6.4) 
2) TA cloned light chain variable domain sequence 
3) ScFv light chain sequence 6 (see fig. 5.5) 
4) ScFv light chain sequence 1 (see fig. 5.5) 
Sequences 1 and 2 were derived from mRNA from one clonal hybridoma cell 
line producing monoclonal antibodies to the CF8 peptide. Sequences 3 and 4 
were derived from mIRNA from two clonal hybridoma cell lines producing 
monoclonal antibodies to the CF2 and CF8 peptides. 1,2 and 3 are assumed to 
encode anti CF8 light chain sequences, variations between them are 
highlighted in bold type. The considerable differences in ScFvHc1 relative to 
FabLcl and TA cloned sequences are probably due to different clonal. derivation 











1 agcagaggcctggacaaggc. ttgagtggattggagagattaatcctagcaacggtcgtac 
2 agcagaggcctggacaaggc. ttgagtggattggagagattaatcctagcaacggtcgtac 
3 agcagagecatggaaagagccttgagtggattggagatattaatcctaacaatggtggtac 










Fig. 6.8 Alignment of heavy chain sequences of ScFv and Fab clones. 
1) Fab fragment Hc3 sequence (see fig. 6.5) 
2) TA cloned heavy chain variable domain sequence 
3) ScFv heavy chain sequence 1 (see fig. 5.7) 
4) ScFv heavy chain sequence 6 (see fig. 5.7) 
Sequences 1 and 2 were derived from mRNA from one clonal hybridoma, cell 
line producing monoclonal antibodies to the CF8 peptide. Sequences 3 and 4 
were derived from mRNA from two clonal hybridoma, cell lines producing 
monoclonal antibodies to the CF2 and CF8 peptides. 1,2 and 3 are assumed to 
encode anti CF8 heavy chain sequences, variations between them are 
highlighted in bold type. The considerable differences in ScFvHc1 relative to 
FabHc3 and TA cloned sequences are probably due to different clonal. derivation 
of the mRNA. Sequence 4 represented in italic is assumed to encode anti CF2 
heavy chain. 
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La Jolla) pers. comm. ) The phage used in the construction of antibody libraries 
do not routinely lyse the cells that they have infected. The extensive lysis of 
the cell culture was most likely to be due to either the presence of residual 
detergent on the glassware used or contamination of the culture with a lytic 
phage. Both these possibilities were addressed. Any glassware used in the 
culture of E. coli. harbouring the antibody phage library was thoroughly rinsed 
several times and filled with distilled water prior to sterilisation by 
autodaving. The water should have assisted removal of any residual detergent 
during the autoclaving process. Attempts were made to avoid contamination 
of the cell cultures with a lytic phage. All solutions used in the panning 
process were freshly prepared and sterilised by autodaving. Fresh competent 
cells were prepared for the initial transformation of the Fab antibody library 
and for reinfection of subsequently panned phage. Fresh helper phage were 
also prepared. Despite these preventative measures, the lysis of the cultures 
persisted. 
63.4 ELISA Analysis of Phage Cultures 
The population of phage recovered from E. coli. transformed with the 
Fab library was precipitated and then tested for binding to BSA conjugated CF8 
and CF7 peptides by ELISA as described in the previous chapter (section 5.2.6). 
The CF7 peptide was included as a negative control to determine whether 
phage binding was specific to CF8 peptide. The colormetric readings of the 
developed ELISA plate did not indicate a significant difference in phage 
antigen binding to the two peptides. 
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6A DISCUSSION 
Confirmation that the constructed Fab 'library' contained heavy and 
fight chain antibody sequences was established by sequencing library clones. 
The sequences obtained. showed strong homology to previously identified 
murine antibody sequences (see figs. 6.6a and b). Barring minor differences, the 
heavy chain sequences and the light chain sequences were found to be 
identical. This was anticipated because the 'library, had been constructed from 
mRNA derived from a clonal hybridoma cell line. Minor differences in 
sequence may be introduced as a result of Taq polymerase errors during the 
PCR amplification of the antibody sequences [Ford et al., 19941. 
Comparisons were made between sequences found in ScFv and Fab 
antibody libraries, both of which had been prepared from MabCF8 producing 
hybridoma cells. Significant heavy and light chain sequence variations were 
found between the two libraries. This raised the possibility that the different 
primer sets used in the construction of the two libraries may preferentially 
amplify different sequences. This was unlikely to be the case because the 
number of heavy chain and light chain sequences available for amplification 
was limited to two for ScFv library construction and one for the Fab library 
construction, according to the number of clonal cell fines used. To clarify the 
situation, mRNA used in the construction of the Fab library was amplified 
with the PCR primers used for the construction of the ScFv library, cloned and 
sequenced. Sequence comparisons revealed that the hybridoma cells producing 
MabCF8 used in the construction of both the ScFv and Fab antibody libraries 
must have been derived from two different clonal populations (figs. 6.7 and 
6.8). 
Selection of antigen binding Fab fragments was attempted by panning. 
Unfortunately, progress in these enrichment steps was limited by the repeated 
lysis of reinfected phage cultures. Since the use of thoroughly rinsed, 
detergent-free glassware did not prevent cell lysis the most likely explanation 
for this problem was contamination of the culture with a lytic phage. This 
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contamination problem persisted despite the use of freshly prepared and 
sterilised materials. A way of overconýdng this difficulty is addressed in chapter 
8. 
The Fab phage expression library, was constructed from a clonal cell line 
and from sequence analysis appeared to consist of only one heavy chain and 
one fight chain sequence. Each Fab fragment should have been virtually 
identical and enrichment of such a library for antigen binding by panning a 
superfluous process. However, it was undertaken in order to assess and 
characterise the selection strategies that could be used in the analysis of a more 
diverse antibody library. 
It is a well established phenomenom, that Fab antibody fragments bind 
antigen in a similar manner to the complete antibody molecule. It was 
anticipated that Fab fragments derived from a hybridoma cell line and 
expressed on the surface of phage would display the same specificity of antigen 
recognition as the monoclonal antibodies produced by the hybridoma cells. 
ELISA analysis had been used to establish that MabCF8 specifically bound to 
BSA conjugated CF8 peptide and not CF7 peptide. However the phage display 
Fab fragments did not appear to display the same discriminatory antigen 
binding. Three possible explanations for this lack of specificity are outlined 
below: 
i) The cloned Fab sequence may have been slightly different to that found in 
the original hybridoma cells due to the introduction of Taq Polymerase errors 
during the PCR amplification step (see section 5.4). 
ii) Fab dimers may be necessary to enable sufficient avidity for antigen binding 
[Crowthers and Metzger, 1972; Pack and Pluckthun, 1992; Pack et al., 19931. The 
pComb3H vector is constructed in such a way as to permit on average only one 
Fab molecule per phage particle [Barbas et al., 19911 which may not exhibit 
sufficient antigen binding affinity to hold phage to the solid phase peptide 
[Clackson et al., 19911. 
iii) The phage antibody specificity could have been masked by the presence 
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of Fab fragments ("stickies") that exhibit non specific binding to the solid 
phase antigen (Greg Winter (MRC, Cambridge) pers. comm. ). 
The first two of the problems described above may be overcome when 
more diverse Fab antibody libraries are panned and screened. When a specific 
antibody sequence needs to be maintained to ensure antigen bindin& then the 
fidelity of the PCR amplification is likely to be critical. However, if a library is 
constructed from the random combination of a varied repertoire of heavy and 
light chain sequences, the introduction of Taq polymerase errors during PCR 
should have a less deleterious effect. Indeed, mutations introduced into the 
antibodý sequences may enhance the antigen affinity of the assembled Fab 
fragments [Panka et al., 1988; Marks et al., 1991b; Barbas et al., 1992b]. 
The dimeric nature of antigen binding sites on antibodies increases the 
potential avidity with which the antibody can bind to antigen [Crothers and 
Metzger, 1972; Carteret al., 1992]. However, the presence of two antigen 
binding sites is not essential for antigen binding [Barbas, 1993c]. When selecting 
from a large diverse antibody library derived from an immunised source 
against the antigen to which the library has been raised, it is reasonable to 
anticipate that some monomeric antigen binding Fab fragments will be 
identified [Burton, 1991; Winter et al., 19941. The following two chapters 
describe the construction of such libraries. 
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CHAFTER 7 
PRODUCMON AND ANALYSIS OF Fab ANTIBODY LIBRARIES 
FROM MICE IMMUNISED WITH CELLS EXPRESSING CFTR 
7.1 INTRODUi-MON * 
CFrR has not yet been isolated *and purified and is therefore not 
available for immunisation. One way of generating immunogen is to express 
rýgions of CFTR as fusion proteins (see Chapters 3 and 8). An alternative 
strategy, described in this chapter, is to use whole cells or membrane 
preparations from cells that express CFTPL 
Cell lines BPV and 2wt were selected for use in the immunisation of 
mice. These cell lines were produced by transf ection of C127 a (non- 
transformed) clonal cell line derived from the mammary tumour of an RIII 
mouse [Lowry et al., 19781.2wt cells were generated by the transfection of C127 
cells with the eukaryotic expression vector CL3AXBPVXT-NEO [Reddy et al., 
19871 into which the CFrR cDNA sequence had been cloned [Marshall et al., 
I 1994]. BPV cells were derived from transfection of C127 cells with 
CL3AXBPVXT-NEO vector without a CIFTR insert. Expression of sequences 
cloned into the CL3AXBPVX17-NEO plasmid is controlled by the mouse 
metallothionein I promoter. Other components of the vector include the 
bovine papilloma virus genome, which facilitates episomal maintenance of 
the plasmid, and the neomycin phosphotransferase gene, which confers 
resistance to the aminoglycoside antibiotic G418. The cell lines were 
generously supplied by Alan Smith (Genzyme). 
CFrR is one of very many potential antigens expressed on the surface of 
the transfected cells. Strategies were pursued to maximise specific 
immunisation to CFTR, see fig. 7.1. 
RIH mice were chosen for direct immunisation. with the 2wt cell line 
which expresses CFTR. The ceU line has been derived from the same mouse 
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Using RIH Mice 
Immunised with 2wt 
cell line as cell 
suspension or as 
solution of membrane 
lysate preparation 
* 
Using Balb-c Mice 
First mouse immunised 
with BPVceU line as cell Give serum from 
suspension or solution of ,.,, 
first mouse to 
membrane lysate second mouse 
preparation 
Second mouse 
immunised with 2wt 
cell line as cell 
suspension or solution 
of membrane lysate 
Fig. 7.1 Strategies for the immunisation of RIH and Balb-c mice. 
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strain, therefore its antigenicity should predominately be due to expressed 
products of the DNA with which it has been transfected, principally CFTR. A 
suspension of cells was given to one set of mice. However, because it was not 
known how long these cells would remain intact in the immunised mice, a 
second set of mice were given a solution of a membrane lysate preparation 
from the cells. This ensured that at least the second set of mice were exposed to 
all epitopes of CFTR that are internal and external to the cell membrane. 
An alternative strategy was followed with Balb-c mice where the cell 
line was not syngeneic with the mouse strain and would therefore present 
many foreign epitopes to the murine immune system. To overcome this 
problem, a primary set of mice were immunised with cell suspension or a 
membrane lysate preparation from the BPV cell line. After three injections, 
serum from the primary set of mice was transferred to a secondary set of mice 
simultaneously with whole cells or a cell lysate preparation from the 2wt cell 
line which differs from the BPV cell line only in, the fact that the 
CL3AXBPVXT-NEO vector used to tranfect the original C127 cells did contain a 
CFI'R insert Antibodies in the serum from the primary mice should mask all 
the antigenic epitopes in the 2wt cells except those presented by CF17R. 
Therefore the immune response raised in the secondary mice should be 
predominately to CFTR- 
The pComb3H-SS vector system (see Chapter Owas adopted for the 
construction of Fab fragment phage display libraries from mRNA derived 
from the spleens of the immunised mice. 
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7.2 MATERIALS AND METHODS 
7.11 RTPCR 
RTPCR was carried out on mRNA isolated from 2wt and BPV tissue 
culture cells, using the CF7, CF8, and CFX primers, as described in section 4.2.2. 
PCR was also carried out using the fonowing pair of oligonucleotide primers: 
Actin 31 5- TGGAGAAGAGCTATGAGCI7G -3' 
Actin 32 5- GGGTACATGGTGGTACCACC -3' 
Actin 31 and 32 prime across exons of mouse beta-actin sequence to 
generate a fragment of 212bp from beta-actin cDNA [Alouso et al., 19861. 
7.2.2 Immunisation Protocols 
The mice were immunised with either suspensions of whole cells or 
solutions of membrane lysates prepared from the cells. Three mice were used 
for each immunisation scheme since, even in genetically identical animals, a 
single antigen preparation will elicit a different antibody response [Harlow 
and Lane, 19881 The immunisation strategies used in this study are 
summarised in fig. 7.1. 
7.2. Z1 Immunisation with Whole Cell Suspensions 
Transfected cells that had grown to confluency in T75 tissue culture 
flasks were removed from the flasks using Hank's Balanced Salt Solution 
(HBSS) containing 1mM EDTA and 5mM HEPES. The culture media was 
removed from the flask and replaced with 10ml supplemented HBSS. The 
flask was left for 30 minutes at room temperature on a mechanical rocker by 
which time the cells had come off the surface of the flask. The cells were 
recovered from the solution by centrifugation in a Sorvall ROB at 1000rpm, 
and 411C for 5 minutes. The cells were washed several times in HBSS 
supplemented solution. For each wash, pelleted cells were gently resuspended 
in the solution and incubated at room temperature on a mechanical roller for 
15 minutes prior to centrifugation as above. The final cell pellet was 
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resuspended in 0-4ml PBS and used for intra-peritoneal injection of the mice. 
One confluent T75 flask of cells was sufficient for the immunisation of 3 mice. 
7.2.2.2 Immunisation. with Membrane Lysate Preparations 
Membrane lysate was prepared from confluent 775 flasks of transfected. 
cells as described in section 2.2.18. The recovered membrane pellet was 
resuspended in 1% Mega-10 in PBS (200pl per T75 flask used). The solution 
was repeatedly passed through a 21 gauge needle attached to a 1ml syringe to 
ensure thorough resuspension of the pellet. The membrane lysate preparation 
was injected intra-venously into mice. Membrane lysate prepared from one 
confluent T75 flask of cells was sufficient for the immunisation of 2 mice. 
7.2.2.3 Immunisation of RIII Mice 
Three RIII mice were immunised with 2wt whole cell suspension and 
three with membrane lysate prepared from 2wt cells. Each animal was given 
four injections of the appropriate antigen at 2 weekly intervals. Ten days after 
the final injection, the mice were bled out and their spleens were removed for 
mRNA preparation. The antisera obtained from each set of mice were pooled 
and tested for 2wt cell specific binding by flow cytometry. 
M2.4 Immunisation of Balb-c hfice 
Immunisation of Balb-c mice was a two stage process. In the first stage, 
three mice were immunised with BPV whole cell suspension and three mice 
with membrane lysate prepared from BPV cells. After three injections at 
fortnightly intervals, a test bleed was taken from each mouse and tested by 
flow cytometry. The second stage of immunisation protocol was initiated 
when a greater antibody response to BPV cells was detected relative to that 
found with pre-immunisation antiserum. 
The Balb-c mice from the first stage of the immunisation protocol were 
bled out and the antisera obtained from each set of three mice was pooled. In 
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the second stage of the immunisation protocol, three mice were immunised 
with 2wt whole cell suspension and at the same time were injected intra- 
peritoneally with 0.15ml antisera derived from the mice immunised with BPV 
cells. Likewise, three other mice were immunised with membrane lysate 
prepared from 2wt cells and at the same time were given intra-peritoneal 
injections of 0.2ml antisera derived from the mice immunised with BPV 
membrane lysate. This dual injection procedure was repeated three more 
times at fortnightly intervals. Ten days after the fourth set of injections the 
mice were bled out and their spleens removed for mRNA preparation. The 
antisera"firom each set of mice were pooled and tested for 2wt cell specific 
binding by flow cytometry. 
7.2.3 Flow Cytometry 
Cell suspensions for flow cytometry were prepared in the same way as 
for the whole cell immunisation protocol described above (section 7.2.2). After 
several washes in EDTA and HEMS supplemented HBSS solution, they were 
pre-incubated for 30 minutes on ice in PBS/0.2%BSA/0.02% sodium azide 
followed by incubation for an hour with 1: 50 dilution of mouse antisera. After 
three washes in PBS/ BSA/ azide the cells were incubated for 45 minutes on ice 
with FITC conjugated goat anti-mouse IgG diluted 1: 500 in PBS/BSA/azide. 
Immediately prior to flow cytometry, cells were washed and resuspended in 
0.2ml PBS/BSA/azide. Analysis was carried out at Bristol University 
Veterinary School on an EPICS CS fluorescence activated cell sorter (Coulter 
Electronics Ltd. ) using an argon laser at 488nm, collecting log green 
fluorescence and forward light scatter. 
7.14 Preparation of Panning Wells for Fab Antibody Library Selection 
The mouse derived Fab antibody libraries were to be panned against 2wt 
cell antigens. 2wt cells that had grown to confluency in a T25 tissue culture 
flask were washed twice with PBS before being scraped into 5ml ice cold PBS. 
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The cells were transferred to a conical tube and pelleted by centrifugation in a 
Sorvall RC3B at 10OOrpm and VIC for 5 minutes. The cells were lysed by 
resuspension of the pellet in 0.3ml 176 Mega-10 in 50mM Tris pH7. The 
solution was transferred to an Eppendorf tube and spun in a microfuge at full 
speed for 3 minutes to pellet any undissolved material. The protein 
concentration in the resultant supernatant was determined by Bradford's 
analysis (section 2.2-20). Wells of an ELISA plate were coated overnight at VC 
with log of 2wt derived protein diluted in bicarbonate coating buffer pH9.5. 
Panning was performed as described in section 6.2.6. 
73 RESULTS 
7J. 1 RTPCR 
The immunisation protocols described above required the use of two 
cell lines, identical except for the fact that only one of them expressed CFrR. 
2wt cells and that BPV cells were analysed for CFrR expression by reverse 
transcription PCR (RTPCR). Oligonucleotide primers designed to amplify a 
DNA fragment spanning two exons of CFTR gave a specific band of the 
appropriate size with cDNA derived from 2wt cells, but not with cDNA 
derived from BPV cells, see fig, 7.2. 
7.3.2 Flow Cytometry 
BPV and 2wt CeUs were processed for flow cytometry and tested with pre 
and post immunisation serum derived from RIH and Balb-c mice. 
7.3.2.1 Flow Cytometric Analysis of RIII Antisera 
As can be seen from from fig. 7.3, there was no significant difference 
between the intensity of fluorescence of 2wt cells relative to BPV cells when 






Fig. 7.2 Agarose gel analysis of PCR products from mRNA obtained from 
2wt (lanes 1-3) and BPV (lanes 4-6) cell lines. Oligonucleotide primers 
designed to amplify a 255bp fragment spanning exons 23 and 24 of CFTR 
were used to amplify the material loaded in lanes 2 and 5. A band of this 
size is observed in lane 2 (2wt) but not lane 5 (BPV) indicating the presence 
of CFTR n-tRNA in 2wt but not BPV cells. Contamination of cDNA with 
genomic DNA was checked for using a pair of oligonucleotide primers 
designed to amplify a 192bp fragment within exon 24 of CFTR. The products 
of these reactions were loaded in lanes 3 and 6. A band of appropriate size is 
more intense in lane 3 (2wt) than lane 6 (BPV) but present in both lanes, 
indicating some contamination of the BPV cDNA with genomic DNA. The 
integrity of the template mRNA was tested using a pair of oligonucleotide 
primers designed to amplify a 212bp fragment spanning exons the mouse 
beta actin gene [Alousa et A, 19861. A very faint band of 212bp is present in 
lanes 1 (2wt) and 4 (BPV) indicating that intact mRNA was present in both 
original samples. DNA fragments of known molecular weight were loaded 













Fig. 7.3 Flow cytometric analysis of antisera obtained from 2wt immunised Rill 
mice. In each figure the uninterrupted line represents the staining of cells with 
pre-immunisation sera and the crossed line represents the staining of cells with 
post-immunisation sera. 
A- BPV cells stained with sera from mice immunised with membrane lysate. 
B- 2wt cells stained with sera from mice immunised with membrane lysate. 
C- BPV cells stained with sera from mice immunised with cell suspension 
D- 2wt cells stained with sera from mice immunised with cell suspension 
Log green fluorescence is plotted on the x-axis versus number of cells on the 
y-axis. All graphs are plotted to the same scale. 
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However, the pre-immunisation sera obtained from the RIII mice did exhibit a 
greater intensity of fluorescence with 2wt cells relative to BPV cells. 
7.3.2.2 Flow Cytometric Analysis of Balb-c Antisera 
Antisera obtained from Balb-c mice that had been immunised with 
either BPV cell suspensions or membrane lysates (in the first stage of the Balb- 
c immunisation protocol) were analysed by flow cytometry, see fig. 7.4. The 
intensity of fluorescence of BPV cells stained with this antisera (panels B and 
D) was greater than that detected with cells stained with pre-immunisation 
serum (panels A and Q. On this basis the antisera was used in the second stage 
of the Balb-c immunisation protocol. 
Flow cytometry was performed using antisera obtained from Balb-c mice 
that had been immunised with either 2wt cell suspensions or membrane 
lysates, together with serum obtained from the mice that had been 
equivalently immunised with BPV cell suspension or membrane lysates, fig. 
7.5 and data not shown. BPV and 2wt cells were stained with this antisera. as 
first antibody. A greater intensity of fluorescence was obtained with post 
immunisation serum on the 2wt cells (panel B) relative to the BPV cells 
(panel A). However, this difference in intensity of fluorescence was not 
detected when the cells were stained with pre-immunisation sera from the 
Balb-c mice. 
73.3 Construction of Fab Antibody Libraries 
Random combinatorial Fab antibody libraries were constructed in the 
pComb3H-SS vector system from mRNA extracted and purified from the 
spleens of the immunised mice. The methods followed for the construction of 
these libraries are described in the previous chapter. Four sets of immunised 
mice were used, namely: 
i) RIII mice immunised with 2wt cell suspensions, 






Fig. 7.4 Flow Cytornetric analysis of antisera obtained from BPV immunised 
Balb-c mice. BPV cells were stained with: 
A- prebleed sera from mice immunised with BPV membrane lysate. 
B- antisera from mice immunised with BPV membrane lysate. 
C- prebleed sera from mice immunised with BPV cell suspension 
D- antisera from mice immunised with BPV cell suspension 
Log green fluorescence is plotted on the x-axis versus number of cells on the 




Fig. 7.5 Flow cytometric analysis of antisera obtained from 2wt immunised 
Balb-c mice. In each figure the uninterrupted line represents the staining of cells 
with pre-immunisation sera and the crossed line represents the staining of cells 
with post-immunisation sera. 
A- BPV cells stained with sera from mice immunised with cell suspension 
B- 2wt cells stained with sera from mice immunised with cell suspension. 
Log green fluorescence is plotted on the x-axis versus number of cells on the 
y-axis. All graphs are plotted to the same scale. 
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iii) Balb-c mice injected with 2wt cell suspensions together with antisera from 
mice immunised with BPV cell suspensions, and 
iv) Balb-c mice injected with membrane lysate prepared from 2wt cells together 
with antisera from mice immunised with membrane lysate of BPV cells. 
cDNA synthesis and PCR amplification of antibody Fd and light chain 
sequences were performed independently on the mRNA obtained from each 
set of mice described above. This allowed for the maximum range of antibody 
sequences to be amplified from mRNA derived from mice immunised with 
the the different protocols. However after examination of the amplified 
antibody sequences by agarose get electrophoresis the PCR products from mice 
sets i) and ii) were pooled as were those from mice sets iii) and iv). Thus two 
Fab libraries were constructed, one derived from RM mice and one from Balb-c 
mice. 
Test ligations were performed prior to the construction of the light and 
heavy chain libraries. This was to assess the extent of the background vector 
ligation, which in turn was indicative of how thoroughly the prepared vector 
DNA had been a) restricted and b) purified from uncut vector DNA. The 
restricted heavy and light chain sequences were purified on Chromaspin 100 
columns prior to ligation into the prepared vector. For the R111 light chain, the 
background vector ligation was 9% that of the test insert ligation and for the 
Balb-c light chain it was 1776. These were considered to be low enough to 
continue with the construction of the light chain libraries. The size of the RIII 
light chain library was estimated to be 1-2x1O7 independent clones and that of 
the Balb-c library to be 8x1O6 independent clones. 
For the heavy chain test ligations the background was found to be 
considerably higher, 30% for RE[[ heavy chains and 28% for the Balb-c heavy 
chains. These were considered to be too high to continue with the construction 
of the heavy chain libraries. The Xho 1 -Spe 1 stuffer fragment in the 
pCornb3H-SS vector is only 300bp Ion& whereas the vector with inserted light 
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chain is 4Kb. When 20-30pg of vector DNA is restricted with Xho 1 and Spe 1, 
precipitated and run out on an 0.8% Seakem GTG gel (see section 6.2.2.2), it is 
difficult to distinguish linearised vector DNA with the heavy chain stuffer still, 
present (-4380bp) from vector DNA with the heavy chain stuffer fragment 
fully excise (-4080bp). This might have resulted in the contamination of the 
Xho 1 and Spe 1 restricted and prepared vector with some vector still 
containing the heavy chain stuffer. one way around this problem was to 
improve the efficiency of Xko 1 and Spe 1 restriction of the vector DNA such 
that all the heavy chain stuffer was restricted out. In an attempt to accomplish 
this the vector preparation protocol described in section 6.2.2.2 and table 6.1 
was modified in the following ways. The amount of Xho 1 enzyme used was 
increased from 9 units per jug DNA to be restricted to 12 u/ jig and the amount 
of Spe 1 enzyme used was increased from 3 units per jig DNA to 5u/ pig. The 
reaction times were also increased from 3 to 4 hours. Half of the total amount 
of enzyme was added at the beginning of the reaction time and half after 2 
hours. Heavy chain test ligations were repeated using vector DNA that had 
been prepared in this manner. The background ligations were reduced to 1% 
for the RIII heavy chain and 5% for the Balb-c heavy chain. The heavy chain 
libraries were subsequently constructed. The estimated size of the R111 heavy 
chain library was 5x106 independent clones and that of the Balb-c library was 
4x106 independent clones. Phagemid DNA prepared from library clones, 
restricted with Sac 1 and Xba 1 and with Xho 1 and Spe 1 and analysed on an 
agarose gel, revealed that 807o of transformants, contained both heavy and light 
chain antibody sequences. 
7.3.4 Sequencing Analysis of Antibody Fragments 
Phagen-dd DNA was prepared by Wizard Mini Prep from 8 colonies of 
each of the two mouse derived Fab libraries. The DNA was sequenced with the 
heavy and light chain primers given in section 6.2.8.1. The DNA sequences 
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were all compared to sequences in the EMBL/Genbank data base, release 
number 39, version 6. The five most homologous sequences identified for each 
chain sequenced are given in fig. 7.6a and b and 7.7a and b. 
7.3.5 Panning the Fab Libraries 
Enrichment of the antibody libraries for Fab fragments that bound to 
antigens in 2wt membrane lysate was attempted by panning. After each round 
of panning eluted phage were reinfected into Exo1i. and rescued with helper 
phage. However, effective panning was hindered by significant lysis of the 
reinfected and rescued cultures, as encountered in the panning of the 
hybridoma derived Fab library described in the previous chapter. Despite the 
considerable cell lysis the cultures did eventually grow sufficiently to continue 
with consecutive rounds of panning. Nevertheless, this was not considered to 
be valid enrichment because only those cells that survived cell lysis were 
selected, not necesssarily those that bound to the antigens. 
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Fig. 7.6a (pages 159 - 162). Light chain sequences 1 to 8, of Fab 
dones derived from the RM mouse antibody library. 
Fig. 7.6b (pages 163 - 166). Heavy chain sequences 1 to 8, of Fab 
clones derived from the RHI mouse antibody library. 
Fig. 7.7a (pages 167 - 170). Light chain sequences 1 to 8, of Fab 
clones derived from the Balb-c mouse antibody library. 
Fig. 7.7b (pages 171 - 174). Heavy chain sequences 1 to 8, of Fab 
clones derived from the Balb-c mouse antibody library. 
The five most homologous sequences identified from the 
EMBL/Genbank data base, release number 39, version 6, for each 
light or heavy chain, are presented in tables below each 
sequence. 
Further information and references for each of the data base 
sequences given, can be obtained from the EMBL / Genbank data 
base, via the appropriate accession number. 
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Fig. 7.6a R111 Light Chain 1. Length: 170 
gatatagtct acbon I --nt --! -a t=agggl; %, g --- 
51 tcaactc)cag -CJtca9c=m agtataagtt - agcaaaft gaactggtar- 
101 caqcagaagt -- intl --- -, -tttat ggmcatcoa 
151 acctggcttc ggagtooct 
Acomsion Description % 
number HonvIW 
i M36252 Mouse Ig light-chain mRNA V region, partial cds. 
H280-10. 98.2 
ii M36258 Mouse Ig light-chain mRNA V region, partial cds, 
from hybridoma H146-24B1VK 98.2 
iii M36259 Mouse Ig light-chain mRNA V region, partial cds, 
from hybridoma H147-25HlVY,. 98.2 
iv M36241 Mouse Ig light-chain mRNA V region, partial cds, 
from hybridoma H163-13OH9. 98.2 
v M36240 Mouse Ig light-chain. mRNA V region, partial cds, 1 
from hybridoma H163-13OF2. 98.2 
Fig. 7.6a Rill Light Chain 2. Length: 284 
1 atgtcocffl ctocactctc cctgactgtc rr 
51 CatCtCtt9C -' agtc' acacagtaat ggaaacaaat 
101 atttacattg -Iý tgaag aagmaggw acitetocaaa, - -1 -1 
151 tacaaagttt 
gg- -_ p___- ,_ _g __ _ 
201 tggatcaggg acagad tt"-- cactcaag&t c-- --agacitg -.. --tgagg 
251 atctgggagt t: tatt: tc tcbcaaagta cac&tgttoc tgga 
Acoffisim Description % 
number HomolW 
i M28131 Mouse gemdine Ig kappa chain gene V-1A region. 
99.3 
ii L22330 Mouse rearranged immunoglobulin kappa-chain _ 
mRNA V-J region, partial cds. 99.3 
iii D00080 Mouse kappa geremline V-region gene; subgroup 
VK-1 idiotype; anti-GAT. 99.3 
iv M15566 Mouse Ig germline V-kappa-1 chain gene (K5.1), 
exons land 2. 99.3 
v S54757 IgG3 VL--anti-DNA IgG3 light chain variable 
region (clone H161) (mice, mRNA, 324 nt). 99.3 
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Fig. 7.6a R111 Light Chain 3. Length. - 236 
Accession Description % 
number HOmOkw 
i M55318 Mouse IgK processed anti ds-DNA antibody chain 
V-region, from hybridoma C8.5. 98.3 
ii X16678 Mouse VK gene for kappa light chain variable 
I regan 
and J4 sequence. 96.2 
iii Z22104 M. domesticus, IgK variable region. 
94.9 
iv M34637 Mouse Ig rearranged kappa-chain (NC13-B12) 
mRNA Vk32-jk5 region, partial cds. 94_. 5 
1 Mouse Ig reaffanged kappa-chain (NC9-B4) 
mIRNA Vk32-jk4 region, partial cds. 94 
Fig. 7.6a R111 Light Chain 4. Length: 267 
11 i11 . 11 .A _9W 1 gatgacocag rm r4r 
t: gr r'l- _LIL 
51 ck-. atctctta MI tacacagtaa tggaaacacr. 
101 tAtttacatt ggtaoctgoa craa agatcctgat 
151 ctacaaa9tt smoogat ttvUrEgmt tto 
201 gtggatcagg acactc tcaqcagagt -.; Ctgag 
251 gatctgggag tttattt 
Accessim Description % 
number Homology 
M28131 Mouse germline Ig kappa chain V-1A region. 
i 99.3 
Z22114 M. domesticus IgK variable region 
ii 99.3 
Z22102 M. domesticus IgK variable region 
iii 99.3 
ý29 Mouse rearranged immunoglobulin kappa-chain 
iv mRNA V-J region, partial cds. 99.3 
Mouse rearranged immunoglobulin kappa-chain 
v L22330 
_mRNA 




Fig. 7.6a R111 Light Chain S. Length: 22s 
Accmsým Description % 
number Homology 
i M12427 Mouse Ig aberrant recombined kappa-chain double 
recombinant product from plasmacytoma PC3609. 98.7 
ii M34634 Mouse Ig rearranged Kappa-chain (NC12-N5) 
mRNA Vk8-jkI regionpartial cds. 98.7 
iii jM62927 Mouse rearranged Ig kappa-chain gene V-region. 
98.2 
iv Z29536 M. musculus (NZB X NZW)F1 mRNA for II 
Immunoglobulin kappa light chain V-region 98.2 
vI X65774 M. musculus DA for IgE antibody light chain 
(vi). 98.2 
Fig. 7.6a R111 Light Chain 6. Length: 23o 
Description % 
number Homoiogy 
i X59097 M. musculus mRNA (L14-3D10) for IgK light chain 
V-region. 99.6 
ii M34592 Mouse Ig kappa-chain mRNA V-j region partial 
cds. 99.6 
iii X59091 M. musculus mRNA (Ii-3B3) for IgK light chain V 
region. 99.6 
iv X14099 Mouse mRNA for kappa-immunoglobulin light 
chain variable r%ion 3SC13 variant 4 V-J4. 99, 
539 I Mouse anti-idio" antibody-resistant variant IgK 




Fig. 7.6a RIII Light Chain 7. Length: 285 
RI]t I 1 gatgaýý I A339'1-ý J. -. x; ocagga 
51 gtctttoctg gcaacaaact acactggt&t 
101 caacaaaaat ctcatcaacjt 
151 gtccabatet gggahr-, nrft 
201 atttcactet -.. I-atcaac agtgtggaga tggaatgtat 
251 ttctgbcaac agagt It--t-t acgtt 
Acoessim Description % 
number Homology 
i M34528 Mouse Ig kappa-chain (anti-insulin Ab 126) 
1 mRNA 
V region, partial cds. 98.2 
ii X02556 Mouse mRNA fragment for G1 kappa 
A 20/44 light chain (V-J). 97.5 
iii L08211 Mouse anti-Dna antibody kappa light chain 
variable region (Vk23 Vk family) mRNA. 97.5 
iv M16162 Mouse Ig kappa-chain VC-region (Vj5C) from 
. 
hyb doma MAK33. 97.5 
v A07699 Synthetic pBT111 DNA ýequence. 1 
97.5 
Fig. 7.6a R111 Light Chain 8. Length: 231 
1 ctcxmgat9a TV! -- agoaaw itt g -.... -gaa 
51 ggbcmmatg aoctgoagtg tgtaivjttac atgtactqgt 
151 aacctcpctt 
201 ctettactet 911119a&tgga 9 
Acoessim Description % 
number HM-101off 
i M97862 Mouse hybridoma. Ig rearranged kappa-chain 
mRNA V-n%i , Ion, partial cds. 98.2 
ii M97866 Mouse hybridoma, Ig rearranged kappa-chain 
mRNA V-region, partial cds. 98.2 
iii L06841 M. musculus, Ig light chain (interleukin 2 receptor 
antibody HU-MIIK-betal) mRNA, V-region. 97.3 
iv M19906 Mouse Ig rearranged kappa-chain m. RNA, clone 
AN02K. 97.3 
v K00746 Mouse Ig kappa active V-region mRNA from 
hybridoma nq2-6.1. 96.9 
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Fig. 7.6b R111 Heavy Chain 1. Length.. 2lL6 
Acoession Description % 
number Homology 
i L26880 Mus musculus (BALB-25) gene fragment. 
93.1 
ii M21814 Mouse/human Ig heavy chain constant region 
mRNA, segment 1. 92.6 
iii M97865 Mouse hybridoma Ig rearranged H-chain mRNA j 
_ 
V-regýon, partial cds. 92.6 
iv M19901 Mouse Ig rearranged gamma-chain mRNA, 
__ , 
segment 1. 92.1 
v S50856 Ig VH=chimeric anti-human neuroblastoma lantibody 
(mice, Genomic, 706nt). 91.7 
Fig. 7.6b R111 Heavy Chain 2. lengft 249. 
1 ggggctgaga h999 -r 
51 tctggctara 
101 tggacaacM cttgaatgga ttqgtatgat "'bor-tto 
151 tttactacaa tcaaatgttc 
_q- aagg ccacattgw gacaaa 
201 toctcragoa cagoctacat qcax3ctcaca gxtxjacatc tg&]gactc 
Acoession Description % 
number llonlokw 
i M95940 Mouse mRNA sequence, partial cds. 
95.2 
ii U01658 Mus, musculus BALB/c anti-Slycophorin A type M 
- 
antibody A09 mRNA, complete cds. 94 
iii J00536 Mouse Ig germline H-chain, c57bl/6 b-np-related 
gene vh3, vhii. 93.6 
iv M34579 Mouse Ig heavy-chain mRNA V-D-j region, 
al cds. 93.2 
v M32855 rouse Ig rearranged H-chain = I 
reg n, p reg 93.2 
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i U07214 Mus, musculus, clone 103 Anti-C5a Ig heavy chain 
V region mRNA, partial cds. 95.9 
ii U07212 Mus musculus, clone 102 Anti-C5a Ig heavy chain 
V region mRNA, partial cds. 94.1 
ifi U07208 Mus musculus clone 100 Anti-C5a Ig heavy chain l 
V region mRNA, partial cds. 94.1 
iv Z12760 M. musculus mRNA for VH-gene sequence of 
naturally occurin& somatically mutated nirmory B 91.8 
v X63047 M. musculus mRNA for IG heavy chain variable 
region (3F11). 91.4 
Fig. 7.6b R111 Heavy Chain L Length: 314. 
Acoessim Description % 
number Homobv 
i Z22125 M-domesticus 19M variable region. 
95.6 
ii M19898 Mouse Ig rearranged ganmma-chain mRNA, 
done AN06g. 95.2 
iii X02458 Mouse germline immunoglobulin V(H)II gene 
H30. 94.5 
iv X02459 Mouse germline immunoglobulin V(H)II gene 
H13-3. 94.4 
v M28251 Mouse Ig rearranged gamma-chain (G-2a) mRNA 
V-region (V-j2), partial cds. 94.2 
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Fig. 7.6b R111 Heavy Chain S. Let4; th. - 249. 
1 qgggctgaw -- I"ggggoctca act_ - -- --- 
51 ttctggctac mortttactA aa 
101 ctggacaggg IM -i myt mgtyyttAta 
151 ctgactacm isaagar-aagg ccac&t'-- ttgac 
201 14 111i--tt- ---- -gam ag=tgacat ctgaggact 
AcwSsion Description % 
number Homology 
i Z22125 M-domesticus IgM variable region. 
94A 
ii M36225 Mouse Ig heavy-chain V region, partial cds. 
H280-15VH. 94.4 
iii M28834 Gamma heavy chain of the monoclonal antibody 
6A4. 93.2 
iv A13735 V-region of a monoclonal antibody that cross j 
reacts with 19 known Pseudomonas aeruginosa 93.2 




Fig. 7.6b R111 Heavy Chain 6. Length: 239. 
1 ctgaactggc aaawctggg - i---_ ---I ---, -tto 
- 
ý, j .,, t-1g 51 qWtacKict t -I-- tggatagaac 'm-n t, 
101 wAgggtctg gg&'-tg, tcctttcaat ggtt ---ttg 
151 aggwAatca gaagUtow-agg gactge agacaa&t= 





i 225 Mouse Ig heavy-chain mRNA V region, partial 
cds. H280-15VH. 92.1 
ii M28251 Mouse Ig rearranged gamma-chain (G-2a) mRNA 
V-region (V-j2), partial cds. 90.8 
iii M19898 Mouse Ig rearranged gamma-chain mRNA, clone _ 
AN06g. 90.4 
iv L22581 Mouse rearranged Ig heavy chain V-region 
sequence. 90.4 
v Z22125 Kdomesticus IgM variable region. 
90.4 
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i X67347 M. musculus immunoglobulin heavy chain V-D-j 
region (focus 1012 DNA #7). 98.4 
ii X67350 M-musculus immunoglobulin heavy chain V-D-j 
region (focus 1012 DNA #9). 98 
iii X67343 M-musculus immunoglobulin heavy chain V-D-j 
region (focus 1012 DNA #3). 98 
iv X67351 M. musculus immunoglobulin. heavy chain V-D-j 
region (focus 1012 DNA #10). 98 
v J00529 Mouse Ig active H-chain, c57bl/ 6 b-np response 
from bl-8, vhii mRNA. 98 
Fig. 7.6b R111 Heavy Chain & Length: 251 
Acwssion Description % 
number lionvlw 
i K00603 Mouse Ig germline H-chafii, BALB/c 
b-NP-equivalent VH3 pseudogene. 89.7 
ii J00535 Mouse 19 gern'line H-chain, c57bl/6 b-np-related 
gene vh6, vh-ii. 89.3 
iii M13788 Mouse % rearranged transcribed H-chain V-region 
VHS% mRNA, clone B4. 88.5 
iv m26W8 Mouse Ig heavy chain mRNA B-region, partial 
cds. 88.5 
v Z12816 I M-musculus MRNA for VH gene seq. of natural- 
joccurin& somatically mutated memory B ce 88.5 
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Fig. 7.7a fWb-c Light chain 1. Length.. 27s 
251 tt&ttattgc cacatttt 
Accession Description % 
number Hmoloff 
j M? nR'40 Mouse IgMk rearranged kappa light chain mRNA 
variable region(V-J-kappa) anti-DNA autoantibod 99.3 
ii M25996 Mouse Ig rearranged kappa-chain Vk 1.60 gene, 
partial cds, ftom B cell hybridoma 1D3-2. 99.3 
iii L22888 Mus musculus rearranged IgH mRNA, V-region, 
cell linr GB-1. 98.9 
iv M17722 Mouse Ig active kappa-chain VOX1-J2 region 
anti-dextran mRNA, hybridoma 42.48.12.2. 98.9 
v Z11917 M. musculus inununoglobulin kappa chain 
variable region. 98.9 
Fig. 7.7a Balb-c Light Chain 2. Length: 228 
Accessim Description % 
number ! LOM 01M 
i X63811 M. musculus mRNA for IgM V(k)MRB11. - 
97.8 
ii J00565 Mouse Ig kappa active gene: vk41 v-j region. 
97.8 
iii M36246 Mouse Ig fight-chain mRNA V region, partial cds, 
from hybridoma H220-23. 97.7 
jv VOOB04 Murine kappa-immunoglobulin gene fragment 
including sign 1!! ptide and variable region. 97.4 
v M64168 Mouse Ig active kappa-chain mRNA V-region. 
97.3 
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Fig. 7.7a Balb-c Light Chain 3. Length: - 214 
1 tgCbo&OWA I'' 
---agCbg 11 -`t-t_j 
51 aoc&tcaoct 
_--acatac 
101 gcagaagbc: a yyu %, - -, t r! rx! -- gettttatgaa ataboaa&&C 
151 taacttcbgg &jtcocacct --I-, tcagtg 
%A_f ii 
_49UW 
%Ajqq=6A; %A.. i%o 
201 tzctctcbca caat 
Acoessim Description % 
number HomblW 
i X05554 Mouse mRNA for X24 kappa immunoglobulin 
light chain. 96.3 
ii X05555 Mouse germline gene for X24 kappa 
immunoglobulin light chain. 96.3 
iii X58204 M. musculus extrachromosomal DNA for V kappa 
and J kappa coding joint (clone pKDE 1). 95.8 
iv M15589 Mouse Ig kappa chain 5G11 mRNA, V-region 
(Vj5C) of phOx-! pecific hybridoma antibody. 90.2 
v M34586 Mouse Ig kappa-chain mRNA V-j region. partial 
cds. 90.2 
Fig. 7.7a Balb-c Light Chain 4. Length: I% 
gacocagact .- tcggt iý__- aa ccwpctoca 
q pi. q. 11 . 11 -.. -- 51 tctcttgcaa mynchot _ tgat, 
101 ttgaattggt tctwaaacjc 
151 tatqgtgbCt aa i actggcag 
Acassion Description % 
number kilbwmdom 
i M25996 Mouse Ig rearranged kappa-chain Vk 1.60 
genepartial cds, from B cell hybridoma lD3-2. 100 
ii M 08 0 -- Mouse IgMk rearranged kappa light-chain mRNA 
variable region(V+kappa) anti-DNA autoantibody 100 
iii L22888 Mus, musculus, rearranged lg1H mRNA, V-region, 
ceH line GB-1. 99.5 
iv M17722 Mouse Ig active kappa-chain VOXl-j2 region 
I , an extran mRNA, 
hybridoma 42.48.12.2. 99.5 
v A07556 I DNA sequence of monoclonal TSH antibody, 
I kappa chain. 99.5 
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Fig. 7.7a Balb-c Light Chain S. Lengtic 196 
1 oooagtctoc N999tagaa 39tr! Elrr! atg 
51 acctcgagtg Rtgn -t" - 
101 gtcaggcaoc Dosaac aaactqgct: i. 
151 ctggagtcoc nynthr! 994 i---- cctctt 
Awssion Description % 
number Homlogy 
i X59179 Mouse immunoglobulin variable region light 
chain (T2-150) mRNA. 93.8 
ii L31516 Mus musculus anticryptococcal Ig 386 L-chain 
mRNA V region, partial cds. 93.4 
iii *i M34527 Mouse Ig kappa-chain (anti-insulin Ab 123) j 
mRNA V region, partial cds. 93.4 
iv Z22128 M. domesticus IgK variable region. I 
93.4 
v M34586 Mouse Ig kappa-chain mRNA V-j region, partial 
cds. 93.4 
Fig. 7.7a Balb-c Light Chain 6. Length: 270 
1 oc&tccagtc I U. -tAT. Mmuc cottg-g-agao aca&ttacca I, -', 
11 
_ -, ,a 
51 tgoCagbCag - t; tt: - gl 1 A-97 
101 gaaatattoc atctataaW citt ii goacacagge 
151 gatooo&tca, -_ -_-, gcagtggatc 
201 ccatzagmq KINNYMIt c-e; lgm"ql-tg ocacttacta ctgl-,: a&mg 
251 ggbcaaagtt wto-atb= 
Accaskm Description % 
number HomokV 
i M19908 Mouse Ig rearranged kappa-chain mRNA, clone 
AN04K. 97.4 
ii L21021 Mus musculus, immunoglobulin light chain (IgL) 
mRNA, Vj region, partial cds. 97.4 
iii M34636 Mouse Ig rearranged kapp*-chain (NC6-CS) 
mRNA VklO-Jk2 region, partial cds. 97.4 
iv L09033 Mus musculus Ig rearranged anti-Sm hybridoma 
niRNA V-region sequence. %. 7 
v Z22052 M-domesticus, variable region. 
95.9 
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Fig. 7.7a lWb-c Light Chain 7. Lengft 223 
1 tctcxatcct n,. nttwbnt W, 16nbn 
51 ogggoaagbc tq9ctLxjc.; tt ak'kgCtgg0tt 
101 cagatggsar- ---I MWItt"tar. gxgmWaa ogtt: tagatt 




Aamssion Description % 
number Honx4ogy 
i X02177 Mouse mRNA fragment for IgG light chain V-j 
region (Gloopl). 94.7 
i ij X02 78 1 Mouse mRNA fragment for IgG light chain V-j 
region (Gloop2). 93.8 
iii M36246 Mouse Ig light-chain mRNA V region, partial cds, j 
for hybridoma H220-23. 93.3 
iv J00565 Mouse Ig kappa active gene: A14 V-j region. 
93.3 
v X63811 M. musculus mRNA for LgM V(k)MRB11. 
93.3 
Fig. 7.7a Balb-c Light Chain & Length-. 279 
Acassien Description 
nuwJ)er 
i M20830 Mouse IgMk rearranged kappa light-chain mRNA 
variable region. 98.9 
ii M25996 Mouse 19 rearranged kappa light-chain Vk 1.60 
- 
ge partial cdsfor B cell 4ybidoma 1D3-2. 98.9 
iii M17722 Mouse Ig active kappa-chain VOX1-j2 region 
anti-dextran nURNA, hybridoma 42.48.12.2. 98.6 
iv L22888 Mus musculus, rearranged IgH mRNA, V-region, 
cell line GB-1- 98.6 
v M20330 Mouse Ig rearranged kappa mRNA V-region, 
_ 
paýal cds, from an anti-digoxin hybridoma 40-150. 98.2 
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Fig. 7.7b Balb-c Heavy Chain iL Leng&. 1L49 
1 aagggctatt taxit gmy na 11. rrr awl , ---t ctxjgat 
51 gtocagoggt 
M -I Ap1t gi, m 101 OW NICtrica gnahrx'-ggpc cagog&4w 
AcwSsim Description % 
number Homology 
i U00927 Mus Inusculus antibody heavy chain FAB mRNA, 
partial cds. 100 
ii U00940 Mus musculus nuclek acid-binding antibody 
heavy Fab ntRNA partial cds. 100 
iii S65761 anti-colorectal carcinoma heavy chain, 
_ 
glycoprotein CANAG-50 specific IgGl kappa. 100 
iv M60430 Mouse Ig rearranged H-chain mRNA constant 
region. 100 
v M60432 Mouse Ig rearranged H-chain constant region. 
I- 100 
Fig. 7.7b Balb-c Heavy Chain 2. Length: 251 
ggaactgago t gamma tygggnot t gtgaaaatat 
51 ttctggatac cilitcactq actacaacat -- ---tg -- --- 
101 atggaaagag ccttgaatgg attygntgtt ttcttactta 
151 actqgcm)a amcagaag it --I 9w -- gteigacag_ 
201 tbc3, --boosgo tc 
251 
Accessim Description % 
number HO-m4off 
i J00488 Mouse Ig gemiline H-chain V gene VH108A, I 
su up VH-11. 94.4 
- H - M83098 Mus, musculus CD33 antigen mRNA, 5' end. 
94.4 
iii M36218 Mouse Ig heavy-chain mRNA V region, partial 
cds. H220-23VH. 94.4 
iv X02461 Mouse germline immunoglobulin V(H)II gene 
H16. 94.4 
v L25332 Mus musculus immunoglobulin heavy chain 
variable region gene, exon. 92.8 
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Fig. 7.7b Balb-c Heavy Chain & Lengdu 313 
Acoessim Description % 
number Honw1W 
i M15873 Mouse Ig active H-chain VD-J4-C MRNA (XRPC24 
family), m myeloma. W3129. 98.2 
ii V00774 Segment of a Mouse germ line V-H gene (V-H 441) 
for a heavy chain variable region. 98.2_ 
iiiI J00541 Mouse germline IgH-chain gene, V441-region, 
su group VH-R done V-H-441. 98.2 
iv M38227 Mouse Ig heavy chain V-D region 1OL126-7 
mRNA, partial cds. 97.5 
v M74424 Mouse Ig rearranged heavy chain m]RNA 
I V-jl-regionpartial cds, done 402-10. 93.7 
Fig. 7.7b Balb-c Heavy Chain 4L Lengthasi 
1 gggoctgun ý, 1---- t999 ga 
51 ttooggctac acpVtWorbg ---- 11, ! 
101 atgcaaagag t. -tagagi-gg attgpatta ttmgtactta 
151 acaaaccaca g cfcr_jkca ga crtagacm 
201 t=tctagft ggaactt agaftgamt, t 
tgoc&tttat 251 
Acaffision Description % 
number Homology 
i S78361 AHT107 VH region=chimeric mouse/human Mab 
against the human_p55 IL-2R H-chain V-region. 94.5 
ii J00494 Mouse Ig active H-chain V-region from bcl-1, 
subgroup VH-IL 93.8 
iii M25465 Mouse Ig rearranged H-chain gene V-region 
(V-D-J-sub-two), 5' end. 93.8 
iv M34523 Mouse Ig gamma-chain (anti-insulin Ab 123) 
mRNA V r! eon, partial cds. 93.2 
v M2o774 Mouse rearranged IgA-chain gene, V region, from 
1.29 B cell lymphoma, clone L7.1 83.6 
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Fig. 7.7b Balb-c Heavy Chain & Length: 307 
Acaesdm Description % 
number Homology 
i X73076 M. musculus VH mRNA (VH5). 
97.6 
11 K00606 Mouse Ig germline H-chain, BALB/ c b-NP 
equivalent VH5 pseudogene, subgroup VH-11. 94.6 
iff - X02458 Mouse germline immunoglobulin V(H)II gene 
H30 94.2 
iv L24557 Mus musculus (SO3) monoclonal antibody; 
v-region. 93.2 
TM3-6-22,5 Mouse Ig heavy-chain mRNA V region, partial 
cds. H280-15VH. 90 
Fig. 7.7b Balb-c Heavy Chain 6. Lengft 294 
Acasim Description % 
number HonvAW 
i M17723 Mouse Ig family J558 active mu-chain V-J3 region 
anti-dextran mRNA, hybridoma. 19.1.2. 94.9 
ii M12392 Mouse Ig active alpha-chain V-JH3 region (J558 
family) anti-dextran mRNA, hybridoma 14.6b. l. 93.8 
iii L17085 Horse immunoglobulin heavy chain mRNA. 
93.7 
iv M12764 Mouse Ig active alpha-chain VJH3 region (J558 _ 
family) anti-dextran MRNA, hybridoma 26.4.1. 93.8 
v M24320 Mouse active 19 mu-chain VJ3-region mRNA, 
artial cds, anti-alpha dextran hybridoma 27.7.2. 92.8 
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Fig. 7.7b Balb Heavy Chain 7. Length: 266 





i M19895 Mouse Ig rearranged gamma-chain mRNA, clone 
AN03g. 98.1 
ii M64150 Mouse Ig active heavy-chain mRNA Wregion. 
98.1 
iii S51485 Influenza virus A/ PR/8/34 hemagglutinin specific 
hybridoma antibody H chain variable region. 98.1 
iv X59105 M. musculus mRNA (U-M) for IgH heavy chain 
V region. 98.1 
v M64148 Mouse Ig active heavy-chain m. RNA V-region. 
Fig. 7.7b Balb-c Heavy Chain & length: 2o6 
Acoesim Description % 
number HOMOIW 
i L26881 Mus musculus, (BALB-26) gene fragment. 
ii Z25455 M-musculus, immunoglobulin gamma heavy 
chain (DBA/ 1) gene, V region. 95.6 
iii X59200 Mouse immunoglobulin variable region heavy 
chain (T6-19) mRNA. 90.7 
iv X59113 M-musculus, mRNA (LI4-6CA) for IgH heavy 
chain V region. 88.8 
v X59186 Mouse immunoglobulin variable region heavy F 
chain (r5-314) mRNA. 88.8 
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7.4 DLSMSSION 
Analysis of antisera from immunised Balb-c mice by flow cytometry 
indicated a higher degree of binding to antigens on the surface of 2wt cells than 
to those on the surface of BPV cells. In addition, differences between pre- and 
post-immunisation sera were only apparent when tested on 2wt cells (fig. 7.4). 
Both cell lines were derived from the transfection of C127 cells with a 
CL3AXBPVXT-NEO vector. The only expected difference between the two cell 
lines was the insertion of the CFrR sequence into the vector with which the 
2wt cells were transfected. RTPCR analysis of mRNA from both cell lines 
indicated that CFTR was expressed in 2wt cells, but not in BPV cells. On the 
basis of these results it seems reasonable to assume that injection of naive mice 
with antisera from BPV immunised Balb-c mice, together with 2wt cell 
suspension or membrane lysate, successfully reduced response to the major 
antigens present in 2wt cells, except for the novel antigen CFIR Accordingly, 
the greater antisera recognition of 2wt cells relative to BPV ceUs was due to the 
presence of expressed CFrR on 2wt cell surface. RNA was extracted from the 
spleens of these mice for the construction of a Fab antibody library. 
Contrary to expectations, flow cytometry analysis of pre-immunisation 
antisera from RIH mice indicated a higher degree of binding to antigens on the 
surface of 2wt cells than to those on the surface of BPV cells. This increased 
fluorescence was not seen with post-immunisation antisera (fig. 7.3). This 
result was indicative of the fact that the RIII mice had previously been exposed 
to antigens cross reacting with cell surface antigens present on 2wt cells and 
not on BPV cells. The principal protein that is present on the surface of 2wt 
cells and not on BPV cells is CFTR, which is a member of the ABC transporter 
class of multiple membrane spanning proteins [Higgins and Hyde,, 1991]. The 
majority of recognised members of this group of proteins are prokaryotic 
[Higgins, 1992). It is therefore highly conceivable that the RIH mice had been 
exposed to a prokaryotic pathogen that expressed a ABC transporter protein 
having significant homology to CFTR. 
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The quality of the antibody libraries was assessed by sequencing 
arbitrarily selected phagemid Fab clones. Important conclusions can be drawn 
from the analysis of these sequences, see figs. 7.6a and b and 7.7a and b. Firstly, 
each of the clones selected contain both heavy and light chain sequence. Each 
sequence had substantial homology (between 88%-100%) to at least 5 
previously identified murine antibody sequences. Secondly, considerable 
diversity was found between either heavy or light chain sequences within each 
Fab library. The sequencing primers were designed to sequence from the 
amino termini of the variable domains of each of the antibody chains. The 
presence of a great variety of heavy and light chain variable domain sequences 
indicates that the libraries were representative of a diverse murine immune 
response. 
The estimated size of the RIH Fab library was 5x`106 independent clones 
and that of the Balb-c library was 4x106 independent clones. These figures are 
about half the estimated number of antibody producing cells in an average 
mouse, which is W06-108 [Huse, 1992]. The libraries were produced from mice 
that had been immunised with antigen. Consequently, relatively high 
concentration antigen specific lymphocytes would have been present in the 
lymphoid tissue of the murine spleens from which the RNA was isolated, for 
the construction of the libraries [Harlow and Lane, 1988). Phage display libraries 
prepared from immunised sources have been used to produce high affinity 
antibodies (> 107mol-1) with regular success [Clackson et al., 1991; Burton et al., 
1991; Zebedee et al., 19921. However, it is unclear how often this random 
combinatorial approach leads to the recovery of the original pairs of heavy and 
light chains expressed in individual B lymphocytes [Winter and milstein, 1991; 
Gheradi and Milstein, 1992]. Variable gene repertoires derived from 
immunised animals, such as the mice used in this study, should give antibody 
libraries that are enriched for heavy and light chains encoding part of an 
antigen combining site. It is anticipated that when these are recombined with 
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one another they should generate high affinity antigen binding fragments 
relatively frequently, even if the original in vivo heavy and light chain 
pairings are not represented [Burton, 1991]. 
Attempts were made to select for CFFR specific Fab fragments by 
panning the antibody libraries against prepared 2wt cell lysate. A different 
approach that could be undertaken would be to select for CFTR at the cell 
surface by panning against whole cells still attached to the surface of a tissue 
culture flask. The ability to isolate specific antibody fragments by selecting 
phage antibody libraries against specific cell surface antigens has been 
previously demonstrated [Marks et al., 19931. The success of this approach 
depends on the presence of antigen specific Fab binders in the library that can 
be selected in preference to binders against other antigens present in and on 
cells. The immunisation protocols, prior to the construction of the Fab libraries 
described above, were designed to reduce the production of murine antibodies 
to 2wt cell antigens other than CFM. If background binding of Fab fragments 
to antigens on the cells other than Cyl does prove to be a problem, it could 
be reduced by pre-absorbing the Fab libraries with BPV cells. These cells do not 
express CFTI; ý but should express all other potential antigens present in 2wt 
cells. Fab fragments that have not bound to BPV cell antigens could then be 
selected against 2wt cell antigens of which CFTR would be novel. So far the 
effective panning of the murine derived Fab libraries has been prohibited by 
the repeated lysis of the phage-antibody library cultures. This problem will 
have to be overcome before the potential of the Fab libraries as sources of 
antigen specific Fab fragments can be fully assessed. As discussed in the 
previous chapter, the lysis of the cultures is probably due to the presence of a 
contaminating lytic phage. A possible way of avoiding this lytic phage infection 
is discussed in the next chapter. 
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CHAPTERS 
PRODUCTION AND ANALYSIS OF Fab ANTIBODY LIBRARIES 
FROM RABBITS IMMUNISED WITH CFTR FUSION PROTEINS 
u uqTRODUCrION 
Tissue rich in antibody producing cells, such as spleen, lymph nodes, 
tonsils and bone marrow, is required for the construction of antibody phage 
display libraries, [Winter et al., 1994; Roitt, 1993]. Bone marrow has been 
identified as a major repository of differentiated B lymphocytes that produce 
antibodies to maintain circulating antibody titres [Lum et al., 19901. Fab 
fragments have been successfully selected from antibody libraries produced 
from human bone marrow [Burton et al., 1991; Barbas et al., 1992b; 1992c; 
Williamson et al., 19931. Rabbit bone marrow has also been used as the source 
of mRNA for the construction phage display antibody libraries (Carlos Barbas 
(Scripps Institute, La Jolla, California) pers. comm. ). 
Polyclonal antibodies have been raised in rabbits to three 
galactosidase/CFrR fusion proteins (see chapter 3). Characterisation of these 
antibodies indicates that they recognise CFTR and/ or other protein(s) that 
have very similar properties to CF1rR (see chapter 4). The three fusion proteins 
cover almost the entire CFrR sequence as represented in fig. 8.1. Two rabbits 
were immunised with all three fusion proteins. The pComb3H-SS vector 
system was then adopted for the construction of a Fab fragment phage display 
library derived from the bone marrow of immunised rabbits. 
Selection of Fab libraries described in the previous two chapters has been 
inhibited by the deleterious infection of phage library cultures with lytic phage. 
The use of freshly prepared and sterilised materials failed to remove the lytic 
phage contamination. An alternative approach to overcoming this problem 
was to produce a cell line resistant to the contaminating lytic phage. The 
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in this cell line is described below. 
&2 MATERIALS AND METHODS 
8.2.1 Rabbit Immunisation 
The P-galactosidase/ CFTR fusions were constructed in the pUEX1 
expression vector and the fusion proteins were prepared from bacterial 
cultures as previously described in sections 3.2.1 - 3.2.4. 
Frozen aliquots of each of the three fusion protein preparations were 
defrosted and boiled for 5 minutes prior to loading onto preparative 87o SDS 
page minigels. One gel of each of the fusion proteins was required for each 
rabbit (i. e. six gels in total). The gels were run at 120mA until the loading buffer 
dye front had reached the bottom of the gel. Proteins from strips off one edge of 
each gel were removed and stained in Coomassie blue solution to reveal the 
protein bands present. The overexpressed bands of the fusion proteins were 
identified and cut from the unstained gels, shredded using scalpel blades and 
soaked in PBS. The PBS/gel solutions from each of the gets were pooled and 
homogenised using a Polytron homogeniser with PT10 head. The resultant 
suspension was injected into two New Zealand white rabbits, subcutaneously 
and intramuscularly, on three occasions at monthly intervals. Prior to the 
fourth injections, which were given intravenously, the acrylamide gel was 
removed from the PBS suspension by centrifugation. Test bleeds were taken 
from the rabbits before the first injection (pre-bleeds). Ten days after the fourth 
injection the rabbits were bled out and the bone marrow was removed from 
their hind leg bones. 
8.2.2 PCR Amplification of Rabbit Antibody Sequences 
Heavy and Light chain antibody fragments were amplified by PCR as 
desaibed in section 6.2.2.1. Rabbit immunoglobulin. primers were synthesised 
based on sequences designated by Carlos Barbas III, Scripps Institute, La Jolla, 
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Califomia. 
Heavy chain Fd Y primers: 
IgG 5- TGGGCAACrAGTCTTGCTGCATGTCGAGGG -3' 
IgM 5'- GCrCACACrAGTGGGCAGCrCrGAGTCCA -3' 
Heavy chain variable domain 5' primers: 
RVH1 5- CAGTCGBTGCFCGAGTCCGGGGGTCGCCr -3' 
RVH2 5'- CAGTCGBTGCTCGACTCCGGGGGAGGC -3' 
RVH3 5- CAGTCGBTGCrCGACTCCGGGGGAGAC -3' 
Where B-- C, G or T 
Light chain constant domain 3' primers: 
RCK1 5- GCGCCGTCrAGATTAACAGTCACCCCrATrGAAGC -3' 
RCK2 5GCGCCGTCrAGATrAACAGTCACCCCrATTGAAGC -Y 
Light chain variable domain S' primers: 
RVK1 5- GCGCCGGAGCrCGTGATGACCCAGACTCCA -31 
RVK2 5'- GCGCCGGAGCrCCATATGACCCAGACrCCA -Y 
RVK3 F- GCGCCGGAGCrCGTGATGACCCAGACrGAA -Y 
8.2.3 Preparation of a Cell Line Resistant to Lysis by Contaminating Phage 
A cell line that was resistant to lysis by contaminating phage was 
prepared to enable several rounds of panning for selection of antigen specific 
Fab fragments from the antibody phage display library. Considerable cell lysis 
occurred in cell cultures that had been been infected with the Fab library and 
rescued. This lysis was apparent in the reduction in the turbidity of the cell 
culture solutions and by the presence of phage plaques on LB amp ageLr plates 
coated with a lawn of cells from the- liquid cultures. These lytic phage 
containing plaques were used to prepare XL1-blue Exo1i. th4l were resistant to 
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lysis by the contaminating phage. 
A plaque was picked from the surface of a contaminated plate and 
transferred to 1ml Minimal media in an Eppendorf tube which was, in turn, 
vortexed. Serial hundred fold dilutions were made of the phage containing 
minimal media. 1#1 of each dilution was transferred to 1001d log phase XL1- 
blue cells, then left at room temperature for 15 minutes before plating out onto 
LB plates. The plates were incubated overnight at 3711C. The following day, a 
plate was chosen where the dilution of the contaminating lytic phage was such 
that almost the entire lawn of E. coli. had been lysed. A few bacterial colonies 
were growing within the obvious phage plaque areas on the plate. These 
represented mutant E. coli. that were resistant to phage lysis. Five such 
colonies were picked and grown in 10ml aliquots of LB broth overnight in a 
shaking incubator at 37"C. 50#1 of the cultures were plated out the next day on 
each of LB amp, LB tet, LB kan and Minimal media agar plates. Further 50111 
aliquots of each culture were infected with 11d of the undiluted lytic phage 
containing minimal media (described above) which, in turn, were plated out 
onto LB agar plates. All the plates were incubated overnight at 37*C. Growth of 
untransformed XL1-blue cells resistant to the contaminating lytic phage would 
have been anticipated on the LB tet, Minimal media and LB (post infection) 
agar plates, but not on the LB amp or LB kan agar plates. Cells thus produced 
could be cultured and prepared for DNA transformation by electroporation as 
previously described, section 2.2.13 method B. 
8.2.4 Preparation of Panning Wells for Fab Antibody Library Selection 
The three P-galactosidase/CFrR fusion protein antigens were prepared 
from mini SDS PAGE gels as described for the preparation'of antigen for the 
final intravenous injection of the rabbits (see section 8.2.1 above). The 
supernatant recovered from the gel/PBS suspension was transferred to a 
Centricon 30 column for concentration by centrifugation in a SOrvaU RC5C at 
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50OOrpm and 4"C for about 40 minutes until the volume was reduced to about 
150jil. The protein concentration of the concentrated solution was determined 
by Bradford's analysis (section 2.2-20) and wells of an ELISA plate were coated 
overnight at 4*C with 1gg of fusion protein antigen diluted in O. 1M 
bicarbonate coating buffer pH8.6. 
8.3 RESULTS 
8.3.1 Rabbit Immunisation 
Two New Zealand white rabbits were each immunised with three p- 
galactosidase/CFrR fusion proteins that between them contain the majority of 
natively expressed CFTR sequence. The bone marrow was extracted from the 
hind legs of the rabbits and used as the source of mRNA in the construction of 
a phage display antibody library. Bleeds were taken from the rabbits pre- and 
post- immunisation. These sera were designated 38 and 49 according to rabbit 
code numbers. 
8.3.2 ELISA Analysis of Rabbit Anfism 
The rabbit antisera were diluted 1 in 400 and screened by ELISA against 
the fusion protein antigens as described in section 2.2.25. The post- 
immunisaton antisera 39 and 43 both gave colormetric: readings that were 
about three times greater than those obtained using either pre-immunisaton 
antisera as the first antibody. 
8.3.3 Western Blot Analysis of Rabbit Antisera - 
The rabbit antisera were screened against Western blots of membrane 
lysate derived from HT29 cells which have previously been shown to express 
CFrR [Denning et aL, 19921. The post-immunisation antisera from both rabbits 






Fig. 8.2 Immunoblots, of HT29 membrane lysate probed with 
polyclonal 39 (lane 2), or polyclonal 43 (lane 4) as primary antibody. 
Premmune sera from rabbit 39 (lane 1), or 43 (lane 3) were used as 
controls. The relative mobilities of molecular weight standards, 
loaded in an adjacent lane, are indicated. 
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pooled pre-bleed antisera see (fig-8.2). 170kDa is the expected size of the fully 
glycosylated form of CFIR [Gregory et A, iggol. 
8JA Cells Resistant to Lysis by COntaminating Phage 
Mutant XL1-blue cells, resistant to lysis by contaminating phage, were 
cultured as described in section 8.2.3. When analysed on a series of agar plates 
growth had occurred on the LB tet, Nfinimal media and LB (post infection) agar 
plates, but not on the LB amp or LB kan agar plates. This pattern of growth 
was indicative of the successful preparation of untransformed, lytic phage 
resistant XL1-blue cells. A single clone of these cells was picked and cultured 
for the preparation of electro-competent cells. 
8.3.5 Construction of a Rabbit derived Fab Antibody Library 
A random combinatorial. Fab antibody library was constructed in the 
pComb3H-SS vector from mRNA extracted and purified from bone marrow 
extracted from the immunised rabbits. The methods followed for the 
construction of this library are described in chapter 6. The mRNA derived 
from each of the two rabbits was independently reverse transcribed and 
amplified by PCFL PCR reactions with different 5' and 3' pairs of heavy and 
light chain primers were carried out separately to maximise the amplification 
of all appropriate mRNA sequences. However, after examination of the 
amplified sequences by agarose gel electrophoresis, all the light chain PCR 
products stemming from both rabbits were pooled, as were all the heavy chain 
PCR products, for the construction of a single rabbit derived antibody Fab 
hbrary. 
Test ligations were performed prior to the construction of the light and 
heavy chain libraries to assess the extent of the background vector ligation. The 
restricted heavy and light chain sequences were purified on Chromaspin 100 
colunins prior to ligation into the prepared vector. The light chain background 
vector ligation was 8% of that of the test insert ligation and the size of the 
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assembled light chain library was estimated to be 7x106 independent clones. 
The pComb3H-S/light chain vector was prepared employing the modified 
restriction conditions described in section 7.3.3 of the previous chapter. The 
heavy chain background vector ligation was 2.57o that of the test insert ligation 
and the size of the assembled Fab library was estimated to be 8X106 
independent clones. Both the initial light and final Fab libraries were 
transferred by electroporation to freshly prepared lytic phage resistant XL1-blue 
cells. 
8.3.6 Sequencing Analysis of Antibody Fragments 
Phagemid DNA was prepared from eight Fab library colonies by Wizard 
Mini Preps and sequenced with the heavy and light chain primers given in 
section 6.2.8.1. The DNA sequences were all compared to sequences in the 
EMBL/Genbank data base, release number 39, version 6. The five most 
homologous sequences identified for each sequenced antibody chain are given 
in figs. 8.3a and b. 
8.3.7 Panning the Fab Libraty 
Enrichment of the Fab library for antibody fragments that bound to the 
CF17R fusion protein antigens was attempted by consecutive rounds of 
selection by panning. After each round of panning, the eluted phage were 
reinfected into mutant lysis resistant Exo1i. and rescued with helper phage. 
Four rounds of panning were completed without the lysis of cell cultures that 
had been encountered on previous occasions (sections 6.3.3. and 7.3.5). 
Enrichment of phage was not detected during the panning process. The colony 
forming units (cfu) put in and recovered from each round of panning were: 
ROUND 1 In - 2.7 x 1011 
ROUND 2 In - 6.3 x 1011 
ROUND 3 In - 2.1 x 1012 
ROUND 4 In - 1.4 x 1012 
Out - 4.8 x 107 
Out - 2.8 x 106 
Out - 1.6 x 105 
Out - 1.6 X 104 
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Fig. Ua (pages 188 -191). Light chain sequences 1 to 8, of Fab 
clones derived from the rabbit antibody library. 
Fig. 8.3b (pages 192 -195). Heavy chain sequences 1 to 8, of Fab 
clones derived from the rabbit antibody library. 
The five most homologous sequences identified from the 
EMBL/Genbank data base, release number 39, version 6, for each 
light or heavy chain, are presented in tables below each 
sequence. 
Further information and references for each of the data base 
sequences given, can be obtained from the EMBL / Genbank data 
base, via the appropriate accession number. 
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Fig. S. U Rabbit Light Chain L Length: 143 
gtgtctgcag i9l, 999 atcaattgac aggwagtga 
51 gswatttat aamisi ii -- agaa - q, -mtgcqt- 
101 CwAawboc -_--t'. 
taoca 999 
ACMs§M Description % 
number Ronw1off 
i K01359 Rabbit Ig kappa (b9) complete mRNA. 
90.2 
ii S50460 b4l=immunoglobuhn kappa L chain variable 
I region 
(Oryctolagus cuniculus=rabbits). 87.4 
iiij _ X14365 Rabbit vkB95r gene for iMmunoglobulin kappa 
light chain variable region. 87.4 
iv X00032 Rabbit mRNA for immunoglobuhn kappa light I 
chain b5 allotype. 86.7 
v K0213 Rabbit Ig germline kappa V-region V-kappa 20 and 1 
flanks. 85.2 
Fig. Ua Rabbit Light Chain 2. Length: 163 
.. 
11 , ctcoagaaw ogtgtctgca 999M9, gc--- I! ' -I 
51 ggtatcagm 
101 comp"a icmam ,,, 1 a agctoctg! tt 
151 catctggggt coc 
Acawsk)II Description % 
number Homology 
i K02131 Rabbit Ig germline kappa V-region V-kappa-20 and 
flanks. 92.6 
ii X00977 Rabbit germ-line V kappa gene V18a. 
89.6 
iii K02438 Rabbit germline gene V18b for immunoglobulin 
kappa light chain variable region. 89 
iv K02439 Rabbit germline gene V19a for immunoglobulin 
_ 
signal peptide; variable region 88.3 
v K01359 Rabbit Ig kappa (b9) complete mRNA. 
88.3 
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Fig. &3a Rabbit Light Chain & Length: 220 
Acoesdm Description 
number Homology 
i X00032 Rabbit mRNA for immunoglobulin kappa light 
chain b5 allotype immunoglobilin. 87.3 
ii X14365 Rabbit vkB95r gene for immunoglobulin kappa 
light chain variable region. 86.8 
iii K01280 Rabbit Ig kappa light chain (bas) V+C mRNA. 
86.3 
iv X02337 Rabbit germline gene V19a for immunoglobulin 
_ 
kappa light chain variable reg! on. 85.9 
v K01359 Rabbit Ig kappa M) complete mRNA. 
85.8 
Fig. &3a Rabbit Light Chain 4. Length: 275 
1 ttn=gbct 9"99=9UR gmygm=nt caccatcaac 
mi..! 1 51 gtcagaqtqt t mac, aoogcttaga awcag 
101 9bCagoCt= 'i-tiag 
151 CjWcoatogo ggtbcaaagg a 1- -1 gggacacacit 
201 catauleW ctggsgtgtg acgatgctgc cacttactac I ____:; g 
251 gtagtact9g I magm-t t! P-t Wttt 
Acamim Description % 
number Homoloff 
i X00977 Rabbit germ-line V kappa gene V18a. 
90.3 
ii K01358 Rabbit Ig kappa L-chain M allotype, mRNA. 
86.7 
iii X02336 Rabbit germline gene V18b for immunoglobutin 
kappa light chain vari 86.5 
iv X14365 Rabbit vkB95r gene for immunoglobuhn kappa 
g am vana region. 84.3 
v X00032 Rabbit mRNA for immunoglobulin kappa light 
chain of b5 allotype immunoglobulin. 83A 
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Fig. 8., U Rabbit Light Chain S. Langth: 181 
1 ctgaatogoc cgtgbc' gctgtgggFbg --Bcagtcam - 
51 gtagctact: t 
jol ctqatctatg --'-gatcgaa tcaa 
151 aggcxjgtgga I"1N 9W "A9 
AccessFM Description % 
number Homology 
i X00977 Rabbit germ-line V kappa gene V18a. 
83.4 
ii X14365 Rabbit vkB95r gene for immunoglobulin kappa 
light chain variable region. 82.9 
iii K01358 Rabbit Ig kappa L-chain M allotype, mRNA. 
82.9 
iv K01280 Rabbit Ig gem-dine kappa V-region V+C mRNA. 
82.3 
v X14364 Rabbit vkB95g gene for immunoglobulin kappa 
light chain variable region. 81.5 
Fig. Ua Rabbit Light Chain 6. Length. - 233 
1 ctocagoew gr, -tgtgggag goacagboac 
51 Caggac4scitc agagtgfctta ta&taacaw ttcttatact ggtatr. &gCa 
101 gaaaacaggg ceqocb=a agctoctgat ctattatgca tcractctgg 
151 Catct9999t 
201 actctcacca ggtgtgtgac gat 
Acoessim Description % 
nuwJJer HonAW 
i K02131 Rabbit Ig germline kappa V-region V-kappa-20 and 
flanks. 91.8 
ii X02336 Rabbit germline gene V18b for immunoglobulin 
kapTa fight chain variable region. 90.6 
iii X00977 Rabbit germ-line V kappa gene V18a. 
90.6 
iv X02337 Rabbit germline gene V19a for immunoglobulin 
kappa light dudn variable regio 89.7 
v X14364 Rabbit vkB95g gene for immunoglobulin kappa 
light chain variable region. 89.3 
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Fig. &3a Rabbit Light Chain 7. Length: 138 
aactatggga 9918 SabCa, 
--- ý, -q1, --Pb, 
t gaaagoatteat 
51 goaactactt agn rt _t -1 cagoagacw -.. acagct ooa-- t--- 
--I - niwtct 
q1 . 11 .g, ; qt: c oft lol atct2tttatg --c :w 
Accession Description % 
number HonvIW 
i K02439 Rabbit germline gene V19a for immunoglobulin 
kappa light chain signal 1?! ptide variable region. 87.2 
ii J00667 Rabbit Ig kappa L-chain M allo, ", MRNA. 
86.5 
iii K01359 Rabbit Ig kappa M) complete mRNA. 
85.8 
iv K01280 Rabbit Ig kappa light chain (bas) V+C mRNA. 
85.1 
v X14365 Rabbit vkB95r gene for immunoglobulin kappa 
. 
light chain variable region. 84.4 
Fig. &3a Rabbit Light Chain & Length: 177 
1 ctccaccttc -- gcwa -C catcaagtmc 
51 ---mmjtg -go i tta 
101 aggwagoct --- 99C, ii 999 
151 gtcacatcoc gmggttcaaa ggcagca 
Acassion Description % 
number RM-WIqV 
i K01359 Rabbit Ig kappa (b9) complete mRNA. 
87.2 
ii X00032 Rabbit mRNA for immunoglobulin kappa light 
-- 
chain of b5 allotype immunoglobulin. 86 
iii kl 4365 Rabbit vkB95r gene for immunoglobulin ýppa 
li ht chain variable region. 84.2 
iv X14364 Rabbit vkB95g gene for immunoglobulin kappa 
light chain variable region. 83.1 
v K01280 Rabbit Ig kappa light chain (bas) V+C mRNA- 
81. 
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Am- Sib Rabbit Heavy Chain L Lengft 246 cr 
AcCeSSIM Description % 
nuMboff Hmvkigy 
i L03903 Rabbit immunoglobulin rearranged H-chain 
V-region, D-region and C-region complete cds. 86.6 
ii L03865 Rabbit immunoglobulin rearranged H-chain 
V-D-C region mRNA, 5' partail cds. 86.2 
iii M93172 Oryctolagus cuniculus Ig gem-dine H-chain gene, 
V-region (VH1-a2), 5' end. 86.2 
iv M77079 O. cunniculus reaffanged IgH heavy chain xnRNA, 
VDJ regionaHoWe VHa2. 86.2 
v L03877 Rabbit immunoglobulin rearranged heavy chain 
1 
V-D-C region gene, partial sequence. 86.2 
Fig. 8.3b Rabbit Heavy Chain 2. Length.. 3oi 
4...., 
1 251 tt-tctgtgoa agggota _-acaat ocagtatgggg 
Accessim Description % 
number Honwk 
i L27322 OrYctolagus cuniculus intervening DNA sequence. 
86.2 
ii L03887 Rabbit immunoglobulin rearranged H-chain 
V, D, and C regions. 86.2 
iii L03M Rabbit immunoglobulin rearranged H-chain 
VDand C regions. 862 
iv S63477 VHl-al=immunoglobulin al VH region (rabbits, 
leukemic B ceUs, Genon-dc, 511nt). 85.6 
v M29947 Rabbit Ig rearranged H-chain (5.5) gene V+D 
ion. 85.6 
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Fig. 8.3b Rabbit Heavy Chain & Length: 24s 
Acaesdm Description % 
number HonwlW 
i M93171 Oryctolagm cuniculus Ig germline H-chain gene, 
I 
V-region (VH1-al), 5' end. 91.5 
ii M29946 Rabbit Ig rearranged H-chain (50) gene V-D-j 
region. 91.5 
iii M29947 Rabbit Ig rearranged H-chain (5.5) gene V-D-j 
region. 91.5 
iv M29948 Rabbit Ig rearranged H-chain (4K7) gene V-D-j 
region. 91.5 
v X52450 0-cunigulus gene for Wal. 
91.5 
Fig. 83b Rabbit Heavy Chain 4. Lengtlu 291 
massim Description % 
number to--M-! M 
i L27315 Oryctolagus cuniculus intervening DNA se 
87.7 
ii M21261 Rabbit Ig H-chain V-region (allotype VHal)mRNA 
(V), clone RVH142. 86.4 
iii 133 Rabbit (a2a2 haplotype) Ig H-chain V-region 
(allotype VHal) gene, clone RVH799. 84.5 
iv M93177 Oryctolagus cuniculus Ig germline H-chain pseudo 
gene, V-region. 83.6 
M21262 Rabbit Ig H-chain V-region (aHotype VHal) 
v mRNA (V-D-J), clone RVH138. 83A 
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Rabbit Heavy Chain S. Length: 166 
p, 1,, I, g 51 gattatCaCt 991, -i i-m 
ggrh 
- ---- 
101 aaggggctgg qI -p 
I 
_j aat mi tvt: 
151 amczwctgg 
Amssion Description % 
number HOW-1 MAW 
i M29946 Rabbit Ig rearranged H-chain (50) ) V-D-j region. 
94 
ii M29948 Rabbit Ig rearranged H-chain (4K7) V-D-j region. 
94 
iii M29947 Rabbit Ig rearranged H-chain (5.5) gene V-D-j 
reg! on. 94 
iv X52450 O. cunigulus gene for VHal. 
94 
v M93171 Oryctolagus cuniculus Ig germline H-chain gene, 
V-reffion (VH1-al), 5' end. 94 
Rabbit Heavy Chain 6. Length: 207 
gagtccgggg q cacxjoct: ggg, 
51 cacagbctct PINIII, gg, "I 'g, 
101 aggctoo&W -p- gaatacatog - ---tckittga uuutaqtWt 
151 cgc&mtact ggcgaaaggc tctocaaaac 
201 ctcTccg 
Acoessim Description % 
number tLOT*U 
i M93181 Oryctolagus cuniculus Ig germline H-chain gene, 
V-region (VH4-al). 92.3 
11 M29948 Rabbit Ig rearranged H-chain (4K7) gene V-D-j 
region. 91.8 
iii M93171 Oryctolagus cuniculus Ig gem-dine H-chain gene, 
V-region (VH1-al), 5' end. 91.8 
iv M29946 Rabbit Ig rearranged H-chain (50) gene V-D-j 
region. 91.8 
v M29947 Rabbit Ig rearranged H-chain (5.5) gene V-D4 




Rabbit Heavy Chain 7. Length: 216 
1 qgMtcgoc - 0979mag0c ctgacactca %A. ýt 
51 ct&-ggatw I Xr-4tcacm agtattggat gtactgggt: c CXKXk'M PtCC 
101 agggaagggg 
151 ggtacgogag i moaaaa Yglrgjtt: t -114 -- --I 
tt 
-1 -tccag , x; wg 





i L03887 Rabbit immunoglobulin rearranged heavy chain 
V-D-C re 89.5 
ii L27322 Oryctolagus cuniculus intervening DNA sequence. 
89.5 
iii M60129 Rabbit (a2a2 haplotype) Ig H-chain V-region 
(allotype VHal) gene, clone RVH732. 85.7 
iv M21261 Rabbit Ig H-chain V-region (allotype VHal) 
mRNA (V), clone RVH142. 84.8 
v M12180 Rabbit Ig germline CL42. VH25 and CL. 42VH34 
genes, VHA3 allotype, 5' end. 84.3 
Rabbit Heavy Chain & Length: 313 
301 attcagacta ctt 
Acwskm Description % 
number Fkxrdba 
i M93181 OrYdOlagus cuniculus, Ig germline H-chain gene, 
V-region (VH4-al). 86.5 
ii L03887 Rabbit immun0glObulin rearranged H-chain 
V-region, D-region and C-regiorL 84.9 
iii L27322 OrYctolagus cuniculus intervening DNA sequence. 
84.9 
iv M12180 Rabbit Ig germline CLA2-VH25 and CL. 42Vh34 
genes, VHA3 aBotype, 5'end. 83.5 





8.3.8 ELISA Analysis of Phage Cultures 
The 'polyclonal' phage supernatants recovered from the initial 
transformed library cell culture and from the cell culture reinfected with phage 
eluted from the fourth round of panning were screened for binding to antigen 
by ELISA. This experiment was repeated in order to validate the results. The 
absorbancy readings at 410nm for the ELISA with the post fourth pan phage 
were 0.976 and 0.769 and the corresponding readings for the ELISA with 
unpanned phage were 0.591 and 0.563. 
SA DISCUSSION 
Positive binding of rabbit antisera 39 and 43 to the antigens to which the 
rabbits had been immunised. was indicated by ELISA. Immunoblot analysis of 
these antisera revealed that they recognised a -170 kDa protein which is the 
expected molecular size of fully glycosylated CFrR [Gregory et al., 19901. Both of 
these results were consistent with the assumption that the rabbits had raised 
an immunogenic response to the CFTR components of the 0- 
galactosidase/CFrR fusion proteins with which they were immunised. It was 
therefore anticipated that a phage display Fab library derived from these 
immunised rabbits would be biased towards the expression of antibody 
fragments that recognised regions of CFTR. 
The successful construction of a phage display library expressing Fab 
fragments was confirmed by sequence analysis of 8 randomly selected library 
clones. Each sequence had considerable homology (>80%) to at least 5 
previously identified rabbit antibody sequences. Some overlaps were seen 
between the top 5 homologous sequences found for the heavy and light chain 
sequences analysed. However, this does not necessarily mean that the diversity 
of this rabbit Fab library is limited. It is more likely a reflection of the fact that 
there are far fewer rearranged rabbit antibody gene sequences in the 
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EMBL / Genbank data, compared, for example, to murine, counterparts. 
XL1-blue cells that were resistant to contaminating lytic: phage lysis were 
successfully prepared. The culture of the Fab library in these cells enabled 
consecutive rounds of phage-antibody reinfection and rescue which had been 
previously been prohibited (see chapters 6 and 7). The library was selected by 
panning for Fab fragments that bound to the fusion protein antigen. ELISA 
analysis indicated that the enriched phage bound antigen more strongly than 
the unpanned phage. This initial result was obtained with the polyclonal 
phage suspension. Further studies need to be carried out to ascertain whether 
individual Fab clones bind to the antigen. 
The pComb3H-SS vector is designed such that free soluble Fab 
fragments can be expressed in E. coli. Removal of the g3p DNA from 
pComb3H/ Fab vector DNA can be achieved by restriction with Spe 1 andNhe 1 
followed by direct religation of the compatible ends. The heavy and light 
antibody chains assemble in the periplasm. of the E. coli. and soluble Fab 
fragments can be recovered from the culture supernatant or from bacterial 
lysate preparations [Burton et al., 1991]. Once individual positive Fab clones 
have been identified by ELISA, the specificity of their antigen binding will 
have to be analysed. Identification of which component of the fusion protein 
antigen mixture particular Fab fragments recognise, can be achieved by 
performing separate ELISA tests against each of the three p-galactosidase/CFTR 
fusion proteins and expressed P-galactosidase alone. 
In conclusion, XL1-blue cells, apparently resistant to the lytic phage 
contamination that was disrupting previous Fab phage display antibody work, 
have been successfully cultured. This enabled antigen selection and binding 
studies to be performed with the rabbit derived, Fab antibody library. The 
results obtained so far augur well for the use of this library as a source of 
specific anti-CFIR antibodies. The mutated strain of XL1-blue cells will also 
facilitate further analysis of the murine derived Fab libraries described in 
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9.1 The production of CFM Specific Antibody Libraries in Ecoli.. 
The emphasis of this study has been on the construction of antibody 
expression libraries for the isolation of anti-CFIR antibody fragments. A 
variety of problems were overcome to enable the construction of five phage 
display libraries from sources immunised to CFrR. Each of these libraries 
appears to contain an appropriate diversity of heavy and light chain antibody 
sequences. Initial difficulties due to the contamination of the libraries with a 
lytic phage have been successfully addressed such that characterisation of the 
libraries by selection against specific antigens is now possible. 
9.2 Progress in the Production of Phage Display Libraries 
Antibody libraries based on phage expression were first described in 1990 
[McCafferty et al., 19901 and rapid progress has followed leading to the 
construction of increasingly elaborate systems (see section 1.2.6.3.6). A number 
of problems associated with the methodologies have been surmounted. Other 
complications, which at present may inhibit a more widespread adoption of 
this technology, are gradually being overcome. Some of these complications 
are discussed below and, where appropriate, they are applied to the systems 
adopted in this study 
9.2.1 PCR Amplification of Antibody Gene Fragments 
The diversity of a cOmbinatorial library is critically dependent on the 
efficacy of the oligonucleotide primers used to amplify the immunoglobulin 
gene fragments by PCR. The escalation of available information on 
immunoglobulin gene sequences has enabled the design of optimised PCR 
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primer sets that encompass essentially all heavy and light chain gene families 
[e. g. Marks et al., 1991a; Zhou et al., 19941. However, certain complications are 
still intrinsically associated with the system. 
it is likely that some heavy and light chain genes are primed relatively 
less efficiently. Coupled with the inherent amplification in PCR, this may lead 
to the under-representation of these chains in an antibody library. This 
problem can be reduced by performing separate PCR reactions with individual 
pairs of primers and pooling the products, rather than carrying out a single 
PCR reaction with a large mixture of primers [Sastry et al., 19891. This method 
was adopted for heavy and light chain amplification prior to cloning into the 
pComb3H-SS phagemid vector (chapters 6,7 and 8). 
The introduction of Taq polymerase errors during PCR amplification 
may result in an altered antibody sequence that does not bind antigen as well 
as the original sequence found within an antibody producing B lymphocyte. 
This is most likely to be a problem in the amplification of -sequences from 
clonal cell populations (see Chapters 5 and 6) which could be overcome with 
the use of Vent polymerase (sections 5.3 and 6.3) [Mattila et al., 1991]. 
However, mutations introduced during the PCR amplifications of heavy and 
light chain antibody sequences from a diverse repertoire of antibody producing 
cells may prove to be advantageous (section 6.4). 
9.2.2 Reduction in the Toxic Effects on Ecoli. of in vivo Antibody Production 
In both the systems used in this study, the expression of the antibody 
fragments was under the transcriptional control of the lac promoter/ operator. 
The lac promoter is repressible and has a relatively low leakage rate in the 
absence of induction, especially in the presence of glucose. This is particularly 
important in the production of antibody fragments to avoid toxic effects on 
E. coli. cells which, at least in part, are caused by incorrectly folded protein 
[Skerra et al., 1991; Knappick et al., 1993]. The stress caused to cells by the 
secretion of antibody fragments is an important consideration for the 
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maintenance of representative libraries. The problems associated with such 
instability of phage display antibody libraries have been recognised in the 
research community [Rapoport et al., in press]. It is quite conceivable that a 
library could be depleted of an important antigen recognising done as a result 
of the poor growth of the Ecoli. harbouring that clone. The molecular basis of 
the poor in viw folding of antibodies has recently been elucidated and 
antibodies have been engineered with an altered framework that do not 
produce any insoluble protein and do not have a detrimental effect on cell 
growth [KnappikA. and PluckthunA., submitted). Antibody framework 
regions designed for improved stability and folding ability may form an 
appropriate basis for the production of semi-synthetic libraries in the future. 
9.13 Efficiency of Antibody Selection fiom Phage Display Libraries 
The efficiency of antibody selection depends on a number of factors, 
including the affinity of antigen binding, the number of antibody fragments on 
a single phage that can simultaneously bind antigen and the extent of non- 
specific binding to the antigen coated surface. 
It has been demonstrated that the binding affinity of a single antibody 
fragment needs to be greater than 105 mol-1 to hold the phage fragment 
carrying it to a solid surface [Clackson et al., 19911. A number of methods that 
have been adopted to increase the affinity of antibody binding were outlined in 
Chapter 1 (specifically section 1.2.6.4.6). One of these is based on theoretical 
studies that suggest that the larger an antibody repertoire, the greater the 
prospect of finding higher affinity antibodies to a given epitope [Perelson et 
al., 19791. Given that the heterogeneous libraries produced in this study 
(Chapters 7 and 8) were from immunised animal sources and contained 4x106 - 
8x1O6 clones, it is anticipated that they should contain high affinity antibodies 
to the appropriate immunogens (pers. comm. Carlos Barbas and Dennis 
Burton (Scripps Inst., La Jolla, California)). 
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The pCantab5 phagemid vector system could potentially facilitate the 
expression of more than one antibody fragment on the surface of an 
individual phage. This was, not expected with the pComb3H-SS phagemid 
vector system [Barbas et al., 1991]. The advantage of multiple expression of 
antibody fragments is that low affinity antibodies may be selected on the basis 
of cumulative avidity [Griffiths et al., 19931. If low antibody affinity is a 
problem this can facilitate the selection of antibodies that can subsequently be 
manipulated to improve individual antigen binding affinities. Antibody 
fragments with specific higher binding avidities have been designed, for 
example "mini-antibodies" [Pack and Pluckthun., 19921 and "diabodies" 
[Hollinger et al., 19931. However, a monomeric expression system (such as 
pComb3H-SS) is preferable for the isolation of high affinity antibody clones 
that are intrinsically present in library [Barbas, 19931. 
Non-specific binding of antibody fragments has proved to be a 
significant problem in the isolation of rare antigen binding clones from phage 
display libraries [Rapoport et al., in press; Griffiths et al., 1994]. This 
phenomenom may introduce complications in the selection of the libraries 
described in this study. A novel approach to selection which links antigen 
recognition to phage replication has been published recently [Duenas and 
Borrebaeck, 19941. This method is based upon the expression of antibody 
fragments on phage, rendered non-infectious by g3p deletions. Antibodies 
were selected with an antigen/g3p fusion protein. The antigen specific phage 
were thus rendered replication competent because the antigen/g3p fusion 
protein was capable of infecting the F-pili of the Ecoli. Thus only the phage 
displaying antigen specific antibodies could be clonally amplified. This method 
of selection may be useful for the isolation of antigen specific clones from the 
rabbit Fab library described in Chapter 8 if non-specific antibody binding proves 
to be a problem. Fusion proteins could be created between the three CF PCR 
products (CF3/10, CF9/8 and CF5/4) and g3p to promote antigen specific 
selection. 
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9.3 The Relative Merits of Fab and ScFv Antibody Libraries 
Both Fab and ScFv have been shown to bind antigen successfully 
[Winter et al., 19941. As previously described in section 1.2.1.2, ScFv fragments 
have proved to be invaluable in circumstances where the small size of an 
antibody fragment is particularly important. Nonetheless, in general 
circumstances, Fab fragments are probably more functional and reliable 
research tools. 
The Fab fragments are held together by a native disulphide bridge. The 
heavy and light chains in ScFvs are covalently joined by a short peptide. The 
rationale behind linking the heavy and light chain variable regions together 
into a ScFv is to promote the correct folding of the Fv region in the periplasm 
of Ecoli. by bringing VH and VL domains sufficiently close together to interact 
and fold [Glockshuber et al., 1990; Huston et al., 19931. The 15 residue 
(Gly4Ser)3 linker was designed to be long enough to avoid strain on the native 
Fv conformation while restricting steric interference with the 
antigen/ antibody combining site from an excessively long peptide. 
The additional extrinsic peptide sequence present in ScFv may interact 
with the antigen binding site and have a deleterious effect. In addition the 
variable domain order (either VH-linker-VL or VL-linker-VH) is normally 
predefined. It has been predicted from theoretical principles and experimental 
results that the conformation of a single chain binding site could sometimes be 
sensitive to the order and orientation of the variable domains [Huston et A, 
1993; Anand et al., 19911. 
NMR data indicate that the linker is a passive entity and as such does 
not influence the folding state reached by the interacting heavy and light chain 
variable regions [Freund et al., 1993]. However, it does not contribute to the 
thermal stability of the fragments. The linker may keep the heavy and light 
chains in the same vicinity in the periplasm of Exo1j. , but it does not have a 
steric effect in keeping them folded together to form an antigen binding unit. 
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The weak interaction between heavy and light chain variable regions is not 
enhanced by the linker. Interactions between the heavy and light chain 
fragments are much weaker for ScFv than for Fabs because of the absence of 
interchain disulphide bonds. 
Comparison of antigen affinities of a number of different ScFv 
fragments and their corresponding Fabs shows that in the majority of cases the 
ScFv fragments have a lower affinity [Bird and Walker, 1991; Huston et 
al., 1991; Ducancel et al., 19931. 
In the light of the disadvantages of ScFv fragments mentioned above, 
most of the effort in the production of antibody libraries in this study was 
applied to the construction of anti-CFrR Fab antibody libraries. It seems likely 
that in the future most phage display antibody systems wiU be based on the 
expression of Fab fragments rather than ScFvs. The most recent significant 
phage display antibody library paper published by Greg Winter's group, who 
up until now have concentrated on the development of ScFv phage display 
systems, describes the production of a phage library based on the expression of 
a large synthetic repertoire of Fab fragments [Griffiths et al., 19941. 
9.3.1 The LKB-Pharmacia Recombinant Phage Antibody System 
The LKB-Pharmacia kit described in Chapter 5 of this study is based 
upon the phage expression of ScFv antibody fragments. As such it is prone to 
the disadvantages outlined above (section 9.1.3). Working with this system 
revealed a number of other innate limitations. 
As described in section 9.1.1, the successful PCR amplification of a 
repertoire of antibody gene fragments is enhanced by carrying out separate 
reactions with individual pairs of primers. In the LKB-Pharmacia kit the 
primers are supplied as a mixed pool such that the amplification of all heavy 
or all light chains can only be carried out in a single PCR. Such reactions have 
previously been shown to not be very effective [Sastry et al., 19891. 
It is recognised that the number of clones in a phage display library 
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directly affects the potential of that library to contain specific antigen binding 
antibody fragments [Winter et al., 19941. In turn, library size is directly 
dependent on the amount of DNA used in the library construction, the 
efficiency of ligation and the competency of the Exo1i. cells to be transformed. 
However, none of these details are emphasised as important in the methods 
provided with the LKB -Pharmacia kit. 
It would be advantageous to be able to express soluble antibody 
fragments which are not attached to the g3p protein as is possible in the 
pComb3H-SS expression system (see section 8-3). This was not possible with 
the vector provided in the original LKB-Pharmacia system, although a new 
vector pCANTAB 5E is now available which facilitates soluble expression of 
ScFv. This is accompished by the addition of an amber stop codon between the 
cloned ScFv and the g3p sequence. In Ecoli. strains lacking an amber 
suppressor (e. g. HB2151, suggested by Pharmacia), the ScFv is expressed as a 
soluble molecule. 
9.4 The Production of Antibodies to CFTR 
Monoclonal and Polyclonal antibodies raised to CFTR have been 
described in this study. Attempts to establish the specificity of these antibodies 
have led to the interesting speculation of the existence of an immunologically 
conserved family of proteins that is structurally and perhaps functionally 
related to CFTR [Walker et al., submitted). Further studies with these 
antibodies, together with anti-CFTR antibodies isolated from the constructed 
Fab libraries, should lead to the identification of members of this family and 
the subsequent assessment of the significance of these findings to the cystic 
fibrosis field. 
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9.5 Epitope Mapping of CFIrR 
A precise confirmation of the predicted topology of CFrR is of key 
importance in the understanding of its exact functions. Until recently no 
experimental verification had been obtained. One of the primary objectives of 
this study was to produce a panel of antibodies that could be used to epitope 
map the protein. Such studies have been successfully carried out on 
mammalian MDR [Yoshimura et al., 1989). 
The first systematic experimental evaluation of the original topological 
model of CFTR was reported this year [Chang et al, 
., 
1994]. Here, glycosylation 
site insertion studies were used to map the cytoplasmic and extracytoplasmic 
loops between the membrane spanning domains of the protein. The predicted 
cytoplasmic or extracellular locations of the loops between the transmembrane 
regions was verified. 
In the light of the encouraging ELISA results obtained from panned 
polyclonal phage from the rabbit derived Fab library (section 8-3.8), it is 
anticipated that clonally pure anti-CTTR antibodies will be successfully isolated 
from the antibody display libraries described in this study. If the specificity of 
these Fab fragments is suitable, they should prove to be useful tools in the 
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